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Abstract
Morbidity and mortality associated with diabetes are due to secondary vascular
complications that include both micro- and macro-vascular organ dysfunctions. Our
recent studies show that vascular dysfunction and inadequate vessel repair in diabetes
may potentially be due to impaired vasculogenesis (de novo vessel formation).
Specifically, we have shown that diabetes enhances adipogenesis in the bone marrow and
reduces the number of marrow-resident vascular regenerative stem cells. In this study, I
have determined the mechanisms of deleterious bone marrow adipogenesis, which may
alter the cellular composition of the marrow and lead to the depletion of vascular
regenerative stem cells.
My initial work focused on understanding the early changes induced by diabetes in the
bone marrow. To identify these changes, I induced diabetes in mice using streptozotocin.
Even as early as 1 month after disease onset, changes—both structural and molecular—
were evident in the bone marrow of diabetic mice. Importantly, I showed that short-term
diabetes enhances adipogenesis in tibiae of mice. This enhanced adipogenesis was found
to be associated with suppressed transforming growth factor beta (TGFB) signalling
pathway.
Using bone marrow-derived mesenchymal progenitor cells (bm-MPCs), I then
investigated the functional significance of TGFB signalling suppression. My studies
showed that exposure of bm-MPCs to high levels of glucose suppresses the TGFB
pathway, similar to the observations in diabetic mice. Supplementation of TGFB
prevented adipogenic differentiation of bm-MPCs. Dissection of the intracellular
signalling pathways revealed that TGFB1 utilizes the non-canonical TGFB-activated
kinase 1 (TAK1)-mediated mechanism to inhibit adipogenesis. Transcriptome-wide gene
expression profiling revealed a potential involvement of the Wnt pathway, confirming
previous studies in our laboratory.
Finally, I tested the effect of a known inhibitor of adipogenesis that blocks peroxisome
proliferator-activated receptor gamma (PPARG) in diabetic mice. My results showed that
ii

adipogenesis inhibition prevents lipid accumulation in the liver of diabetic mice but does
not affect the enhanced adipogenesis in the bone marrow.
Taken together, my studies identified enhanced bone marrow adipogenesis in diabetic
mice before other known diabetic complications become evident. I further identified
suppressed TGFB signalling pathway as a mechanism that potentially leads to deleterious
adipogenesis in bones. This suggests that restoration of TGFB signalling in the marrow
may offer therapeutic benefit to patients with diabetes and help preserve vascular
regenerative stem cells to endogenously repair the damaged vasculature.

Keywords: diabetes, diabetic complications, stem cells, vasculogenesis, bone marrow,
adipogenesis, cell differentiation, adipocytes, progenitor cells, TGF-beta signalling, stem
cell niche, CXCL12
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Summary for Lay Audience
Our blood vessels are lined by cells called endothelial cells. Endothelial cells react to
their environment and chemicals in the blood to regulate immune response, blood
clotting, and blood flow. In patients with diabetes, blood vessel endothelial cells in the
heart, kidneys, and eyes become dysfunctional and are lost. Patients then succumb to
heart failure, kidney failure, stroke, and blindness. Previous work in our laboratory has
shown that diabetes reduces the number of stem cells, which normally repair these
damaged blood vessels. Additionally, diabetes increases fat in the bone marrow that
disrupts cellular harmony. Therefore, I explored how diabetes may be mediating these
effects at the cellular and molecular levels.
To understand the early changes occurring in the bones, I made mice diabetic by using a
chemical. I noticed fat accumulation in the long bones of these diabetic mice. I then
identified a protein that accompanied these fatty changes in the bones. Using cells in a
petri dish, I showed that the protein regulated fat cell formation. Next, I examined
whether inhibiting fat formation would preserve the cellular composition in bones of
diabetic mice using another chemical that is known to prevent fat development. This
chemical is called BADGE. My studies showed that bones of diabetic mice remained
damaged, and BADGE was not able to prevent fatty changes. Although we have yet to
find a proper treatment for diabetic bone disease, my studies have identified new targets
that warrant further exploration and testing in the mouse model of diabetes. Ultimately,
the goal is to prevent fatty changes in bones and preserve our body’s own stem cells to
repair damage caused by diabetes.
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Chapter 1
1
1.1

Introduction
Diabetes and diabetic complications

Diabetes mellitus (diabetes) is a chronic disease that is characterized by the body’s
inability to synthesize or effectively utilize insulin, resulting in hyperglycemia. The main
types of diabetes include type 1, type 2, and gestational diabetes. Type 1 diabetes is an
autoimmune disease that entails pancreatic beta-cell destruction. As pancreatic beta-cells
are the insulin-synthesizing cells, loss of these cells results in very little or no insulin
production [1]. People living with type 1 diabetes need daily insulin injections to control
blood glucose levels. Type 2 diabetes, on the other hand, is often associated with obesity
and sedentary lifestyles, and is characterized by insulin resistance and/or relative insulin
deficiency. Type 2 diabetes can occur at any age; however, there has been an increasing
prevalence of type 2 diabetes in children and adolescents [2]. People living with type 2
diabetes are often prescribed exercise and/or dietary changes to manage their disease, but
many people still require medication and/or exogenous insulin. Lastly, gestational
diabetes is characterized by elevated glucose levels during pregnancy, which leaves the
mother and baby at risk of developing type 2 diabetes later in life. Modification of diet,
lifestyle, and application of pharmacological interventions have shown some beneficial
effects in reducing the risk of progression to type 2 diabetes [reviewed in [3]].
The global prevalence of diabetes is expected to be approximately 10% (592 million
people) by 2035 with an increased incidence of diabetes among youth [1, 2, 4-6]. The
growing prevalence of diabetes worldwide has significantly highlighted various diabetic
complications. If not controlled, hyperglycemia will eventually lead to blood vessel
impairment in select organ systems and produce secondary complications (Figure 1-1).
These complications manifest as both microvascular (retinopathy, nephropathy,
cardiomyopathy, neuropathy) and macrovascular dysfunctions (accelerated
atherosclerosis; coronary artery disease, peripheral arterial disease, and stroke) [7].

1

A previous study has found that diabetic microvascular complications are more prevalent
than macrovascular complications [8]. While men appear to be at a higher risk for
diabetic microvascular complications, women appear to see greater consequences of
macrovascular complications [9]. The top three most prevalent microvascular
complications are neuropathy, nephropathy, and retinopathy [8].
Diabetic nephropathy is one of the major causes of end-stage renal failure worldwide. It
is characterized by proteinuria, increased glomerular basement membrane thickening, and
accumulation of extracellular matrix [10]. Although hyperglycemia-induced vascular
dysfunction is the primary initiating mechanism in diabetic nephropathy, progression of
the disease is also driven by excessive oxidative stress, inflammatory responses, and
fibrosis. Despite the current standard of therapy to control blood pressure and
hyperglycemia, diabetic nephropathy progresses with patients requiring dialysis. Further
exacerbating the situation, patients also experience dialysis-associated complications
[11].
Diabetic retinopathy is the leading cause of blindness in the working population. Greater
than 78% of patients with type 2 diabetes for 15-plus years develop retinopathy [12], and
nearly all patients with type 1 diabetes for 20 years develop clinical signs of retinopathy
[13, 14]. Clinically, diabetic retinopathy is classified as background retinopathy (BDR),
pre-proliferative retinopathy (PPDR), and proliferative retinopathy (PDR) [15]. BDR
shows capillary basement membrane thickening, microaneurysms and increased vascular
permeability. PPDR shows a gradient of activity, ranging from mild to very severe nonproliferative retinopathy, and includes macular edema, intra-retinal hemorrhages, and
intra-retinal microvascular abnormalities [15]. Finally, PDR is characterized by
neovascularization in response to sustained ischemia. These new, fragile vessels grow in
the retina and into the vitreous. Currently, management of retinopathy is achieved by
delaying the progression through laser therapy or anti-vascular endothelial growth factor
(VEGF) monoclonal antibody therapy [16, 17].
Approximately one-half of all people with diabetes will also have some form of
neuropathy [18, 19]. Diabetic neuropathy is the main initiator of foot ulcers and lower
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extremity amputation [20]. The mechanisms leading to neuropathy in diabetes are
complex, with competing theories on cell types initiating the disease. Hyperglycemia
may directly affect neurons [21]. Many studies have provided mechanisms of how
neurons are damaged in diabetes, which include glucose neurotoxicity and reactive
oxygen species [21-23]. Hyperglycemia may also damage neuronal cells indirectly by
impairing vasodilation and increasing capillary basement membrane thickening [24].
Inhibitors of the renin-angiotensin system (RAS) and alpha-1 antagonists have shown
some benefit in improving nerve conduction velocities [25]. However, other than
glycemic control and management of neuropathic pain, there are no major therapies
approved for diabetic neuropathy.
One positive sign, in an otherwise negative and challenging situation, is that there are
agents to aid in controlling blood glucose levels – the apparent instigator of diabetic
complications. These include drugs that stimulate pancreatic beta-cells to produce insulin
(sulphonylureas), reduce the production of hepatic glucose (biguanides), and improve
insulin sensitivity (thiazolidinediones) [26-28]. However, despite the selection of
therapies that are currently available to temporarily control high blood glucose levels,
injury to vascular endothelial cells is almost inevitable.
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Figure 1-1: Schematic illustration of chronic diabetic complications.
Schematic illustrating target organ dysfunction in chronic diabetes. Diabetes leads to
damage to both small and large vessels in target organs, including retinopathy
(blindness), cardiomyopathy (heart failure), nephropathy (kidney failure), peripheral
vascular disease and neuropathy (leg amputation), and stroke.
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Evidence from the Diabetes Control and Complications Trial (DCCT) and the UK
Prospective Diabetes Study (UKPDS) nicely shed light on the critical role that
hyperglycemia plays in producing microvascular complications of diabetes [29, 30].
Essentially, all microvascular complications present similar pathophysiological features.
Initially, high levels of glucose directly damage blood vessel-lining endothelial cells [31].
Interestingly, although perivascular cells wrapped around endothelial cells can adapt to
the different circulating glucose levels through the regulation of glucose transporters,
endothelial cells lack this adaptive response and, hence, are more vulnerable to the
hyperglycemic environment [31]. For this reason, many studies have investigated the
potential mechanisms of endothelial dysfunction in hyperglycemia [32]. A plethora of
mechanisms underlying hyperglycemia-induced endothelial cell damage has been
identified. These include increased flux of glucose through the polyol pathway, enhanced
production of advanced glycation end-products, accumulation of reactive oxygen species,
decreased production of nitric oxide, and abnormal activation of protein kinase C [32,
33]. The outcome of these biochemical changes is defective vasculature and endothelial
cell loss, leading to tissue ischemia and organ dysfunction.
Normally, in response to hyperglycemic injury, the proliferation of endothelial cells
(replacement) and expansion of vessels through angiogenesis would be expected to
counteract this damage. However, this reparative process is hindered in diabetes. This
may not be surprising as pre-existing vessels are dysfunctional and compromised
endothelial cells may not be able to proliferate and repair the defect [34, 35]. It is
important to note that angiogenesis is not the only mechanism of neovascularization. We
know that, at least during development, blood vessel formation begins with the process
known as vasculogenesis. Vasculogenesis is the de novo vessel formation that involves
the differentiation of non-endothelial precursors into endothelial cells and the formation
of a vascular plexus [25, 36]. Angiogenesis also plays a role in blood vessel formation by
creating new vessels from pre-existing vessels [37, 38]. Historically, neovascularization
through vasculogenesis was thought to be restricted to early development. However,
isolation of circulating endothelial progenitor cells (EPCs; now more accurately called
endothelial colony-forming cells or ECFCs) in the peripheral blood by Asahara and
colleagues provided evidence that vascular networks could also potentially be formed in
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adults through vasculogenesis [36]. This area is under intense investigation because of
the promise it holds. Understanding the stem cell microenvironment, how stem cells form
vascular networks, and how they may be potentially affected in diabetes could offer
viable treatment options for diabetic patients.
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1.2

Stem cells in the bone marrow

The bone marrow is one of the richest sources of postnatal, non-induced stem cells.
Various stem cell populations have been identified in the bone marrow. However, before
we discuss how diabetes may potentially affect marrow-resident stem cells, we should
first review the classification and nomenclature of precursor cells to frame the discussion.
This is partly because of the inconsistent classification and identification of precursor
cells, which have resulted in contradictory findings in the context of diabetes. Stem cells
are defined by two ‘classical’ properties: 1) capacity for self-renewal, and 2) capacity to
give rise to mature/differentiated cell types. Self-renewal, of course, entails the division
of cells while maintaining an undifferentiated state. The second property is related to a
term called ‘potency’ and refers to the varying ability of different stem cells to generate
specialized cells [39]. In other words, not all stem cells are equal. There is also a third
property of stem cells, although it is not much discussed. This third property of stem cells
is the hierarchical arrangement of cells. Possibly with the exception of uni-potent or
lineage-restricted cells, most stem cells exist in a hierarchy of specialization generated by
their own progeny. This progeny may be important in creating stem cell niches, as is the
case in the marrow of bones.
In the bone marrow, there are at least two stem cell populations that can generally be
classified either into hematopoietic or non-hematopoietic stem cells (Figure 1-2) [40].
Hematopoietic stem cells are known to give rise to all blood cells of the body [41]. In
addition, derivation of blood vessel-forming cells originating from marrow suggests the
presence of another distinct population of non-hematopoietic stem cells that I refer to as
mesodermal/vascular regenerating stem cells (Figure 1-2). These vascular regenerative
stem cells are different from hematopoietic stem cells, as they do not express
hematopoietic cell marker, CD45 [42]. Vascular regenerative stem cells are an attractive
target for diabetic patients to initiate new vessel formation and replace damaged ones, as
these stem cells are capable of differentiating into mesenchymal/mesodermal progenitor
cells (MPCs) and ECFCs (Figure 1-2) [43, 44]. Previous studies from our laboratory have
shown that both ECFCs and MPCs resist glucose-induced cytotoxicity, unlike
mature/differentiated vascular cells [45]. Moreover, these non-hematopoietic mesodermal
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stem cells can also give rise to progenies that serve as niche cells, including osteoblasts
and adipocytes [42, 45].
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Figure 1-2: Stem cells in the bone marrow.
Schematic showing the presence of at least two types of stem cells in the bone marrow
and their respective progeny(ies) [SC: stem cell; CMP: common myeloid progenitor;
CLP: common lymphoid progenitor; ECFC: endothelial colony-forming cell; MPC:
mesenchymal progenitor cell; EC: endothelial cell].
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1.3
1.3.1

Stem cell function in diabetes
Hematopoietic stem cells

The bone marrow is the de facto site for hematopoietic stem cells (HSCs) in adults. HSCs
constantly replenish the pool of immature cells throughout life [46] and give rise to
common lymphoid and myeloid progenitors (specialized cells), which differentiate into
all blood cells (Figure 1-2) [47, 48]. Various ‘markers’ to identify HSCs have been used
in various studies. Commonly, these include Lineage-Sca-1+c-Kit+ for mouse and
Lineage-CD34+ for humans [49]. A previous study has found that CD133+/CD34- HSCs
from humans are more primitive and are capable of differentiating into CD34+ cells [50].
HSCs have been identified in two locations within the bone marrow, near osteoblasts, and
near sinusoidal endothelial cells (ECs). Studies have shown that quiescent HSCs reside
closer to the osteoblasts, with more mature and actively dividing subsets residing
progressively further away from the bone edge and closer to the marrow core
(perivascular niche) [51-53]. In support of this finding, aged HSCs have been found to
reside more distantly to the osteoblasts compared to the young HSCs, suggesting age is a
factor in HSC niche remodelling [54]. These studies highlight the importance of the niche
in maintaining HSC stemness.
Granulocyte colony-stimulating factor (G-CSF) is the most widely used mobilizing agent
to elicit HSC mobilization from the bone marrow into the circulation [55]. In animal
models of type 1 and type 2 diabetes, HSC (Lineage-Sca-1+c-Kit+) mobilization by GCSF is reported to be impaired with reduced ability to reconstitute hematopoiesis in
lethally-irradiated recipients [56]. This impairment is termed diabetic mobilopathy. This
deficit is suggested to be due to changes in adhesive and chemotactic properties of HSCs
in diabetic mice [56]. Interestingly though, when HSCs from streptozotocin (STZ)induced diabetic mice were transplanted into non-diabetic recipients, no difference in
mobilization was observed [56]. What this study shows is that the defect in diabetes may
be limited to the niche rather than the HSCs. Furthermore, HSCs harvested from STZinduced diabetic mice co-cultured with the osteoblastic niche from non-diabetic mice
show reversal of altered molecular expression patterns [57], again hinting that diabetes
alters the niche cells. In contrast, HSCs derived from non-diabetic mice cultured with the
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osteoblastic niche from diabetic mice showed altered molecular expression [57]. This
altered molecular pattern involved genes regulating HSC self-renewal, survival, and
quiescence. In further support of altered niche and not HSCs in diabetes, we and others
have also shown that the number of HSCs in marrow samples of human type 2 diabetes is
unaltered [42, 58]. Therefore, as far as HSCs are concerned, diabetes may lead to
alteration in the stem cell niche rather than causing direct assaults to the HSCs. In the
context of diabetic vascular disease and impaired neovascularization, restoring the niche
for HSCs may also be an effective strategy to explore. HSCs have been shown to
indirectly enhance neovascularization by releasing paracrine factors and regulating
angiogenesis [59, 60].

1.3.2

Non-hematopoietic stem cells

The majority of the CD34+ cells from cord blood co-express CD45, a common
hematopoietic cell marker; however, rare cells were identified to be CD34+CD45- [61].
Interestingly, CD34+CD45- cell populations have endothelial colony-forming ability and
are termed ECFCs. These cells do not show hematopoietic ability. In contrast,
CD34+CD45+ cells exhibit enriched hematopoietic activity but do not generate
endothelial cells [61]. This study, in part, confirms the existence of a rare, non-HSC that
may regenerate endothelial cells. Studies have found that these rare cell populations in
the bone marrow as well [62-64]. The true identity and immunophenotype of these
vascular regenerative non-HSCs are still not clear. Based on numerous studies that have
isolated cells from marrow and circulation through enrichment for cell surface markers
and assayed for in vitro differentiation, we know that cells giving rise to vascular cells
likely lack the expression of CD45. A potential marker (although not exclusive) of these
non-HSCs may be CD133 (also known as prominin-1). CD133, at least in humans, is an
important marker for the identification as well as enrichment of primitive stem cells.
CD133+ cells have the capacity to give rise to lineage-restricted endothelial and
mesenchymal progenitor cells (MPCs; cells restricted to mesenchymal lineages) (Figure
2) [65, 66]. Could these CD133+ cells potentially mark the elusive mesodermal stem
cells?
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Our laboratory has shown that human CD133-selected stem cells are resistant to glucose
toxicity unlike mature/differentiated endothelial and perivascular cells [45]. Although
resistant to glucose toxicity, we and others have shown that these stem cells are
significantly depleted in human diabetes and in experimental models of the disease [42,
58]. Our laboratory has identified these vascular regenerating stem cells as CD133+CD45in humans [42] and showed a dramatic decrease in type 2 diabetic patient samples;
however, CD133+CD45+ HSCs were unaltered. An independent study showed the exact
same phenomenon. Immunofluorescence staining of human bone marrow samples
showed that CD45+CD34+ cells are not affected in type 2 diabetes, whereas a significant
reduction in the abundance of CD45-CD34+ cells is clear [58]. In addition, a significantly
reduced number of CD45dimCD34+ were detected in type 2 diabetic patients, and the
relative abundance of these cells can be predicted by the duration of diabetes [58].
Similarly, CD133+CD34+ bone marrow cells were significantly reduced in type 2 diabetic
patients [58]. Although the mechanism of this depletion is not clear, these independent
studies show that diabetes selectively targets these vascular regenerative, non-HSCs.
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1.4

Stem cell differentiation and progeny in diabetes

Here, I will discuss the progenies of vascular regenerative stem cells and the reported
effect of diabetes on these cell types.
1.4.1

Lineage-restricted endothelial progenitor cells/endothelial colony-forming
cells

The detection of circulating ‘endothelial progenitor cells’ (EPCs) by Ashara and
colleagues was, no doubt, the first step towards the implication of postnatal
vasculogenesis [36]. However, even after 20-plus years of research in the field, the
imprecise definition of an EPC muddies scientific knowledge. Our laboratory has shown
that true endothelial precursor cells display properties of both ECs and unipotent
precursor-like cells, including a high proliferative capacity [67-69]. These endothelial
precursors are derived from CD133-expressing cells but CD133 expression is readily lost
upon culture [67]. Endothelial precursors show lower population doubling time and
higher cumulative population doublings compared to mature ECs [69]. More recently, we
showed that endothelial precursors are stimulated by anti-angiogenic collagen fragment,
endostatin, whereas mature ECs are inhibited [67]. Over time, these endothelial
precursors resemble mature ECs in terms of marker expression and all cellular activities.
However, most studies on EPC number and function in diabetes comprise of what we
now know as early outgrowth cells (or myeloid angiogenic cells). These cells are
typically characterized by Ulex europaeus agglutinin binding and DiI-labeled acetylatedlow density lipoprotein uptake [70-72]. Although ECs do bind Ulex, it is not a specific
marker. Ulex europaeus agglutinin is a lectin that binds to fucose residues that also marks
hematopoietic cells. Similarly, acetylated-LDL also marks monocytes [73]. These
findings suggest that most studies on the role and function of EPCs in diabetes, while far
from clear, likely document changes in hematopoietic-like cells. The most important
properties of true endothelial precursors are endothelial cell differentiation and
participation in blood vessel formation. An appropriate term for these cells, therefore, is
endothelial colony-forming cells (ECFCs), as recently put forth in a recent consensus
statement of endothelial progenitor nomenclature [74].
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Many studies have gone in-depth analyzing how endothelial precursors are affected in
diabetes. When the number of ECFC was quantified in marrows of mice with STZinduced diabetes, there was no difference. However, when G-CSF was injected to
mobilize the ECFCs from the marrow to the circulation, a blunted mobilization response
was observed, similar to HSCs [75]. ECFCs isolated from type 2 diabetic patients had
significantly impaired ability to form tubule networks [72]. This lack of tubule formation
was also accompanied by fewer ECFCs, which were inversely correlated with glycated
hemoglobin levels and duration of diabetes [72]. Interestingly, the reduction of ECFCs
was more profound when diabetic patients had associated peripheral vascular
complications [76]. Similarly, cells isolated from type 1 diabetic patients showed
impaired angiogenic ability in vitro along with a 44% reduction in number compared to
the control subjects, where the difference was inversely correlated to glycated
hemoglobin levels [77]. Likewise, when the researchers cultured ECFCs from diabetic
patients and mice in a normoglycemic environment, the cells remained dysfunctional and
were unable to support HSCs to give rise to colony-forming units [75, 77]. It is possible
that ECFCs, unlike stem cells that have restored function upon culturing in a normal
environment, remain dysfunctional in a normoglycemic environment due to impairment
of the intrinsic signalling of the cell and/or dysfunctional ECFCs in diabetes not
responding to external signals.

1.4.2

Mesenchymal progenitor cells

Mesenchymal progenitor cells (MPCs) are multipotent cells that may also be derived
from the CD133-positive cell population in humans [66]. These cells are also called
mesenchymal stem cells, mesodermal stem cells, and multipotent stromal cells (MSCs)
[78]. However, no studies to date have shown self-renewing capacity in these cell types.
Furthermore, the term ‘stromal’ may be misleading and point to a supportive role of these
cell types, which, depending on the cell and process of interest, may not be the case. For
these reasons, our laboratory has termed these cells as MPCs [79]. These cells have been
found in various tissues, but bone marrow is the main source for isolating multipotent
MPCs [80, 81]. They are a heterogeneous population of cells that exhibit the ability to
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differentiate in vitro into mesenchymal lineages (adipocytes, osteoblasts, and
chondrocytes) [79]. The minimal criteria to define cells as MPCs are: 1) cells must be
adherent to plastic under standard culture conditions, 2) express CD105, CD73, and
CD90, 3) lack CD45, CD34, CD14 or CD11B, CD79A or CD19 and human leukocyte
antigen (HLA)-DR, and 4) differentiate into osteoblasts, adipocytes and chondrocytes in
vitro [82].
As MPCs give rise to cells of mesenchymal lineages of the bone marrow niche,
osteoblasts and adipocytes (Figure 1-2), they have been extensively studied in the
diabetic setting. We have shown that MPCs differentiate into adipocytes more readily
when exposed to high glucose conditions, which is demarked by a significant induction
of adipogenesis-associated transcription factor, PPARG [45]. In contrast, RUNX2 and
SP7, genes involved in osteogenesis induction, are significantly reduced in the same high
glucose culture conditions [45]. Other studies have shown that chondrogenic
differentiation is also impaired with high levels of glucose [83]. This suggests that high
levels of glucose enhance adipogenic lineage differentiation, while inhibiting osteogenic
and chondrogenic differentiation of MPCs (Figure 1-3). This is very interesting as
increased marrow adiposity is frequently observed clinically in both type 1 and type 2
diabetic patients and in animal models of diabetes [45, 58, 84]. Associated with increased
bone marrow adiposity, a reduced number of MPCs can be suspected. However, MPCs
that were identified as CD34-CD45-CD14-CD90+CD73+CD105+ were shown to be
unaffected in type 2 diabetic patients compared with the non-diabetic controls [58]. These
studies suggest that diabetes does not deplete the pool of MPCs but skews their
differentiation into adipocytes, at the expense of osteoblasto- and chondro-genesis.
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Figure 1-3: Effect of high levels of glucose on non-hematopoietic, mesodermal stem
cells.
Experimental evidence collected in our laboratory suggests that high levels of glucose
(HG; 25 mmol/L in vitro) do not alter the derivation of ECFC and MPC from marrow and
circulating stem cells. However, HG skews the differentiation of MPCs to adipocytes,
while inhibiting differentiation of cells into other mesenchymal lineages, such as
osteoblasts and chondrocytes [grey diamond arrowheads indicate inhibition]. [SC: stem
cell; ECFC: endothelial colony-forming cell; MPC: mesenchymal progenitor cell].
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1.5
1.5.1

Cellular composition changes in bones in diabetes
Bone and the marrow

Bone homeostasis is critical for maintaining the skeleton, which is the framework of the
body that provides major functions, including support, red blood cell production, and
endocrine regulation. The structure of long bones includes the cortical bone, the
trabecular bone and the bone marrow. The cortical bone is the dense, white, solid outer
structure that is responsible for rigidity and surrounds the marrow space. It makes up
80% of the adult human skeleton. The trabecular bone is the internal tissue of the bone
that is typically highly porous and weaker compared with the cortical bone. The cellular
form of bone interspersed in the marrow is metabolically active and makes up the
remaining 20%.
Bone is a specialized and dynamic tissue that remodels throughout life. Remodelling is
the process where old bone is resorbed and new bone is formed to maintain bone strength
and mineral homeostasis. The key cell types involved in bone remodelling are osteoblasts
and osteoclasts. Osteoblasts are of mesenchymal origin and are responsible for
synthesizing the new bone matrix and its subsequent mineralization. In contrast,
osteoclasts are of hematopoietic origin that are responsible for bone matrix resorption. In
brief, the remodelling cycle consists of four phases: activation, resorption, reversal, and
formation. The activation phase involves recruiting preosteoclasts to anchor to the bone
matrix; resorption phase involves osteoclasts secreting different factors, including
hydrogen ions to digest the organic matrix; reversal phase is where bone resorption
transitions to bone formation; and formation phase is where osteoblasts synthesize new
bone matrix and regulate matrix mineralization. During the bone formation phase,
osteoblasts may become buried within the matrix to become osteocytes, the cells that act
as mechanosensors that facilitate intercellular communication. The balance of osteoblasts
and osteoclast function is critical for maintaining proper bone homeostasis [reviewed in
[85, 86]].
Skeletal fragility has been identified as a complication of diabetes. Elevated blood
glucose is known to have negative effects on bone and increase the risk of bone fractures
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[87]. Briefly, bone formation has been reported to be reduced in animal models of
diabetes and in patients with type 1 diabetes. Streptozotocin-induced diabetic rats had a
reduced osteoprogenitor pool in the bone marrow and decreased ability to mineralize new
bone [88]. Hence, this reduction in the progenitor pool was likely implicated with
impaired osteoblastogenesis in diabetic animals. The decrease in size of the
osteoprogenitor pool coupled with the lack of insulin and low levels of insulin-like
growth factor 1 (IGF1) prevented terminal differentiation of cells to osteoblasts and
stunted skeletal growth, which resulted in a lack of peak bone mass [89-92]. Previous
studies have also found an increase in bone fragility [93] and cortical porosity [94] in the
diabetic rat model. In type 2 diabetes, chronic inflammation and associated microvascular
disease negatively affected bone tissues that increased the risk of bone fractures
[reviewed in [95]].
As mentioned earlier, primitive HSCs are found near osteoblasts (endosteal niche), while
actively dividing cells reside closer to the central marrow regions [51-53]. These studies
highlight that the osteoblasts create a supportive microenvironment that signals and
maintains stem-ness. However, in diabetes, the marrow microenvironment is altered. In a
model of type 1 diabetes in mice (streptozotocin induction), reduced bone and marrow
volume fractions have been observed, along with increased fat accumulation [84]. The
marrow vascular density was also significantly decreased in type 1 diabetic mice with
increased permeability and cell apoptosis. Possibly resulting from this remodelling
alteration, immunohistochemical staining of tissues has shown a reduced number of Sca1+c-Kit+ stem cells, particularly at the osteoblastic niche [84]. This finding shows that
diabetes may alter the primitive stem cells [96], but likely through an indirect mechanism
involving the stem cell niche. Interestingly, the distance of these stem cells from the
osteoblastic niche to sinusoids was longer in the marrow of type 1 diabetic mice
compared with the non-diabetic controls [84], which may, in part, be due to increased
adipocytes in-between. These marrow remodelling alterations are also evident in type 2
models of experimental diabetes and in human type 2 diabetes. Specifically, decreased
bone and marrow volume fractions were evident with reduced vascular density in the
marrow, which were further compromised when diabetic patients exhibited critical limb
ischemia [42, 58]. Overall, it is quite clear that bone marrows of diabetic patients and
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experimental animals have less bone and vascular density, coupled with adipocyte
accumulation.
Bone marrow adipose tissue constitutes over 10% of the total fat mass in healthy
individuals [97]. However, marrow adiposity increases with various pathophysiological
conditions, including ageing [98] and diabetes [42, 58]. While bone marrow adipocytes
resemble the morphological properties of white adipocytes in subcutaneous adipose
tissue, bone marrow adipocytes have distinct lipid metabolic features compared with
white adipocytes [99]. Enhanced adipogenesis in the marrow raises an important question
as to how these adipocytes may interact with stem cells and other marrow-resident cells.
It is well-known that adipocytes secrete various proteins, including adiponectin. But
adiponectin expression does not always correlate with adiposity. For example,
experimental models of obesity show reduced adiponectin levels [100, 101]. Reduced
adiponectin expression has been associated with insulin resistance [102]. Moreover,
expression of adiponectin is significantly decreased in obese subjects and circulating
adiponectin has been associated with a lower risk for type 2 diabetes [103-106]. These
studies suggest that reduced adiponectin, despite increased adipocyte depots, may be
involved in pathological alterations in diabetes. Interestingly, adiponectin has positive
effects on ECFCs. Adiponectin administration reverses high glucose-induced ECFC
impairment and senescence by increasing the activity of endothelial nitric oxide synthase
[107]. In addition, adiponectin deficiency has been shown to enhance adipocytes and
Nestin+ cells in the marrow [108].
In summary, research has shown that diabetes and the persistent hyperglycemic
environment directly damage the cellular components in the bone marrow [84].
Specifically, bone marrow is significantly remodelled in diabetes with increased fat
deposition and decreased bone and marrow volume fractions [42, 58]. Furthermore,
diabetes reduces vascular density in the marrow while inducing bone marrow
microangiopathy [58, 84]. Our laboratory has suggested that these changes in the marrow
cause various alterations to stem cells and their microenvironment, which may affect the
endogenous self-repair capabilities of stem cells.
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1.5.2

Mechanisms regulating adipogenesis and osteogenesis

1.5.2.1 Adipogenic differentiation mechanisms
The mechanisms of adipocyte differentiation have been extensively investigated.
Adipogenesis is regulated by a network of transcription factors that coordinate the
expression of proteins responsible for establishing a mature adipocyte phenotype
[reviewed in [109]]. The current understanding of adipogenesis is largely derived from
mouse preadipocyte cell lines [110] and is described as a two-phase process: 1)
determination phase, and 2) differentiation phase [as reviewed in [111]]. The
determination phase is where precursor cells are committed to the adipocyte lineage,
expressing early adipogenic transcription factors to facilitate the expression of
peroxisome proliferator-activated receptor gamma (PPARG) and CCAAT-enhancerbinding protein alpha (CEBPA). This phase also includes a mitotic clonal expansion of
the cells. Following this phase, the differentiation phase occurs where the pre-adipocyte
adopts characteristics of a mature adipocyte, such as storing lipid droplets through
induction of lipid transporters in a mechanism involving PPARG and CEBPA
cooperation. Adipogenesis in human cells seems to closely follow that from preadipocyte cell line studies [112]. Together, adipogenesis is regulated by a network of
transcription factors, with CEBPA, CEBPB, CEBPD, and PPARG being the key players
[81].
PPARG is well-positioned as the master regulator, obligatory transcription factor, or
initiator of adipogenesis. Without PPARG, cells cannot undergo adipogenesis [113].
Additionally, gain-of-function studies where Pparg was ectopically expressed in mouse
fibroblasts showed emergence of mature adipocytes [114, 115]. PPARG is expressed as
two major protein isoforms, PPARG1 and PPARG2, as a result of alternate promoter
usage and splicing. PPARG2 is identical to PPARG1 with the addition of 30 amino acids
at the N-terminus [114]. PPARG1 is expressed in many tissues, but PPARG2 expression
is restricted almost exclusively to the adipose tissue [114, 116]. No other factor has been
discovered to promote adipogenesis in the absence of PPARG, confirming its critical role
in adipogenic differentiation [117].
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CEBPs are basic leucine zipper transcription factors that play an important role in
adipogenesis. In adipogenic differentiation of the 3T3-L1 preadipocyte cell line, CEBPB
and CEBPD are expressed in the early determination phase of adipogenesis before
CEBPA [112, 118]. This expression of CEBPB and CEBPD activates transcription of
CEBPA and PPARG to produce a mature adipocyte [119]. Cells in culture lacking
CEBPB and CEBPD failed to express CEBPA and PPARG [120]. However, in vivo,
induction of CEBPA and PPARG was observed without the expression of CEBPB and
CEBPD, although adipogenesis was impaired [121]. These findings suggest that there is
redundancy in the early steps of adipogenesis. Once CEBPA and PPARG2 are expressed,
these factors create a positive feedback loop to reinforce and maintain the terminally
differentiated state of adipocytes [117, 122].

1.5.2.2 Osteogenic differentiation mechanisms
Osteogenesis from marrow-derived progenitor cells has also been extensively studied.
The master transcriptional regulator of osteogenesis is RUNX2. Mice with Runx2
homozygous mutation exhibited an absence of ossification [123]. Additionally, Runx2-/embryos and newborns displayed dwarfism and the absence of calcification of the
skeleton. Although Runx2-deficient calvarial cells did not differentiate into osteoblasts,
they retained the ability to differentiate into chondrocytes and adipocytes [124].
Moreover, Runx2 gene transfer enhanced the osteogenic activity of MPCs in vitro and in
vivo [125]. These studies provided evidence that RUNX2 is essential for osteoblast
differentiation and osteogenesis [123, 126]. In addition to RUNX2, the transcription
factor SP7, also known as Osterix, acts downstream of RUNX2. SP7 is also important for
proper osteoblast maturation as it is required for intramembranous and endochondral
ossification [127].
Currently, the model for osteoblastogenesis begins with RUNX2 expression in MPCs to
form committed osteoprogenitors. These bipotential progenitor cells can differentiate into
chondrocytes or osteoblasts; however, when SP7 is induced, the osteoprogenitors become
pre-osteoblasts that can deposit matrix. Upon maturation of the pre-osteoblasts, the cells
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can express functional osteoblast marker genes, including osteocalcin (BGLAP) [127,
128]. Osteocalcin is one of the most abundant non-collagenous proteins present in bone.

1.5.2.3 Role of Wnt signalling pathway in adipo- and osteo- lineage
Wnt signalling pathway is an ancient and evolutionarily conserved pathway that regulates
cell fate determination. ‘Wnt’ is called as such because of fusing the name of the
Drosophila segment polarity gene wingless and the name of its vertebrate homolog,
integrated or int-1. Wnt pathway activation has been shown to regulate the balance of
adipogenic and osteogenic differentiation. The central player of the Wnt pathway is
Catenin beta-1 (CTNNB1), a transcription factor that regulates cell proliferation and
differentiation [129]. The canonical Wnt/CTNNB1 signalling is inactive in the absence of
the secreted lipid-modified Wnt ligand proteins. In the absence of Wnt ligands, CTNNB1
is degraded by the destruction complex composed of glycogen synthase kinase-3 beta
(GSK3B), axin, casein kinase 1, and adenomatous polyposis coli [130]. Degradation
prevents CTNNB1 from translocating to the nucleus and regulating the expression of
target genes. However, when Wnt binds to its receptor, Frizzled (FZD), it complexes with
a co-receptor, low-density lipoprotein receptor-related protein 5/6 (LRP5/6). This
complex recruits dishevelled (Dvl) then axin and inhibits the destruction complex from
degrading CTNNB1. CTNNB1 then translocates to the nucleus to activate Wnt target
genes with the T cell factor/lymphoid enhancer factor (TCF/LEF) family of proteins
[reviewed in [131]]. Wnts can also activate the non-canonical, CTNNB1-independent
pathway that is further subdivided into the planar cell polarity (PCP) pathway and the
Wnt/Ca2+ pathway [reviewed in [132]]. These non-canonical Wnt signalling proteins can
regulate transcription to antagonize canonical CTNNB1 signalling [133].
In pre-adipocytes, canonical Wnt signalling has been shown to be suppressed as cells
differentiate into mature adipocytes. The expression of Wnt10b, Wnt receptors (Fzd1,
Fzd2, Fzd5, Lrp5, and Lrp6), Ctnnb1, and Ccnd1 also decrease with increased levels of
Cebpa [134]. Other studies have also supported this inverse relationship between
canonical Wnt signalling and adipogenic differentiation of cells [135]. 3T3-L1 cells
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overexpressing Wnt1 blocked the induction of CEBPA and PPARG, with increased
CTNNB1 expression [134-136]. Canonical Wnt signalling activity has also been shown
to play a role in osteoblastic differentiation. Bone marrow-derived MPCs isolated from
neonatal rats were incubated with lithium chloride, a GSK3B inhibitor. This enhanced the
activation of canonical Wnt signalling, leading to a significant increase of CTNNB1,
RUNX2, and collagen type I alpha 1 chain (COL1A1), whereas it significantly decreased
PPARG and CEBPA [137]. Moreover, Wnt10b-expressing ST2 cells, a stromal cell line
derived from the mouse bone marrow expressing a canonical Wnt ligand, induced
expression of an osteoblast transcription factor, Runx2, while inhibiting Pparg [138].
Additionally, a mouse model and culture studies using mouse embryonic fibroblasts
displayed increased Runx2 expression promoter activity with canonical Wnt signalling
activation [139]. Similar effects were also found in animal studies. Using a transgenic
mouse model, expression of Wnt10b from the fatty acid binding protein 4 (FABP4)
promoter increased trabecular bone mass [138, 140]. In contrast, Wnt10b-/- mice
displayed decreased bone mass and bone volume fraction. Moreover, Wnt10b transgenic
mice, where Wnt10b is under the control of Fabp4, displayed less subcutaneous (50%
less), epididymal and perirenal (60% less) adipose tissues compared with the wild-type
mice [140]. Also, the transgenic mice showed improved glucose tolerance and insulin
sensitivity, which has been suggested to be due to reduced inflammation in adipose tissue
[141]. These results suggest that the activation of the canonical Wnt signalling pathway
regulates MPC differentiation; specifically, hinders adipogenic differentiation, while
enhancing osteogenic differentiation [138, 142].

1.5.2.4 Transforming growth factor signalling pathways in adipo- and osteodifferentiation
The transforming growth factor-beta (TGFB) superfamily is comprised of TGFBs, bone
morphogenetic proteins (BMPs), activins, nodal and other related proteins.
TGFB receptors (TGFBRs) are single-pass transmembrane serine/threonine kinases.
There are two types: TGF-beta receptor type-1 (TGFBR1) and TGF-beta receptor type-2
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(TGFBR2). TGFBR2 are constitutively active and can auto- and trans-phosphorylate
TGFBR1 to form a heteromeric complex for further activation by the three TGFB
ligands, TGFB1-3. Although TGFB1 is the most abundant, universally expressed and
widely studied isoform, all three ligand isoforms signal similarly by cell surface receptors
and have similar cellular targets. The complex of TGFBs and its receptors recruits and
phosphorylates canonical receptor-regulated SMADs (R-SMADs, for example,
SMAD2/3 in the TGFB/Activin/Nodal branch, and SMAD1/5/8 in the BMP branch). RSMADs then associate with its common (co-) SMAD4. This SMAD complex can then
translocate into the nucleus and regulate the transcription of TGFB target genes [143]. In
addition to the canonical SMAD pathway, TGFB signalling can induce the noncanonical, SMAD-independent pathways [144-146]. These signalling pathways include
mitogen-activated protein kinases (MAPKs: ERK, JNK, p38) and PI3K-Akt signalling
[reviewed in [147]]. Although many downstream proteins have been identified to
associate with the TGFB receptor complex, the exact mechanism of the cooperation
between the canonical (SMADs) and non-canonical (non-SMADs) signalling pathways
are unclear. BMP signalling also signals through both canonical and non-canonical
pathways. The main difference from the TGFB signalling is that BMP ligand-receptor
complex phosphorylates SMAD1/5/8 for canonical signalling. In addition, SMAD6
(inhibitor-SMAD; I-SMAD) negatively regulate BMP signalling specifically, whereas
SMAD7 negatively regulates the TGFB branch [reviewed in [148]].
TGFB/BMP signalling has been previously identified to regulate adipogenesis and
osteogenesis. Extensive studies have investigated the role of TGFB in regulating bone
formation. In vitro, TGFB1 inhibits alkaline phosphatase (ALP) expression in the clonal
murine calvaria-derived MC3T3-E1 cells [149]. Similarly, another study also observed
that TGFB1 (above 0.0001 ng/mL) inhibits ALP activity, especially at high
concentrations (0.1 - 10 ng/mL), under serum-containing conditions. However, bi-phasic
effects were observed with ALP activity, where the low concentration of TGFB1 (0.001
ng/mL) stimulated ALP activity under serum-free conditions in MC3T3-E1 cells [150].
In vivo, however, TGFB1 administration directly onto the periosteum of parietal bones of
neonatal rats simulated local bone formation [151]. In rat osteoblastic cell line, ROS
17/2.8, the addition of TGFB1 in culture (0.2 ng/mL) increased ALP activity [152].
24

Similar to the TGFB pathway, many studies have supported the positive role of BMP2 on
osteoblasts. When mouse myoblast cell line, C2C12, was cultured in the presence of
BMP2 for 6 days, multinucleated myotube formation was inhibited [153]. However, over
90% of the cells were ALP-positive cells, suggesting that BMP2 skewed the
differentiating potential from myogenic to osteoblastic lineage. Interestingly, the effect of
BMP2 was reversible, as the BMP2-exposed ALP-positive cells that were further
maintained for 12 days in the absence of BMP2, reverted to myogenic lineage by
expressing troponin T, a marker of muscle cells. Interestingly, the combination of TGFB1
and BMP2 has shown to have an additive effect compared with BMP2 alone. In vivo,
TGFB1 further enhanced ectopic bone formation in mice compared with ectopic bone
formation induced by BMP2 alone, confirmed by micro-computed tomography (microCT) imaging after 14 days of treatment [154]. In human maxilla teeth bone cells, the
addition of TGFB1 increased BMPR1B mRNA expression after 24 hours in vitro [155].
With suboptimal TGFB1 pre-treatment for 24 hours followed by BMP2 for 30 minutes,
the bone cells increased phospho-SMAD1/5/8 levels. Furthermore, ALP activity was
significantly increased. These data suggest that TGFB1 can alter the downstream
signalling cascade by inducing various TGFB-superfamily receptors, such that it can have
additive/synergistic effects when given together.
TGFB has also been reported to inhibit adipocyte formation [156-158]. In 3T3-L1
preadipocytes, TGFB exposure (even a transient 4-hour exposure) immediately before the
differentiation phase was sufficient to prevent adipogenic differentiation [158].
Additionally, in NIH3T3 fibroblasts that overexpressed CEBPB and CEBPD, TGFB was
effective in inhibiting the transcription factor activity. Specifically, SMAD3 that was
induced with TGFB was effective at repressing transcriptional activation of Cebpb,
Cebpd, and Cebpa [157]. Other ligands that signal via the SMAD2/3 pathway have also
been shown to inhibit adipogenic differentiation of cells. For example, 3T3-L1 and
C3H10T1/2 MPC cell lines exposed to BMP3 failed to undergo adipogenic
differentiation as BMP3 activated the SMAD2/3 pathway in both cell lines [159].
Moreover, growth/differentiation factor 10 (Gdf10; also known as BMP3b) knockdown
in 3T3-L1 preadipocytes using siRNA significantly induced Fabp4 and Pparg. In
contrast, the overexpression of the Gdf10 gene significantly reduced the mRNA levels of
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the adipogenesis-associated genes [160]. Additionally, transgenic mice overexpressing
GDF10 in adipose tissues displayed improved glucose tolerance and insulin sensitivity
when fed a high-fat diet. The transgenic mice were also protected from high-fat dietinduced obesity with enhanced energy expenditure [161].
Adding to the complexity of TGFB pathway signalling, studies have shown that the
SMAD1/5/8-mediated pathway may induce adipogenic differentiation in cells.
Constitutively active BMP receptor 1 (BMP receptor 1A, BMPR1A; and BMP receptor
1B, BMPR1B) that activated the SMAD1/5/8 pathway in C3H10T1/2 cells induced
adipogenic differentiation without any BMP ligand [162]. Additionally, BMP4 also
induced adipogenic differentiation of C3H10T1/2 cells by the SMAD1/5/8 pathway
[162]. Interestingly, BMP4 and BMP7 pre-treated C3H10T1/2 cells implanted
subcutaneously into athymic nude mice developed into a heterogeneous population
containing both uncoupling protein 1 (UCP1)-positive brown adipocytes and unilocular
white adipocytes [163]. Collectively, these studies suggest that BMP ligands that signal
through SMAD1/5/8 induce adipogenic differentiation. Additionally, BMP4 has been
shown to regulate the stem cell niche. A mouse model that contains a point mutation to
decrease the amount of mature BMP4 ligand displayed a significant reduction in the
number of Lin-Sca-1+Kit+ HSCs in the femur. Moreover, wild-type HSCs transplanted
into a BMP4-deficient host displayed reduced functional activity to self-renew [164].
Therefore, not only is BMP4 a regulator of differentiation, but it may also be an
important stem cell niche factor.
An interesting non-canonical mediator of the TGFB pathway is TGFB-activated kinase 1
(TAK1; also known as MAP3K7). TAK1 can be activated by numerous stimuli,
including TGFB, BMP, interleukin-1 beta (IL1B) and tumor necrosis factor (TNF), and is
an important regulatory molecule in cell survival, development, tissue homeostasis, and
immune signalling pathways [reviewed in [165]]. In cells, TAK1 can be found as a
heterotrimeric complex as it is bound constitutively to TAK1-Binding Protein 1 (TAB1),
an adaptor protein, and to either TAB2 or TAB3. Once activated, TAK1 can activate
other MAPKs (such as P38 and JNK), and nuclear factor NF-kappa-B (NFKB)
transcription factor. Interestingly, in the bone marrow, TAK1 knockout, which led to the
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inactivation of JNK signalling, resulted in bone marrow failure with significant loss of
hematopoietic cells with intrinsic defects [166]. This suggests that activation of TAK1JNK in hematopoietic cells provides pro-survival cues [166]. Moreover, TAK1 has been
shown to interact with R-SMADs, I-SMADs, and co-SMAD4 [167]. Interestingly, active
TAK1 affects the intracellular distribution of SMADs where cytoplasmic accumulation
was predominant as opposed to nuclear translocation after activation [167]. By interfering
with the nuclear accumulation of activated SMADs, TAK1 activation interfered with
BMP2-induced SMAD1-mediated osteoblast differentiation in C3H10T1/2 cells [167].
These studies suggest that the balance of canonical and non-canonical TGFB signalling
pathways may be important in adipo- versus osteo- differentiation in cells.

1.5.2.5 Other potential mechanisms
Besides the signalling mechanisms highlighted above, other potential pathways have also
been shown to be involved. The epidermal growth factor receptor (EGFR), fibroblast
growth factor (FGF), and insulin-like growth factor (IGF) signalling pathways have all
been shown to play a role in MPC differentiation and, therefore, will be elaborated
below.
EGFR signalling has been noted for playing a role in proliferation and differentiation of
MPCs. Upon epidermal growth factor (EGF) binding to its receptor, intracellular signals
are activated, including the extracellular-regulated kinase (ERK) and AKT pathways.
With regards to osteogenic differentiation, it has also been shown that weak and temporal
EGFR signalling (by soluble EGF) has an anti-osteogenic effect, whereas a strong and
sustained EGFR signalling (by a tethered EGF) has a pro-osteogenic effect on
immortalized and primary MPCs [168]. In support of these in vitro findings, EGFR
deletion significantly decreased the trabecular bone mass of the tibia, which was coupled
with an increase in osteoclast number [169]. Another study showed that EGFR-deficient
mice have delayed endochondral ossification due to dysfunctional osteoclast and
osteoblast recruitment [170]. On the other hand, constitutively active EGFR presented an
increase in trabecular and cortical bone content [169]. EGFR signalling has also been
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investigated with regards to adipogenic differentiation. EGF at low concentration (1
nmol/L) enhanced adipogenic differentiation of 3T3-L1 preadipocytes when added in
culture after 6 days. However, at a high concentration (10 nmol/L) of EGF, adipogenic
differentiation was reduced [171]. Interestingly, the timing of when the cells were
exposed to EGF presented different outcomes as EGF at 1 nmol/L added at the start of
when the preadipocytes were cultured significantly reduced adipogenic differentiation
[171]. These in vitro findings suggest that EGF has a biphasic effect, where EGF inhibits
preadipocytes from undergoing adipogenic differentiation, whereas it promotes
adipogenic differentiation of preadipocytes that have already started this process. When
EGF was administered subcutaneously to newborn NCI-Black-Reiter (NBR) rats for 10
days, these rats exhibited significantly decreased body weight and fat pad weight in a
dose-dependent fashion (0.3 - 1 µg/g of weight) [172]. Although it is difficult to
determine how much of the dose reaches the adipose tissue, the dose that was
administered may be targeting the preadipocytes to prevent the start of adipogenic
differentiation. These findings suggest the importance of signalling intensity and the
timing of EGFR signalling activation on the overall effect of the EGFR signalling
pathway.
FGF signalling is also critical for development, tissue repair and homeostasis. FGF
ligand-receptor dimerization activates downstream signalling pathways that include
MAPK, PI3K/AKT pathway, and the phospholipase C gamma (PLCG) pathway
[reviewed in [173]]. FGFR signalling is important in osteoblasts for increased cell
proliferation and bone formation [reviewed in [174]], and any aberration of the signalling
pathway results in skeletal malformations. For instance, fibroblast growth factor 2 (Fgf2)
null mice displayed a significant reduction in femur bone volume density and trabecular
number. Specifically, the reduction of bone mineral density was evident after 5 months of
age in the female mice [175]. Moreover, cells isolated from Fgf2–/– mice had reduced
ability to differentiate into osteoblasts compared with cells from the wild-type mouse
[176]. In support of this, human MPCs cultured with FGF2 increased their ability to
induce higher bone formation [177]. Interestingly, Fgf2–/– mice also displayed enhanced
marrow adiposity of the tibia at 20 months of age [175]. Further in vitro examination of
the bone marrow-derived MPCs from these mice at 5 and 14 months of age displayed a
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significant reduction in osteogenic differentiation, while this was normalized with the
addition of exogenous FGF2 [175]. Coupled with this reduction in osteogenic
differentiation, cells from the Fgf2–/– mice displayed significantly increased levels of
adipogenesis-associated genes (Cebpa, Pparg, and Fabp4) when the cells were exposed
to rosiglitazone, a PPARG agonist [175]. Interestingly, the addition of FGF2 to
rosiglitazone significantly reduced Oil Red O-stained neutral lipids compared to
rosiglitazone alone [175].
IGF signalling is important for growth as the primary mediator of the effects of the
growth hormone. IGF signalling has also been noted to play an important role in bone
mass. In a previous study, changes in Igf1 and Igf2 levels were observed in rat osteoblast
cultures [178]. The study categorized osteogenic differentiation into three phases: 1)
proliferation (day 0 to 11), 2) matrix maturation (day 11 to 20), and 3) mineralization
(day 20 to 26) [178]. From examining the osteoblast cultures undergoing a developmental
sequence, Igf1 and Igf2 levels peaked at day 11 and decreased subsequently until day 26
[178]. Interestingly, IGF1 protein secretion by osteoblast cultures showed a different
pattern, where it was the lowest at day 11 and increasing in concentration until day 26
[178]. These findings suggest that IGF1 is required for osteoblast precursors to
differentiate into osteoblasts in culture. To support this, Igf1 knockout mice displayed a
significant size reduction compared to wild-type littermates at 4 months. Moreover, the
tibia size and cortical thickness were significantly reduced [179]. Disruption to the Igf1
gene in female mice caused a significant reduction in the osteoblast number and
trabecular thickness, and an increase in the trabecular spacing in the femurs.
Interestingly, IGF1 concentration in the marrow of aged rats was lower than in young
rats, which was directly correlated with an age-related reduction in bone mass. This was
also seen in humans, where IGF1 levels in the bone marrow were significantly lower in
individuals with osteoporosis [180]. On the other hand, IGF1 has also been shown to
promote adipogenic differentiation of the cultured stromal vascular fraction cells from
human adipose tissue. Interestingly, when IGF1 was encapsulated in a scaffold that
sustainably released IGF1 for 4 weeks in the inguinal fat pad of mice in vivo,
adipogenesis was also enhanced [181]. These findings suggest that IGF1 can work to
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enhance adipogenesis and osteogenesis depending on the cellular context and signals that
may be available.
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1.5.3

Previous studies supporting bone marrow dysfunction in diabetes as a
potential unifying mechanism

Unlike mature vascular endothelial cells that are affected by high levels of glucose, our
laboratory has found that CD133-selected stem cells that yield ECFCs are resistant to
glucose toxicity [45]. However, despite this resistance, a sub-population of CD133expressing stem cells is significantly depleted in diabetes [42, 58]. Specifically,
CD133+CD45- vascular regenerative stem cells (putative mesodermal stem cells) are
significantly decreased in type 2 diabetic patient samples, whereas CD133+CD45+ HSCs
remain unaffected [42]. Similarly, Spinetti and colleagues have shown that CD45precursor cells are significantly depleted in the marrow of type 2 diabetic patients,
whereas the CD45+ population remains unaffected [58]. There is also evidence that
suggests that diabetes affects HSCs by impairing mobilization that may result in the
reduction of HSCs number in the peripheral blood [56, 182].
Depletion of vascular regenerative stem cells is an interesting finding in diabetes, as these
stem cells are capable of differentiating into MPCs and endothelial cells [45]. We believe
that the depletion of these unique stem cells is associated with the altered cellular
composition of the marrow with enhanced adipogenesis and impaired osteoblastogenesis
[45]. Bone marrow-derived MPCs (bm-MPCs) exposed to high levels of glucose readily
differentiate into adipocytes [42]. Our findings complement pre-clinical and clinical
findings. Pre-clinical data confirm increased marrow adiposity in animal models of
diabetes [84, 183]. Clinically, diabetic patient bone marrows show more adipocytes and
less marrow and bone fraction [42, 58]. Moreover, our laboratory has shown that when
CD133+ stem cells are directly co-cultured with adipocytes in vitro, stem cell markers,
such as NANOG and OCT4, are significantly decreased leading to loss of stem cell
phenotype [184]. Collectively, these findings suggest that the change in bone marrow
cellular composition may influence vascular regenerative stem cells, leading to the
depletion of these cells. This stem cell depletion may help to explain why diabetic
patients experience vascular dysfunction and inadequate repair mechanisms leading to
diabetic complications. Hence, investigating the mechanisms to preserve these stem cells
are of great interest to combat diabetic complications.
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1.6

Thesis overview

Diabetic patients develop vascular complications that lead to selective target organ
damage. Identifying stem and progenitor cells in the bone marrow that can repair the
vascular damage in diabetic patients is a promising approach to enhance endogenous
repair mechanisms in patients. Accumulating evidence shows that there is selectivity in
how various stem cell populations are affected in diabetes. For example, hematopoietic
stem cells in the bone marrow are reported to be unaffected in diabetes, whereas
vasculogenic (vascular regenerating) mesodermal stem cells are depleted [42, 58].
Previous studies in human diabetes have shown increased marrow adiposity [45, 58].
This changing cellular composition of the bone marrow may deplete blood vesselforming precursor cells potentially through 1) direct reduction of the stem cell pool
through inductive signals from ever-increasing adipocytes, or 2) indirect exhaustion of
these stem cells to replenish the mesenchymal progenitor cells or committed cells known
to differentiate into adipocytes. Although there is no convincing evidence currently to
suggest one mechanism over another, the endpoints are clear: sustained hyperglycemia
leads to significant marrow remodelling that negatively regulates the mesodermal stem
cell microenvironment. Therefore, understanding how to maintain marrow homeostasis in
diabetic patients to preserve endogenous mesodermal stem cells is an attractive area for
research to prevent diabetic complications that arise.
The fundamental questions at the core of this dissertation are whether enhanced bone
marrow adiposity depletes the regenerative vasculogenic stem cells in diabetes, and
whether inhibiting adipogenesis preserves these stem cells and vascular homeostasis.
Therefore, I investigated pathological changes in the bone marrow in experimental
diabetes and explored means of inhibiting adipogenesis and potential consequences to the
cellular composition of the bone marrow.
In Chapter 2, my aim was to understand how diabetes affects the bone marrow. My
studies consisted of the following:
1. characterization of the early changes in bone marrows of diabetic mice, and
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2. staging diabetes-induced changes in the bone marrow in relation to other known
diabetic complications.
In Chapter 3, I explored the functional consequence of early diabetes-induced bone
marrow changes by utilizing an in vitro model of bone marrow-derived cell
differentiation. For this study, my aims were to
1. identify potential regulators of directed adipogenic differentiation of bone marrow
mesenchymal progenitor cells,
2. determine the role of transforming growth factor-beta signalling pathway in
adipogenic differentiation of bone marrow mesenchymal progenitor cells, and
3. examine the crosstalk between transforming growth factor-beta pathway and other
known pathways that regulate adipogenic differentiation of cells.
In Chapter 4, I tested the effect of a known adipogenesis inhibitor on potentially
normalizing enhanced diabetes-induced marrow adiposity. My studies consisted of the
following:
1. exploring the effect of adipogenesis inhibitor administration on tissue
histopathology in mice, and
2. investigation of the effect of adipogenesis inhibitor on diabetes-induced bone
marrow alterations in mice.
Collectively, the results from my studies 1) identified early pathogenetic changes in the
bone marrows of diabetic mice, 2) identified the potential signalling mechanisms leading
to enhanced bone marrow adipogenesis in diabetes, and 3) demonstrated that a common
adipogenesis inhibitor is ineffective in preventing diabetes-induced adipogenesis in the
marrow. These results have provided novel insight into a previously under-appreciated
diabetic complication and identified new targets for the development of therapeutic
approaches.
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Chapter 2
2

Discovery of early bone marrow changes in a streptozotocin-induced
diabetic mouse model

2.1

Introduction

The global prevalence of diabetes has been steadily increasing worldwide. In 2015, the
prevalence in adults was estimated to be 8.8% and projected to rise to 10.4% by the year
2040 [1]. Furthermore, 16.2% of live births in 2015 were associated with hyperglycemia
during pregnancy, and the incidence of diabetes among youths has also significantly
increased in recent years [1, 2]. Diabetes poses a substantial burden on the health care
system due to challenges associated with managing various secondary complications.
These complications include retinopathy, cardiomyopathy, nephropathy, and
atherosclerosis. More recently, human diabetes and experimental models of the disease
have shown that the bone marrow may also be a target organ of diabetic complications
[3-5].
We and others have previously observed enhanced bone marrow adiposity coupled with
stem cell loss in the marrow of diabetic patients [6, 7]. Bone marrows of streptozotocin
(STZ)-induced diabetic mice mimic human diabetes and show bone marrow adiposity [8,
9]. There are a number of fundamental unanswered questions in this emerging new
diabetic complication: 1) what are the mechanisms that cause enhanced bone marrow
adipogenesis in diabetes, 2) what is the consequence of enhanced bone marrow
adipogenesis on resident stem cell function in diabetes, and 3) when do these bone
marrow alterations take place, in relation to other complications of diabetes. Answering
these questions requires an experimental model of diabetes that recapitulates human
diabetes. Researchers have used a number of different rodent models to provide critical
insight into diabetic complications [10]. Among the various models of diabetes, STZinduced diabetic mice and rats are the most well-established and recommended by the
Animal Models of Diabetic Complications Consortium (http://www.diacomp.org). Using
this chemically induced diabetes model, researchers have shown a precise timeline of
pathological changes in target organs. For example, for diabetic retinopathy, astrocyte
activation and gliosis take 4-5 weeks of diabetes onset [11, 12]. Retinal ganglion cells are
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reduced at 6 weeks [13, 14], and both inner and outer nuclear layers thin at approximately
10 weeks [14]. Capillary basement membrane thickening is evident at approximately 17
weeks of hyperglycemia [15] and vascular cells are lost at 6 months [11]. Similarly, for
diabetic nephropathy, mild to moderate albuminuria takes 6 months of diabetes duration
[16]. Renal pathological changes, including glomerular hypertrophy, thickening of the
glomerular basement membranes, and mesangial matrix expansion take more than 6
months of diabetes [16, 17]. For cardiac dysfunction, studies have shown reduced and
increased left ventricle fibrosis at 8 weeks following STZ-induced diabetes [18].
Collectively, these studies provide support for the use of STZ-induced diabetic model to
identify and benchmark bone marrow dysfunction in diabetes.
In this study, I examined the effect of STZ-induced diabetes in C57BL/6 mice at 1-month
follow-up, with the goal of identifying early changes that may mediate increased bone
marrow adipogenesis. Unlike other studies where diabetes is induced with STZ in mice at
8-plus weeks of age, I induced diabetes at 5-weeks of age. This was done for two reasons:
1) we know that ageing increases bone marrow adipogenesis from 6-8 weeks of mouse
age, and 2) the increasing prevalence of diabetes in younger patients. Therefore, to
examine how diabetes affects the marrow without the confounding ageing-related
changes and to have clinically relevant model of diabetes, I selected 5-week-old mice for
my studies. My results show that 1 month of diabetes is sufficient to enhance marrow
adiposity in the tibiae of mice. This alteration was observed before structural changes in
other organs of diabetic complications. Additionally, I show that STZ-induced
hyperglycemia suppresses the transforming growth factor-beta (TGFB) pathway in the
bone marrow, highlighting the possible mechanism of enhanced adipogenesis. Finally, I
show that diabetes causes early changes in stem cell homing factor, Cxcl12, in the mouse
bone marrow.
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2.2
2.2.1

Materials and methods
Diabetic mouse modelling

All mouse studies were initiated after receiving approval (Animal Use Protocol: 2019125) from Western University and Animal Care and Veterinary Services.
Four-week-old male C57BL/6 mice (Charles River Canada) were obtained and allowed
to acclimate for 1 week. Mice were kept on a light/dark (12 h/12 h) cycle at 23°C and
received food (standard lab chow) and water ad libitum. Mice were divided into diabetic
and non-diabetic groups by ensuring the body weights were similar between the two
groups. Diabetes was induced by multiple low-dose intraperitoneal injections of freshly
prepared streptozotocin (STZ; 50 mg/kg in citrate buffer, pH 4.5; Sigma-Aldrich; Cat#
S0130) for 5 consecutive days [19]. Non-diabetic control mice received an equivalent
volume of freshly prepared citrate buffer alone. Body weights were measured daily for
the duration of the study. Mice were also monitored daily for body condition scores and
overall health. Hyperglycemia was confirmed 1 week after the last STZ injection by
measuring the non-fasting blood glucose level from the tail vein using a glucometer
(CONTOUR Next One, Ascensia Diabetes Care). This day was considered as day 0 (d0).
Mice with non-fasting blood glucose levels greater than 11.1 mmol/L (>200 mg/dL) were
considered diabetic. Mice that did not meet the threshold were measured again after 2
days to confirm hyperglycemia. Each group contained seven mice.
One day prior to euthanasia, blood glucose levels were measured. Following CO2
euthanasia, mice were monitored for cessation of breathing/heartbeat. An incision in the
chest wall was made immediately to reach the heart. A small slit was made into the right
atrium. Mice were then perfused with 5 mL of cold PBS by inserting a 28G needle into
the left ventricle. Femurs and tibiae were then removed and freed from soft tissue. Limbs
from one side were used for histology, and the other side was used for preparing flush
samples. For histological analyses, the bones were fixed in formalin (Sigma-Aldrich;
Cat# HT501128) overnight at room temperature, decalcified in 0.5 mol/L
ethylenediaminetetraacetic acid (EDTA; Fisher Scientific; Cat# S311) for 7 days at 4°C,
and rehydrated in 30% sucrose solution (Sigma-Aldrich; Cat# 84100) overnight at 4°C
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prior to being embedded in paraffin. Tissues were sectioned at 4 μm thickness. For gene
expression analyses, the epiphyses of the femurs and tibiae were removed and
centrifuged at 10,000 xg for 15 seconds to flush the bone marrow. This method of
preparing cell suspensions removed all cellular content from the marrows, as can be
detected by histological analysis before and after the procedure (Appendix 1). The
resulting flush was stored in a cell freezing medium solution (90% fetal bovine serum and
10% DMSO; Millipore; Cat# S-002-5F) at -20°C until further analysis. For RNA
isolation from the marrow cells, the flush samples were quickly thawed to 37 °C in a
water bath and centrifuged at 300 xg to pellet the cells. Cells were then suspended in
RLT cell lysis buffer (RNeasy Plus Mini Kit; Qiagen, Cat# 74134).
In addition to the bone tissues, most other tissues from the mice were also collected.
Specifically, eyes, heart, lung, kidney, liver, pancreas, and epididymal adipose tissue
were removed for histology. The tissues were fixed in formalin (Sigma-Aldrich; Cat#
HT501128) overnight at room temperature prior to paraffin embedding. Non-bone tissues
were sectioned at 5 μm thickness for staining and other histological studies.
A longer-term diabetes study was also performed. Following the same procedure as
indicated above, non-diabetic and STZ-induced diabetic mice were followed up at 2
months. Femurs and tibiae were removed and processed as indicated above. Bone
marrow flush samples were also prepared for gene expression studies.
For some studies, a high-fat diet-induced model of obesity and glucose intolerance was
used. A detailed method for this mouse model is explained elsewhere [20]. Briefly, 5week-old male 129S6/SvEvTac mice (Taconic) were fed regular rodent chow (Chow) or
a Western diet containing 42% of calories from animal fat (HFD; Envigo; Cat#
TD.88137) ad libitum for 6 months. Prior to euthanasia, an oral glucose tolerance test
was performed following a 6-hour fast and oral gavage of a 20% solution of D-glucose to
deliver 1 g glucose per kg body weight. Blood glucose levels were determined by a
handheld glucometer. At the end of the study, mice were euthanized by CO2. Blood
samples were collected for measurement of plasma insulin and for lipid profiling. Plasma
insulin was measured by ELISA (ALPCO; Cat# 80-INSMS-E01). Plasma triglyceride,
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cholesterol, and free fatty acids were measured using enzymatic, colorimetric assays
(Wako Diagnostics). Epididymal fat weights were also determined. The femurs and tibiae
were removed and processed for histology and gene expression studies as indicated
above.

2.2.2

RNA isolation, mRNA profiling & quantitative PCR

Total RNA from marrow flush samples was isolated using RNeasy Mini Plus Kit
(Qiagen, Cat# 74134). RNA from formalin-fixed paraffin-embedded (FFPE) epididymal
adipose tissue sections (total of 20 μm thickness) was collected using the PureLink FFPE
RNA Isolation Kit (Thermo Fisher, Cat# K156002). Total RNA was measured using
Qubit RNA Broad Range Assay (Thermo Fisher; Cat# Q10210) or the Qubit RNA High
Sensitivity Assay (HS; Cat# Q32852) in a Qubit Fluorometer (Thermo Fisher; Cat#
Q32857). cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad
Laboratories; Cat# 1708841). qPCR reactions for SYBR-based amplification and
detection consisted of 10 µL RT2 SYBR Green qPCR Mastermix (Qiagen; Cat# 330502),
2 µL of both forward and reverse primers (Table 2-1, Table 2-2) at 10 µmol/L
concentration, 2 µL cDNA, and 6 µL nuclease-free H2O (Ambion; Cat# AM9937). For
TaqMan-based chemistry, the reactions consisted of 5 µL TaqMan Fast Advanced Master
Mix (Thermo Fisher; Cat# 4444963), 0.5 µL of the gene probe (Table 2-3), 1 µL cDNA,
and 3.5 µL nuclease-free H2O. All reactions were run on CFX Connect Real-Time PCR
Detection System (Bio-Rad). Target gene mRNA data were normalized to housekeeping
genes identified in the figure legends. SYBR Green-based reactions were performed for
40 cycles using the following temperature profiles: 95°C for 15 seconds (initial
denaturation); and 60°C for 60 seconds (annealing and extension). TaqMan-based
reactions were performed for 40 cycles using the following temperature profiles: 95°C for
3 seconds (initial denaturation); and 60°C for 30 seconds (annealing and extension). Data
were analyzed by CFX Manager Software (Bio-Rad; Cat# 1845000) using the normalized
(ΔΔCT) method.
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Table 2-1: Mouse gene primers for SYBR Green-based qPCR.
Gene

Gene description

bp

Catalogue*

Actb

Actin, beta

149

QT00095242

Fabp4

Fatty acid binding protein 4, adipocyte

150

QT00091532

Pparg

Peroxisome proliferator activated receptor gamma

144

QT00100296

Sp7

Sp7 transcription factor

69

QT00293181

Tgfb1

Transforming growth factor, beta 1

145

QT00145250

Tgfbr1

Transforming growth factor, beta receptor 1

120

QT00135828

Tgfbr2

Transforming growth factor, beta receptor 2

76

QT00135646

*Qiagen
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Table 2-2: Mouse gene primer sequences for SYBR Green-based qPCR.
Gene

Gene description

Sequence

Adipoq

Adiponectin

Atp5f1

ATP synthase, H+
transporting,
mitochondrial F0
complex, subunit B1

Cebpa

CCAAT Enhancer
Binding Protein Alpha

CAAGAACAGCAACGAGTACCG

Cxcl12

C-X-C Motif
Chemokine Ligand 12

CTGTGCCCTTCAGATTGTT

Lpl

Lipoprotein lipase

Pgk1

Phosphoglycerate
kinase 1

AAAGGAGAGCCTGGAGAA
GAATGGGTACATTGGGAACA
GTCCAGGGGTATTACAGGCAA
TCAGGAATCAGCCCAAGACG

GTCACTGGTCAACTCCAGCAC
AGCTTTCTCCAGGTACTCTT
GGGAGTTTGGCTCCAGAGTTT
TGTGTCTTCAGGGGTCCTTAG
GGGTGGATGCTCTCAGCAAT
GTTCCTGGTGCCACATCTCA

[Ref.]
[21]

[22]

[21]
[21]
[21]
[22, 23]

Source: Thermo Fisher
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Table 2-3: Mouse gene primers for TaqMan-based qPCR.
Gene

Gene description

bp

Assay ID*

Actb

Actin, beta

143

Mm02619580_g1

Gapdh

Glyceraldehyde-3-phosphate dehydrogenase

107

Mm99999915_g1

Kit

Kit oncogene

71

Mm00445212_m1

Kitl

Kit ligand

91

Mm00442972_m1

Cxcl12

Chemokine (C-X-C motif) ligand 12

85

Mm00445553_m1

Map3k7

mitogen-activated protein kinase kinase 7
(TAK1)

94

Mm00554514_m1

Cxcr4

Chemokine (C-X-C motif) receptor 4

99

Mm01292123_m1

Ptprc

protein tyrosine phosphatase, receptor type, C;
Cd45

73

Mm01293577_m1

Runx2

Runt related transcription factor 2

91

Mm00501584_m1

Tgfbr2

Transforming growth factor, beta receptor 2

86

Mm00436977_m1

Tgfb1

Transforming growth factor, beta 1

59

Mm01178820_m1

Tgfbr1

Transforming growth factor, beta receptor 1

85

Mm00436964_m1

Sp7

Sp7 transcription factor

63

Mm04933803_m1

Bmp4

Bone morphogenetic protein 4

61

Mm00432087_m1

Smad2

SMAD family member 2

72

Mm00487530_m1

Smad3

SMAD family member 3

59

Mm01170760_m1

Smad6

SMAD family member 6

71

Mm00484738_m1

Ctnnb1

Catenin (cadherin associated), beta 1

77

Mm00483039_m1

Wnt11

wingless-type MMTV integration site family,
member 11

75

Mm00437328_m1

*Thermo Fisher
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2.2.3

Histomorphometric analyses

Histomorphometric analyses were performed on mouse retina, epididymal fat, and bone
tissues. The thickness of retinal layers and bone lengths were quantified using QuPath
[24]. The frequency of the area of adipocytes found in the white adipose tissue was
analyzed using Adiposoft, an automated software [25]. The number of nuclei per area in
tissues was determined by QuPath [24]. Bone marrow analysis was conducted while
considering the guidelines and standards previously reported [26]. The bone marrow
histological sections were analyzed using MarrowQuant [27] and QuPath [24].

2.2.4

Hematoxylin & Eosin (H&E), Picro-Sirius Red, and PAS staining

The deparaffinized tissue sections were stained using hematoxylin (Leica Biosystems;
Cat# 3801561) and eosin (Leica Biosystems; Cat# 3801601) for routine histological
analysis. Picro-Sirius Red (Abcam; Cat# ab246832) was used to mark collagen
deposition. Periodic Acid-Schiff (PAS) stain kit (Abcam; Cat# ab150680) was used to
detect the presence of carbohydrates and carbohydrate compounds such as
polysaccharides, mucin, and glycogen. Liver sections were also subjected to α-amylase
(Sigma-Alrich; Cat# A3176) treatment prior to PAS (PAS-diastase Staining) to remove
glycogen. The stained slides were digitalized using Aperio slide scanning system (Aperio
Technologies, Inc., Vista, CA) with a 20X and 40X objective and saved in Tagged Image
File Format (TIFF format). Image analyses were performed with the ImageJ software
package (National Institutes of Health, Bethesda, MD, USA). Picro-Sirius Red-stained
area was automatically assessed by means of a macro
(https://github.com/northcottj/picrosirius-red). The Picro-Sirius Red-positive area of the
specimens was quantified using ImageJ software and shown as a percentage of the total
section area.
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2.2.5

Immunostaining of tissue

Tissue sections (all except bone tissues) were deparaffinized in xylene, hydrated in an
ethanol gradient, and subjected to a heat-induced antigen retrieval process using
Citrate/EDTA buffer (10 mmol/L sodium citrate, 1 mmol/L EDTA, 0.05% Tween-20, pH
6.0) or Tris/EDTA buffer (10 mmol/L Trizma base, 1 mmol/L EDTA, 0.05% Tween-20,
pH 9.0) in a 2100 Retriever (Electron Microscopy Science, Hatfield, PA). Sections were
incubated with rabbit anti-mouse perilipin-1 (PLIN1; Abcam; ab3526; 1:200 dilution) or
insulin (INS; Thermo Fisher Scientific; 15848-1-AP; 1:1000 dilution) at room
temperature for 1 hour. FITC- or peroxidase-conjugated secondary antibodies (Vector
Laboratories, Burlington, ON) were used for detection. Where peroxidase-conjugated
secondary antibody was used, AEC (3-amino-9-ethylcarbazole) substrate (Vector
Laboratories; Cat# SK-4200) was used, followed by hematoxylin counterstaining. For
immunofluorescence staining, sections were exposed to Vector TrueVIEW
Autofluorescence Quenching Kit (Vector Laboratories; Cat# SP-8400-15) for five
minutes, followed by counterstaining with DAPI (Sigma Aldrich; Cat# F6057).
Fluorescence images were captured by an Olympus BX51 epi-fluorescence microscope
equipped with Infinity 3-1 Color CCD (Teledyne Lumenera, Ottawa, Canada) and
Infinity Analyze software (Teledyne Lumenera). The AEC-stained slides were digitalized
using Aperio slide scanning system (Aperio Technologies) with a 20X objective and
saved in TIFF format.
2.2.5.1 Bone tissue immunostaining
Bone tissue sections were deparaffinized in xylene and rehydrated through an ethanol
gradient. Tissue sections were then subjected to a heat-induced antigen-retrieval process
using a microwave. Briefly, jars containing the antigen retrieval buffer (10 mmol/L
sodium citrate, 1 mmol/L EDTA, 0.05% Tween-20, pH 6.0; or 10 mmol/L Trizma base, 1
mmol/L EDTA, 0.05% Tween-20, pH 9.0) were placed in the microwave and the buffer
was boiled. Tissue sections were then immersed in the jar when the buffer had cooled and
was not boiling. This process was repeated until the tissues had been subjected to a total
of 15 minutes in a heated buffer. Sections were then blocked in 1% bovine serum
albumin (Sigma-Aldrich; Cat# A7906) solution in PBS containing 0.1% Tween-20
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(Sigma-Aldrich; Cat# P9416) for 1 hour then incubated with primary antibody (Table 24) for 1 hour at room temperature, followed by Alexa Fluor 488-conjugated anti-goat
(Thermo Fisher Scientific; A-11079), FITC-conjugated anti-rabbit (Thermo Fisher
Scientific; F-2765), or FITC-conjugated anti-mouse (Vector Laboratories; Cat# FL-2000)
secondary antibody incubation for 1 hour at room temperature. All sections were then
exposed to Vector TrueVIEW Autofluorescence Quenching Kit (Vector Laboratories;
Cat# SP-8400-15) for 5 minutes, followed by counterstaining with DAPI (Sigma Aldrich;
Cat# F6057). Negative control sections were included for all staining studies and
consisted of the same tissue and same procedure except for the omission of the primary
antibody. Fluorescence images were captured using an Olympus BX51 microscope.
Where fluorescence intensity was measured, sections from all experimental conditions
were subjected to the same exposure time. Fluorescence staining intensity per area of the
sections was performed using QuPath and ImageJ.
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Table 2-4: Antibodies tested on paraffin-embedded mouse bone marrow sections.

Target

CD31

CD45

CXCL12

FABP4

Alternative
names

PECAM1

Ly5, LCA

SDF-1

AP2

NANOG
OCT4

POU5F1

Osteocalcin

BGLAP

PhosphoSMAD2
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Clone

Source

Catalogue
number

Target Species

Host
Species

Working

Poly

Novus
Biologicals

AF3628

Mouse, Rat

Goat

Yes

EPR17259

Abcam

ab182981

Mouse, Rat, Human

Rabbit

Yes

Poly

Santa Cruz

sc-1505

Human

Goat

No

Poly

Thermo Fisher 20103-1-AP

Human, Mouse, Rat

Rabbit

Yes

Poly

Abcam

Mouse, Rat, Human

Rabbit

Yes

Poly

Thermo Fisher 14-7992-81

Mouse, Rat

Rabbit

Yes

Poly

Thermo Fisher PA5-114344

Human, Mouse, Rat

Rabbit

Yes

79018

R&D

MAB350

Mouse, Human

Mouse

Yes

Poly

Novus
Biologicals

NBP2-29480

Human, Rat

Rabbit

No

Poly

Thermo Fisher 12802-1-AP

Human, Mouse, Rat

Rabbit

Yes

Poly

Thermo Fisher IHC-00205

Mouse

Rabbit

No

GT486

Abcam

ab184665

Mouse, Human

Mouse

No

Poly

Abcam

ab19857

Mouse, Human

Rabbit

No

190125

R&D Systems

MAB1419

Human, Rat

Mouse

No

D27F4

Cell Signaling
Technology

8828

Human, Mouse, Rat,
Monkey

Rabbit

No

ab10558

(Ser465/467)
/ SMAD3
(Ser423/425)
PLIN1

Poly

Abcam

Poly

ab3526

Mouse

Rabbit

No

Thermo Fisher PA5-55046

Human, Mouse, Rat

Rabbit

Yes

POU3F2

OCT7

Poly

Thermo Fisher PA5-23400

Bovine, Dog, Horse, Human,
Mouse, Rat

Rabbit

No

SCF

KITLG

Poly

Thermo Fisher PA5-79558

Human, Mouse, Rat

Rabbit

No

Poly

Thermo Fisher PA1-41026

Human, Mouse, Non-human
primate, Sheep, Rat

Rabbit

No

EPR5984

Abcam

ab109526

Human

Rabbit

No

Poly

Novus
Biologicals

NB10056363

Mouse, Human

Rabbit

No

TBX2

4D6

Abcam

ab140345

Human

Mouse

No

TGFB1

Poly

Proteintech

21898-1-AP

Human, Mouse, Rat

Rabbit

Yes

TGFBR1

Poly

Abcam

ab112095

Human

Rabbit

No

TLE1

EPR9386(2)

Abcam

ab183742

Human

Rabbit

No

SMAD6

TAK1
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MAP3K7

2.2.6

Statistical Analysis

All data were expressed as Mean ± standard deviation (SD). Statistical and graphical
analyses were performed using GraphPad Prism 7 and Microsoft Excel (basic statistical
functions). Data were tested for normality. When comparing parametric data from two
groups, a student’s unpaired t-test was used. For multiple comparisons, an analysis of
variance (ANOVA) followed by Bonferroni post hoc analysis was performed. P values
<0.05 were considered statistically significant.
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2.3
2.3.1

Results
STZ-induced diabetic mice show hyperglycemia and impaired weight gain.

Chemically induced models of diabetes have been used extensively [10]. The STZinduced diabetic mouse model is one of the most established models to examine diabetic
complications. Previous studies have induced diabetes by STZ at various ages (Appendix
2). Inducing diabetes in mice at 8 weeks of age or older has some advantages, including
stabilization and uniformity of body weights. However, this age group may not be
representative of human diabetes, which may be diagnosed earlier. Therefore, to examine
the early changes in the bone marrow of diabetic mice, I employed an adolescent mouse
model that equates to 15-20 human years. I induced diabetes in 5-week-old C57BL/6
mice with multiple low-doses of STZ on 5 consecutive days. This model was originally
described in 1976 by Like and Rossini and was shown to induce pancreatitis [19]. One
week after the last injection of STZ (d0), I measured the body weight and observed that
the difference from d-11 was significantly lower in the STZ group compared with the
non-diabetic control mice (Figure 2-1B). As expected, the STZ group also had
significantly higher blood glucose levels (Figure 2-1C). At 1 month following d0, the
body weight difference from d-11 was even greater in the control mice compared with the
STZ group (Figure 2-1D). Moreover, the STZ-induced mice displayed elevated blood
glucose levels (above 10 mmol/L; ranging between 14-24 mmol/L) (Figure 2-1E). At the
time of confirming hyperglycemia and 1 month following, the cumulative body weight
difference from d-11 in the STZ-induced diabetic mice was significantly less compared
with the control mice (Figure 2-1F). These results show impaired weight gain in diabetic
mice and elevated hyperglycemia, as is expected in a diabetes model.
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Figure 2-1: Streptozotocin-induced diabetes causes impaired weight gain in mice at
1 month.
(A) Experimental scheme for diabetic mouse study. Diabetes was induced in C57BL/6
mice with daily intraperitoneal injections of streptozotocin (STZ; 50 mg/kg) for 5
consecutive days. Non-diabetic control mice received an equal volume of citrate buffer.
Blood glucose levels were checked 1 week after the last STZ injection to confirm
hyperglycemia. (B) The body weight difference from d-11 was calculated 1 week after
the last STZ injection. [Mean ± SD; n = 7; each data point represents a mouse; two-tailed
student’s t-test: * p<0.05]. (C) Non-fasting blood glucose levels in mice measured 1 week
after the last STZ injection [Mean ± SD; n = 5-7; each data point represents a mouse;
two-tailed student’s t-test: * p<0.05]. (D) Body weight difference from d-11 at the
conclusion of the study (d29) [Mean ± SD; n = 7; each data point represents a mouse;
two-tailed student’s t-test: * p<0.05]. (E) Non-fasting blood glucose levels measured at
the conclusion of the study (d28) [Mean ± SD; n = 7; each data point represents a mouse;
two-tailed student’s t-test: * p<0.05]. (F) Cumulative average body weight difference
from d-11 to d29 comparing non-diabetic control and STZ mice [Mean ± SD; n = 7;
Two-way ANOVA followed by Bonferroni post hoc analysis: * p<0.05].
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As the blood glucose levels measured were non-fasting, I aimed to confirm that STZ
administration induced diabetes in mice. To do this, I examined the insulin-producing
beta-cells of the pancreatic islets. STZ is known to cause alkylation of the pancreatic
beta-cell DNA [28], resulting in hypoinsulinemia [29]. Based on these studies, I expected
significantly diminished pancreatic beta-cells in mice administered the toxin. Although
the H&E-stained sections displayed no drastic morphological differences, the size of the
islets was smaller in the diabetic group (Figure 2-2A). Coupled with the decrease in the
islet size, I also observed a significant reduction in the number of pancreatic beta-cells
immunoreactive to insulin in STZ-induced mice compared with the control mice (Figure
2-2B).
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Figure 2-2: Diminished pancreatic islets in streptozotocin-induced diabetic mice at 1
month.
Pancreata were harvested from C57BL/6 male mice, 1 month after administration of
streptozotocin (STZ; 50 mg/kg) or citrate buffer control (Control). (A) Representative
images showing H&E-stained sections (upper panel) and insulin immunoreactivity (lower
panel; brown). (B) The number of pancreatic islets (insulin-positive islets; manual count)
per pancreatic area (determined by QuPath) is shown [Mean ± SD; n = 4-5; each data
point represents a mouse; two-tailed student’s t-test: * p<0.05].
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To properly stage the disease, I examined key target organs that are known to be affected
in diabetes [30]. We know that diabetic complications manifest as increased extracellular
matrix deposition and basement membrane thickening [31], cell loss [32], and infiltration
of myeloid cells and inflammation in target organs [33]. These structural features become
obvious in STZ-induced models at different times, but typically require 2-plus months of
diabetes duration. Examination of H&E-stained sections of heart, liver, kidney, and lung
did not reveal any significant changes in the STZ-induced diabetic mice compared to the
non-diabetic mice at 1 month of disease duration (Figure 2-3A). Retina, heart, and kidney
sections were then stained with Periodic Acid-Schiff (PAS) to detect changes in
polysaccharide deposition. Again, no changes were observed (Figure 2-3B). Next, I
stained tissues with Picro-Sirius Red to highlight collagen deposition and observed no
significant fibrosis (Figure 2-3C-F). These results show that 1 month of diabetes does not
produce hallmark structural changes in target organs.
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Figure 2-3: Histological analyses of STZ-induced diabetic mice at 1 month.
Tissues were harvested from C57BL/6 male mice, 1 month after administration of
streptozotocin (STZ; 50 mg/kg) or citrate buffer control (Control). (A) Representative
H&E-stained images of heart, lung, kidney, and liver tissues of mice. (B) Periodic AcidSchiff (PAS)-stained images of retina, heart, and kidney tissues. (C) Picro-Sirius Redstained tissues of mice. (D-F) Quantitative assessment of Picro-Sirius Red-stained area of
the heart (D), lung (E), and kidney (F). Stained areas were determined with ImageJ
[Mean ± SD; n = 3-4; each data point represents a mouse; two-tailed student’s t-test: *
p<0.05].
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Analysis of retina tissues revealed a significant change in the thickness of specific cell
layers. Specifically, I observed a significant decrease in the thickness of the inner nuclear
layer in the diabetic mice (Figure 2-4D), whereas the other retinal layer thickness did not
change. These observations are consistent with a recent study in diabetic rats highlighting
early structural changes in the retina at 1 month [34].
Epididymal fat of mice also showed a difference between STZ-induced diabetic mice and
non-diabetic controls. Diabetes was associated with increased nuclei per area suggesting
adipocyte hyperplasia (Figure 2-5A-C). Interestingly, levels of adipogenesis-associated
genes, including Pparg, Cepba, Fabp4, Lpl, and Adipoq were suppressed in epididymal
fat of diabetic mice compared with the controls (Figure 2-5D-H). This may be due to the
overall loss of fat pad mass through lipolysis with STZ administration in mice [8] and/or
the smaller sized adipocytes evident in the STZ group.
Detailed examination of liver tissues harvested from diabetic mice showed reduced
glycogen storage and marked increases in vacuole accumulation, as highlighted by PASdiastase staining (Figure 2-6A). To determine whether these vacuoles are lipid droplets, I
stained the liver sections with perilipin-1 (PLIN1), a selective lipid droplet-associated
protein. Interestingly, liver tissues isolated from the STZ-induced diabetic mice displayed
robust PLIN1 immunoreactivity indicating that the vacuoles are indeed lipid droplets
(Figure 2-6B). Collectively, these results suggest that the STZ-induced model of diabetes
is effective and causes only early changes in mice after 1 month.
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Figure 2-4: Reduced inner nuclear layer thickness of the retina in mice after 1
month of streptozotocin-induced diabetes.
Eyes were harvested from C57BL/6 male mice, 1 month after administration of
streptozotocin (STZ; 50 mg/kg) or citrate buffer control (Control). (A) Representative
H&E-stained sections of the retina in C57BL/6 mice. (B-I) The thickness of the retinal
layers was measured as a percentage of the neuronal retina thickness in the control and
diabetic mice [Mean ± SD; n = 6-8; each data point represents a mouse; two-tailed
student’s t-test: * p<0.05]. Abbreviations: NFL, nerve fiber layer; GCL, ganglion cell
layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer;
ONL, outer nuclear layer; PL, photoreceptor layer; and GCC, ganglion cell complex.
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Figure 2-5: Cellular hyperplasia in white adipose tissue of streptozotocin-induced
diabetic mice at 1 month.
Epididymal fat was harvested from C57BL/6 male mice, 1 month after administration of
streptozotocin (STZ; 50 mg/kg) or citrate buffer control (Control). (A) Representative
H&E-stained sections. Inserts showing higher magnification. (B) The number of nuclei
per tissue area was measured by QuPath [Mean ± SD; n = 6-7; each data point represents
a mouse; two-tailed student’s t-test: * p<0.05]. (C) Frequency of the area of the
individual adipocytes of different sizes found in epididymal adipose tissue. Frequency
was determined by Adiposoft [Mean + SD; n = 6-7; two-way ANOVA followed by
Bonferroni post hoc analysis: * p<005]. (D-H) mRNA levels of Pparg (D), Cebpa (E),
Fabp4 (F), Lpl (G), and Adipoq (H) in epididymal adipose tissue [Data normalized to
Actb; Mean ± SD; n = 6-7; each data point represents a mouse; two-tailed student’s t-test:
* p<0.05].
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Figure 2-6: Increased lipid accumulation in the liver of streptozotocin-induced
diabetic mice at 1 month.
Liver tissues were harvested from C57BL/6 male mice, 1 month after administration of
streptozotocin (STZ; 50 mg/kg) or citrate buffer control (Control). (A) Representative
images of the liver showing periodic Acid-Schiff (PAS) staining performed with or
without the combination of diastase (α-amylase). Inserts showing higher magnification.
(B) Immunofluorescence staining of liver tissues for perilipin-1 (PLIN1; green). Sections
were counterstained with DAPI (blue). Inserts showing higher magnification.
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2.3.2

Diabetes induces enhanced adipogenesis in the tibia but not the femur.

Tibiae and femurs were isolated for the discovery of early pathogenetic changes in the
bone tissues that may entail disrupted osteo- and adipogenesis, leading to enhanced
marrow adiposity. No changes in the lengths of the bones were observed between the two
experimental groups (Appendix 3). Using MarrowQuant, a semi-automated image
analysis plug-in for QuPath [27] (Figure 2-7), I observed a significantly increased area
and the number of adipocytes per tibia area (Figure 2-8A-C). To confirm this finding, I
stained the tibia sections with PLIN1 and observed a significant increase in PLIN1
intensity in the marrows of diabetic mice (Figure 2-8D-F). To bolster these findings, I
also stained the bone tissues for FABP4. Interestingly, FABP4 immunoreactivity was not
different between the two groups (Figure 2-9A-C). Similarly, Fabp4 transcript levels
showed no statistically significant difference between the groups (Figure 2-9D).
However, this could be explained by the fact that FABP4 stained both endothelial cells
and adipocytes (Figure 2-9A,B). Previous studies have shown that endothelial cells
express FABP4 [35]. Although PLIN1 showed a significant increase in my study, CD31
(used to primarily identify endothelial cells) showed a significant reduction in its
intensity per area in the diabetic marrow (Figure 2-10).
Enhanced adipogenesis in the tibia of STZ-induced diabetic mice did not appear to be
associated with any alteration in the nucleated area (majority of the cells being of
hematopoietic origin) and Cd45 mRNA levels (Figure 2-11). We and others have
previously shown that diabetes does not alter hematopoietic areas in experimental and
human diabetes, respectively [6, 7]. Therefore, this result is not unexpected.
Unlike the tibia, no difference was observed in any of the histomorphometric analyses
conducted in the femur (Figure 2-12). These findings suggest that diabetes, at least early
on, disrupts the tibia and not the femur.
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Figure 2-7: Workflow diagram of MarrowQuant.
Bone marrow morphometry was performed using MarrowQuant (QuPath). A typical
workflow of the platform is illustrated in this figure. (A) An H&E-stained section of the
bone is loaded into QuPath. (B) The user defines ‘Tissue Boundaries’, ‘Background’, and
‘Artifacts’. (C) MarrowQuant is run with pre-set or user-adjusted parameters. Figure
within the dotted red box masks the bone marrow compartment areas detected by
MarrowQuant (Proximal tibia of a 2-month-old C57BL/6 female mouse). (i) H&E image,
arrowhead represent manually excluded artefacts; (ii) bone detection (green); (iii)
nucleated cell detection (violet); (iv) adipocyte ghost detection (yellow); and (v)
interstitium and microvasculature (pink). (D) Results can be saved as bone marrow mask
images and a .txt file of the area and calculated outputs. (E) User and/or pathologists’
feedback is integrated by removing false-positive adipocyte selection and if necessary,
processing images with adjusted adipocyte parameters. This figure was originally
published in Tratwal J. et al. (2020) MarrowQuant Across Aging and Aplasia: A Digital
Pathology Workflow for Quantification of Bone Marrow Compartments in Histological
Sections. Front. Endocrinol. 11:480. Doi: 10.3389/fendo.2020.00480. This figure is
under an open-access distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. The modified figure shown here is different from the original and is being
included for educational purposes only.
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Figure 2-8: Increased adipocyte number and area in the tibia of streptozotocininduced diabetic mice at 1 month.
C57BL/6 male mice were administered streptozotocin (STZ; 50 mg/kg) or citrate buffer
control (Control). Bone tissues were harvested after 1 month. (A) Representative images
of the H&E-stained tibia. Inserts showing higher magnification. (B, C) Quantification of
adipocyte area per bone area (B) and adipocyte number per bone area (C). Parameters
were measured by MarrowQuant [Mean ± SD; n = 6-7; each data point represents a
mouse; two-tailed student’s t-test: * p<0.05]. (D, E) Immunofluorescence staining of
mouse tibia for perilipin-1 (PLIN1; green). Sections were counterstained with DAPI
(blue). Figure showing shaft (D) and distal regions (E) of the tibia. (F) Quantification of
PLIN1 intensity per area, as determined by ImageJ [Mean + SD; n = 3; 12-13 images per
mouse were measured; two-tailed student’s t-test: * p<0.05].
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Figure 2-9: Streptozotocin-induced diabetic mice show no changes in adipocyte
marker FABP4 at 1 month.
Tibia of control and diabetic (STZ) mice was stained for adipocyte marker, FABP4. (A,
B) Representative immunofluorescence staining of FABP4 (green) in the shaft (A) and
distal regions (B) of tibia. Sections were counterstained with DAPI (blue). (C)
Quantification of FABP4 staining intensity per area, as determined by ImageJ [Mean +
SD; n = 3; 7 images per mouse were measured; two-tailed student’s t-test: * p<0.05]. (D)
Fabp4 mRNA levels in the tibia flush samples from control and diabetic (STZ) mice,
after 1 month of diabetes onset [Data normalized to Actb, Atp5f1, and Pgk1; Mean ± SD;
n = 5-6; each data point represents a mouse; two-tailed student’s t-test: * p<0.05].
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Figure 2-10: Streptozotocin-induced diabetic mice show bone marrow endothelial
cell alteration at 1 month.
Mouse tibia was stained for endothelial cell marker, CD31. (A) Representative staining
image (CD31 = green; DAPI = blue). (B) Quantification of CD31 staining intensity per
area, as determined by ImageJ [Mean + SD; n = 3; 9-10 images per mouse were
measured; two-tailed student’s t-test: * p<0.05].
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Figure 2-11: Hematopoietic area in the tibia of streptozotocin-induced diabetic mice
at 1 month are not altered.
Immunofluorescence staining of the tibia of control and diabetic (STZ; 1 month) mice for
CD45 (green). Sections were counterstained with DAPI (blue). Inserts showing higher
magnification. (B) Quantification of CD45 intensity per area, as determined by ImageJ
[Mean + SD; n = 3; 8 images per mouse were measured; two-tailed student’s t-test: *
p<0.05]. (C) Cd45 mRNA levels in tibia flush samples [Data normalized to Actb and
Gapdh; Mean ± SD; n = 6-7; each data point represents a mouse; two-tailed student’s ttest: * p<0.05]. (D) Nucleated area per bone area measured using MarrowQuant [Mean ±
SD; n = 6-7; each data point represents a mouse; two-tailed student’s t-test: * p<0.05].
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Figure 2-12: No change in adipocyte number and area in the femur of
streptozotocin-induced diabetic mice at 1 month.
Representative H&E-stained images of the mouse femur. Inserts showing higher
magnification. (B-D) Quantification of adipocyte number per bone area (B), adipocyte
area per bone area (C), and nucleated area per bone area (D). Parameters were measured
using MarrowQuant [Mean ± SD; n = 4-5; each data point represents a mouse; two-tailed
student’s t-test: * p<0.05].
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As histomorphological changes in the tibia were observed, I examined whether
adipogenesis-associated genes were altered in the tibia. My results show that
adipogenesis-associated transcriptional factors, Cebpa and Pparg, and adipocyte-related
adiponectin (Adipoq) are not upregulated in the tibia (nor femur) after 1 month of
diabetes (Figure 2-13). Although this is unexpected, analysis of epididymal fat tissue
suggests there may not be a positive association between adipocytes and the expression
of adipogenesis-associated genes.
In support of the notion that diabetes disrupts the osteo- and adipogenesis balance, I did
observe a significant reduction in the osteogenesis-associated gene, Runx2, in both the
tibia and femur (Figure 2-14). Another osteoblast transcription factor, Sp7, was only
downregulated in the femur but not the tibia at 1 month. Previous studies have shown that
RUNX2 is the first transcription factor required for determination of the osteoblast
lineage, while SP7 further directs the fate of mesenchymal cells to osteoblasts [36]. These
findings show that early diabetes may cause suppressed osteoblastogenesis in mice, and
the effects may be more pronounced in the femur compared with the tibia.
As marrow adiposity is reported to be minimal before 12 weeks of age in mice [37] and
as I did not observe changes in the adipogenesis-associated genes after 1 month of
diabetes (Figure 2-13), I analyzed the bone marrows of mice at 2 months of diabetes
duration. As expected, diabetic mice weighed significantly less and had significantly
higher blood glucose levels compared with the non-diabetic control mice at 2 months
(Figure 2-15A,B). Moreover, I observed enhanced adiposity in the tibia of diabetic mice,
coupled with a significant increase in Cebpa mRNA (Figure 2-15C,D). Similar to the 1month diabetic mouse model, the femur showed no significant increase in adiposity nor
upregulated mRNA levels of genes associated with adipogenesis even after 2 months
(Figure 2-15H-J). Interestingly, Sp7 was downregulated in the tibia of diabetic mice at 2
months (Figure 2-15G), unlike the results at 1 month. Furthermore, Adipoq, an insulinsensitizing hormone [38], levels were significantly reduced in the bone marrow of
diabetic mice (Figure 2-15F,K), which supports the clinical findings often observed in
patients with diabetes [39]. Together, these findings suggest that the STZ-induced mouse
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model after 1 month of diabetes allows examination of early marrow changes with
enhanced adiposity in the tibia.
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Figure 2-13: Expression of adipogenesis-associated genes shows no difference in the
bone marrow after 1 month of streptozotocin-induced diabetes.
Tibia (A-C) and femur (D-E) of non-diabetic control and streptozotocin (STZ)-induced
diabetic mice, 1 month after the onset of diabetes, were flushed to isolate marrow cells
for mRNA analyses. Levels of adipogenesis-associated genes were measured [For panels
A and D, data normalized to Actb and Gapdh; for panels B,C,E, and F, data normalized to
Actb, Atp5f1, and Pgk1; Mean ± SD; n = 6-7; each data point represents a mouse; twotailed student’s t-test: * p<0.05].
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Figure 2-14: Osteogenesis-associated genes are significantly reduced in the bone
marrow of streptozotocin-induced diabetic mice at 1 month.
mRNA levels of osteogenesis-associated genes were measured in the tibia (A,B) and
femur (C,D) of control and diabetic (STZ) mice. Analyses were performed 1 month after
the onset of diabetes [Data normalized to Actb and Gapdh; Mean ± SD; n = 4-7; each
data point represents a mouse; two-tailed student’s t-test: * p<0.05].
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Figure 2-15: Enhanced adiposity in the tibia of mice after 2 months of
streptozotocin-induced diabetes.
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C57BL/6 male mice received streptozotocin (STZ; 50 mg/kg) or citrate buffer (nondiabetic controls). Tibiae were harvested 2 months after the onset of diabetes. (A) Body
weights of mice at the conclusion of the study [Mean + SD; n = 6; two-tailed student’s ttest: * p<0.05]. (B) Non-fasting blood glucose levels in mice, 2 months after the onset of
diabetes [Mean + SD; n = 6; two-tailed student’s t-test: * p<0.05]. (C) Representative
H&E-stained sections of the tibia showing proximal, shaft, and distal regions. (D-G)
mRNA levels of adipogenesis-associated (D, E, F) and osteogenesis-associated (G) genes
in marrow flush samples of mouse tibia [Data normalized to Actb, Atp5f1, and Pgk1;
Mean ± SD; n = 3-6; each data point represents a mouse; two-tailed student’s t-test: *
p<0.05]. (H) Representative H&E-stained sections of the femur showing shaft and distal
regions. (I-L) mRNA levels of adipogenesis-associated (I, J, K) and osteogenesisassociated (L) genes in marrow flush samples of mouse femur [Data normalized to Actb,
Atp5f1, and Pgk1; Mean ± SD; n = 3-6; each data point represents a mouse; two-tailed
student’s t-test: * p<0.05].
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2.3.3

Suppressed TGFB signalling in bone tissues of diabetic mice is evident at 1
month of disease onset.

TGFB signalling has been reported to play a critical role in lineage specification of
mesenchymal progenitor cells in the marrow [40]. Therefore, I examined the influence of
hyperglycemia on TGFB signalling in diabetic mice. In the tibia, Tgfbr1, Tgfb1, Smad3,
Smad6, and Bmp4 mRNA levels were significantly lower in the STZ-induced diabetic
mice compared with the non-diabetic controls (Figure 2-16A-E). Similarly, in the femur,
diminished levels of Smad2, Smad3, Smad6, and Bmp4 were observed in the diabetic
mice (Figure 2-16F-I). To complement these findings, I performed immunostaining of
tibiae for TGFB1 (Figure 2-16J). Staining intensity showed a p-value of 0.06 and did not
meet my cut-off of 0.05 (Figure 2-16K). However, suppressed expression of the TGFB
pathway genes in bone tissues of mice and previously reported study [40] suggest that the
TGFB pathway is involved in the early diabetes-induced changes in bone tissues.
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Figure 2-16: Suppressed TGFB pathway in the bone marrow of streptozotocininduced diabetic mice at 1 month.
Tibia and femur samples were harvested from control and streptozotocin (STZ)-induced
diabetic mice after 1 month. (A-E) mRNA levels of the TGFB pathway genes in the tibia
of mice [For panels A and B, data normalized to Actb, Atp5f1, and Pgk1; for panels C,D,
and E, data normalized to Actb and Gapdh; Mean ± SD; n = 5-7; each data point
represents a mouse; two-tailed student’s t-test: * p<0.05]. (F-I) mRNA levels of the
TGFB pathway genes in the femur of mice [For panels F to I, data normalized to Actb
and Gapdh; Mean ± SD; n = 5-7; each data point represents a mouse; two-tailed student’s
t-test: * p<0.05]. (J) Immunostaining of tibia marrow for TGFB1 (green). Sections were
counterstained with DAPI (blue). Inserts showing higher magnification. (K)
Quantification of TGFB1 intensity per area, as determined by ImageJ [Mean + SD; n = 3;
7-8 images per mouse were measured; two-tailed student’s t-test: * p<0.05].
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2.3.4

Alterations in bone tissues of diabetic mice include reduced CXCL12 stem
cell niche factor.

A recent study found that the deletion of Tgfbr2 in Osx-Cre targeted mesenchymal cells
significantly increased the CXCL12-abundant reticular (CAR) cell number and led to
changes in Cxcl12 mRNA expression in the bone marrow [40]. Therefore, I also
examined if stem cell niche factors, including CXCL12, were affected in diabetes. As
anticipated, there was a significant reduction in Cxcl12 mRNA levels in the tibiae and
femurs of diabetic mice (Figure 2-17A,C). I also found that the CXCL12 staining
intensity in the bone marrow was reduced in diabetic mice (Figure 2-17F). Unlike
Cxcl12, however, no significant changes were seen in Kit and Kitl levels in the tibia or
femur (Figure 2-17B,D; Kitl in tibia and Kit in femur and data not shown), indicating
specificity in the changes. In support of a selective effect on Cxcl12 is the observation
that the CXCL12 receptor, Cxcr4, was not altered in the tibia or femur (data not shown).
Analysis of bone tissues from diabetic mice at 2 months revealed a significant reduction
in TGFB signalling and Cxcl12 mRNA in the tibia and femur (Figure 2-18), suggesting
that these changes are sustained over time. Collectively, these findings show that
hyperglycemia downregulates the TGFB signalling pathway and Cxcl12 in the bone
marrow, which may contribute to the disruption of the marrow cellular composition in
diabetes.
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Figure 2-17: Diabetes reduces stem cell niche factors in the bone marrow at 1
month.
mRNA levels of stem cell niche factors were detected in the tibia (A, B) and femur (C,
D) of control or diabetic (STZ) mice. Analyses were performed 1 month after the onset of
diabetes [For panels A,B, and D, data normalized to Actb and Gapdh; for panel C, data
normalized to Actb, Atp5f1, and Pgk1; Mean ± SD; n = 5-7; each data point represents a
mouse; two-tailed student’s t-test: * p<0.05]. (E) Immunostaining of mouse tibia marrow
for CXCL12 (green). Sections were counterstained with DAPI (blue). Inserts showing
higher magnification. (F) Quantification of CXCL12 intensity per area, as determined by
ImageJ [Mean + SD; n = 3; 8 images per mouse were measured; two-tailed student’s ttest: * p<0.05].
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Figure 2-18: Diabetes reduces TGFB signalling and stem cell niche factors in the
bone marrow of mice at 2 months.
mRNA levels of TGFB pathway and stem cell niche factors were detected in the tibia (AD) and femur (E-H) of control or diabetic (STZ) mice after 2 months of diabetes onset
[Data normalized to Actb and Gapdh; Mean ± SD; n = 3-5; each data point represents a
mouse; two-tailed student’s t-test: * p<0.05].
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2.3.5

The Wnt signalling pathway is not altered in the bone marrow of diabetic
mice.

Our laboratory has previously found that non-canonical WNT11 mediates the high
glucose-induced adipogenic differentiation of MPCs in culture [6]. Additionally, previous
studies have reported a potential crosstalk between the TGFB and Wnt signalling
pathways [41]. Therefore, I examined whether canonical and non-canonical Wnt
signalling pathways may be altered in the STZ-induced model of early hyperglycemic
alterations. I used Ctnnb1 and Wnt11 levels as a proxy for the canonical and noncanonical Wnt signalling, respectively. Analysis of bone tissues, however, showed no
changes of the Wnt signalling pathway (Figure 2-19). These findings suggest that TGFB
alteration may precede Wnt alteration.
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Figure 2-19: Wnt signalling pathway genes are unaltered in the marrow of mice
after 1 month of diabetes.
mRNA levels of Ctnnb1 (catenin beta-1) and Wnt11 (non-canonical Wnt ligand) were
detected in the tibia (A,B) and femur (C,D) of control or diabetic (STZ) mice after 1
month of diabetes onset [Data normalized to Actb and Gapdh; Mean ± SD; n = 3-6; each
data point represents a mouse; two-tailed student’s t-test: * p<0.05].
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2.3.6

TGFB1 signalling in the bone marrow is not changed with a high-fat diet.

Rodent models of high-fat diet (HFD)-induced obesity have also reported higher marrow
adipose tissue [42, 43]. These models were used as type 2 diabetes models as glucose
intolerance develops over time [44, 45]. Even though our in vitro and in vivo studies
pointed to hyperglycemia as the trigger for enhanced adipogenesis in cells and rodents [6,
46], I wanted to determine whether similar alterations are exhibited in HFD-fed mice as
STZ-induced diabetic mice. Five-week-old male 129S6/SvEvTac mice were fed a
Western-style diet with significant calories from fat for 6 months. Mice fed regular chow
and HFD had no difference in food consumption (Figure 2-20A). HFD-fed mice had
significantly higher body weight and fat mass compared with mice fed regular chow
(Figure 2-20B,C). Although oral glucose tolerance test did not show a difference between
the groups (Figure 2-20D), a significant increase in plasma insulin, cholesterol, and
triglyceride was observed in HFD-fed mice (Figure 2-20E,G,H). Analysis of bone tissues
showed increased Pparg and Sp7 transcripts in HFD-fed mice. However, histological
analyses did not show enhanced marrow adiposity (data not shown). In addition, no
alteration in Tgfb1 and Tgfbr1 levels were found in HFD-fed mice (Figure 2-20I). These
results suggest that diabetes-induced marrow adiposity may be due to hyperglycemiaassociated changes in TGFB signalling.
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Figure 2-20: High-fat diet mouse model shows no effect on TGFB1 signalling
pathway in the bone marrow.
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Five-week-old male 129S6/SvEvTac mice were fed regular rodent chow (Chow) or a
Western diet containing 42% of calories from animal fat (HFD) for 6 months. Bone
marrows from mice were flushed for gene expression analyses. (A) Food consumption in
mice [Mean ± SD; n=7-8; each data point represents a mouse]. (B) Body weights of mice
at the time of tissue harvest [Data normalized to Actb; Mean ± SD; n = 7-8; each data
point represents a mouse; two-tailed student’s t-test, *p<0.05]. (C) Epididymal fat
weights in mice [Mean ± SD; n = 7-8; each data point represents a mouse; two-tailed
student’s t-test, *p<0.05]. (D) Levels of blood glucose during an oral glucose tolerance
test after administering glucose solution orally via gavage (1 g of glucose/kg) [Mean +
SD; n = 6-8]. (E) Plasma insulin levels as measured by ELISA [Mean ± SD; n = 7; each
data point represents a mouse; two-tailed student’s t-test, *p<0.05]. (F-H) Serum lipid
profile showing free fatty acids (F), total cholesterol (G), and triglycerides (H). Lipids
were measured using standard colourimetric assays [Mean ± SD; n = 7-8; each data point
represents a mouse; two-tailed student’s t-test, *p<0.05]. (I) mRNA levels of Tgfb1,
Tgfbr1, and adipogenesis- and osteogenesis-related transcription factors [Data normalized
to Actb; Mean + SD; n = 3-4; two-tailed student’s t-test: * p<0.05].
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2.4

Discussion

My studies discovered that diabetes mediates rapid structural alterations in the bone
marrow. Bone marrow alterations were noted before structural hallmark changes in other
target organs of diabetic complications, such as fibrosis and inflammation. The key
findings of my study include: 1) 1 month of diabetes is sufficient to observe enhanced
tibia marrow adipogenesis in mice, 2) femur may be more resistant to diabetes-mediated
adipogenesis compared with the tibia, while both are susceptible to reduced osteogenesis,
3) TGFB signalling pathway is suppressed in bone tissues of diabetic mice, and 4) Cxcl12
alteration may underlie the recently discovered diabetic ‘mobilopathy’.
It is well established that STZ-induced hyperglycemia in rodents generates readouts that
mimic human diabetic complications, including skeletal fragility and enhanced adiposity
in the bone marrow [8]. Moreover, microangiopathy, neuropathy, and stem cell
rarefaction are observed in human diabetic patient bone marrows and in experimental
models [6, 7, 47]. My studies show increased adipocytes in the tibia after a month of
STZ-induced diabetes. Although the femur tissues did not show increased adipogenesis at
this time point, it has been previously noted that the accumulation of marrow adipocytes
in the tibia is much more robust than the femur with ageing [27]. It is possible that with a
longer duration of STZ-induced hyperglycemia, the femur will also show enhanced
adiposity. The inherent differences in the tibia versus femur may also be due to
differential basal Wnt signalling. Wnt pathway activation has been previously shown to
inhibit adipogenic transcription factors, CEBPA and PPARG [48]. A comparison of the
Wnt pathway-associated transcripts between the femur and tibia in my study displayed
significantly lower levels of Ccnd1 (Appendix 4E). Therefore, Wnt signalling may be
more prominent in the femurs that suppresses adipogenesis. Moreover, stem cell niche
factor transcript levels, including Cxcr4, Kit, and Kitl also were significantly lower in the
tibia (Appendix 4A-C). It is possible that the Wnt signalling in the femurs positively
shapes the stem cell niches to support the regenerative stem cells [49].
In the STZ-induced diabetic mouse model, I observed enhanced adiposity in the tibia to
be associated with suppressed TGFB pathway. TGFB has been reported to play a role in
adipogenic differentiation of bone marrow mesenchymal progenitor cells (bm-MPCs), as
92

well as regulating bone mass and quality. A recent study investigated the effect of the
TGFB signalling pathway in bone tissues. Inactivating TGFB signalling by deleting
Tgfbr2 using a doxycycline-repressible Sp7 (osterix)-Cre transgene (Osx-Cre) in mice 3
weeks of age resulted in a significant reduction in growth, body weight, and bone mass
and quality [40]. Moreover, marrow adiposity was significantly enhanced in Osx-Cre,
Tgfbr2fl/fl mice, where osmium staining and Oil Red O-positive cells in the bone marrow
increased almost 80-fold. Furthermore, adipocyte-specific Pparg and Fabp4 expression
in the marrow was also significantly increased [40]. These studies point to the critical
role of the TGFB signalling pathway in suppressing adipogenic differentiation of bmMPCs. In STZ-induced diabetic mice, reduced expression of the TGFB pathway,
including the downstream mediators, Smad3 and Smad6, may remove the suppression
and allow bm-MPCs to readily differentiate into adipocytes. Therefore, an interesting
future direction would be to induce diabetes in transgenic mice with constitutively active
canonical TGFB signalling (SMAD2/3) to assess whether restoring active TGFB
signalling cells prevents diabetes-induced adipogenesis in the bones.
Another interesting finding of my study is the reduced expression of Cxcl12 in the
marrow of diabetic mice. CXCL12 has also been shown to play an important role in
maintaining hematopoietic stem cells [50]. In vitro, CXCL12 acts as a potent
chemoattractant for primitive bone marrow CD34+CD38– cells that include hematopoietic
stem cells [51-53]. In vivo, CXCL12 has been shown to promote the engraftment of
transplanted hematopoietic cells in the bone marrow and subsequent hematopoietic
reconstitution [54]. Based on these studies, my findings may have uncovered the recently
described ‘diabetic mobilopathy’. The mechanism of suppressed Cxcl12 may be related
to the disrupted TGFB pathway in diabetes as well. Osx-Cre, Tgfbr2fl/fl mice do display a
significant reduction of Cxcl12 transcript expression, despite having an increased number
of the CXCL12-abundant reticular (CAR) cells [40].
Although enhanced adipogenesis was detected in the tibia and not the femur of the
diabetic mice, both long bones showed alterations in osteogenesis. Specifically, my
results show that Runx2 and Sp7 are significantly suppressed in the marrow of diabetic
mice. This suggests suppression of osteogenesis occurs prior to enhanced adipogenesis in
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diabetes. Impaired osteogenesis in diabetes may be related to and trigger the reduction in
CXCL12 signalling, as previous studies suggest that decreased CXCL12 expression is
secondary to the loss of osteoblast lineage cells [55]. Therefore, it is likely that enhanced
adipogenesis, together with suppressed osteogenesis and CXCL12 signalling disruption,
in the bone marrow of diabetic patients likely contributes to disrupting the stem cell niche
that depletes vascular regenerative stem cells [6, 7]. Therefore, effective treatment
modalities to preserve stem cells in diabetes may need to correct both enhanced
adipogenesis and suppressed osteogenesis.
The TGFB signalling pathway may also have age-related physiological relevance.
Ageing has also been shown to increase adipocytes in the tibia and femur [56]. MPCs
have also been examined following isolation from adult (6- to 8-month old) and old (20to 26-month old) mice to determine how the TGFB signalling pathway manifests with
age [57]. Interestingly, the inhibitory SMADs, Smad6 and Smad7, were significantly
decreased in MPCs derived from old mice [57]. Since the expression of the inhibitory
SMADs is under the control of TGFB, the decrease in the transcript levels of the
inhibitory SMADs suggests an overall decrease in TGFB signalling. Moreover,
osteoclasts isolated from aged (26 months) mice had blunted TGFB signalling shown by
reduced p-SMAD2/3 staining of the femur compared with young (4 months) mice [58].
This consequently reduced the availability of Wnt1 that contributes to osteoblast
differentiation in the bone [58]. Taken together, the altered levels of TGFB signalling in
the bone and the marrow affect other cells to enhance adipogenesis, while suppressing
osteogenesis.
I also investigated an HFD-induced obesity mouse model to explore whether this model
also displays enhanced marrow adiposity [36, 37]. This seemed to be an appropriate
model to investigate, especially as obesity is the leading risk factor for type 2 diabetes
[38, 39]. The HFD-fed 129S6 mice displayed a significant increase in Pparg and Sp7
transcript levels. This supports the findings of the diet-induced obesity model in adult
C57BL/6 mice that also exhibited higher bone mass and fat volume in the tibia [40].
Interestingly, the HFD marrow did not present changes in the Tgfb1 and Tgfbr1 mRNA
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levels. The model also did not show glucose intolerance or hyperglycemia. This suggests
that the TGFB signalling alteration may be primarily mediated by hyperglycemia.
In summary, my studies identified bone marrow alterations as one of the early
complications of diabetes. I show that 1 month of STZ-induced diabetes enhances bone
marrow adiposity in the tibia of mice. These changes were associated with suppressed
TGFB signalling, a known regulator of cell differentiation. Furthermore, I discovered
reduced expression of Cxcl12 as an early alteration, which may mediate diabetes-induced
deficits in stem cell mobilization from the marrow.
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Chapter 3
3
3.1

Disrupted transforming growth factor-beta signalling as a potential
mechanism regulating enhanced marrow adipogenesis in diabetes
Introduction

Enhanced marrow adiposity and skeletal fragility are chronic complications of diabetes
[1-3]. Our laboratory has previously shown that high glucose conditions enhance
adipogenic differentiation of bone marrow-derived mesenchymal progenitor cells (bmMPCs), while inhibiting osteoblastogenesis [2]. Moreover, we and others have provided
evidence that diabetes leads to a significant depletion of CD45-negative vascular
regenerative stem cells in the bone marrow, whereas CD45-expressing hematopoietic
stem cells remain unaffected [2, 4]. These findings suggest that changes in the marrow
composition from enhanced adipogenesis deplete the vascular regenerative stem cells and
may lead to organ dysfunction in diabetes. Interestingly, our laboratory has observed that
when human CD133+ stem cells are directly co-cultured with adipocytes, stem cell
markers, such as NANOG and OCT4, are significantly decreased leading to loss of stem
cell phenotype [5]. This loss of phenotype was not observed when the same stem cells
were seeded on osteoblasts. Therefore, understanding how diabetes enhances
adipogenesis and leads to depletion of stem cells is imperative.
Multiple mechanisms have previously been reported to regulate adipogenesis in
mesenchymal cells. These include the transforming growth factor-beta (TGFB) pathway
[6-8]. In humans, the TGFB superfamily consists of over 30 ligand genes, TGFB
isoforms, Activins, Nodals, Growth Differentiation Factors (GDFs), and Bone
Morphogenetic Proteins (BMPs), that signal through transmembrane serine/threonine
kinase receptors [reviewed in [9]]. TGFB is a multifunctional cytokine that includes three
main isoforms—TGFB1, TGFB2, and TGFB3—with TGFB1 being the most prevalent in
mammalian and bone tissues [10, 11]. Interestingly, all three isoforms signal similarly by
cell surface receptors and have similar cellular targets. The heteromeric complex of
TGFB and its receptors recruit and phosphorylate receptor-regulated SMADs (RSMADs). These R-SMADs include SMAD2/3 in the TGFB signalling branch and
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SMAD1/5/8 in the BMP signalling branch. R-SMADs then associate with a common
SMAD4. This SMAD complex translocates to the nucleus to regulate the transcription of
TGFB target genes [12]. There are also inhibitory SMADs (I-SMADs), SMAD6 and
SMAD7, that modulate SMAD-mediated signalling. SMAD6 negatively regulates the
BMP signalling pathway [13], whereas SMAD7 has been shown to antagonize
TGFB/activin and BMP signalling [14-16].
In addition to activating the canonical SMAD signalling pathways, TGFB can also
activate the non-canonical pathways, which include TGFB-associated kinase 1 (TAK1)
[17-20], AKT (also known as protein kinase B, PKB) [21], and other mitogen-activated
protein kinases (MAPKs) [22-27]. Numerous signalling networks of the TGFB pathway
have been identified, and it is clear that the outcome of the cellular response to TGFB is
the balance of canonical SMAD and non-canonical signalling pathways.
Previous studies have investigated the role of the TGFB signalling pathway in adipogenic
differentiation of mouse pre-adipocyte cell lines [28-30]. In NIH3T3 cells, TGFB
signalling activation repressed transcriptional activity of CEBPs via interaction with
SMAD3/4 [28]. Similarly, mouse 3T3-L1 cells exposed to TGFB1 expressed
significantly lower levels of CEBPB and CEBPA [30]. In mice, the deletion of Tgfbr2 in
mesenchymal progenitors has been shown to affect osteoblastogenesis and adipogenesis
in the bone marrow [31]. Collectively, these studies highlight the role of the TGFB
signalling pathway in differentiation to adipocytes and osteoblasts.
In the present study, I have characterized how high levels of glucose in diabetes may
affect TGFB signalling in bone marrow-derived cells in culture. Results of my studies
show that high levels of glucose suppress TGFB and enhance adipogenic differentiation
of bm-MPCs. The addition of exogenous TGFB inhibited adipogenesis through activation
of the non-canonical TAK1 pathway. Then, using a genome-wide expression profiling
approach, I report that the TGFB regulates lipid and nutrient metabolism pathways.
Furthermore, crosstalk with the Wnt pathway emerged as a potential downstream
mechanism of TGFB action in bm-MPCs.
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3.2
3.2.1

Materials and methods
Isolation, culture, and differentiation of MPCs

Human bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were prepared
from freshly isolated human bone marrow mononuclear cells (Lonza Inc., Walkerville,
MD). Multiple donors were used in these studies (Lot# 081032A, 43Y Caucasian female;
Lot# 081109A, 43Y Hispanic male; Lot# 080511A, 20Y Black female; Lot# 080500B,
19Y Black male; Lot# 081362A, 27Y Caucasian female; Lot# 080455B, 19Y Black
male; Lot# 081393A, 19Y Black female). Bone marrow mononuclear cells were seeded
on tissue culture plates in low glucose Dulbecco’s Modified Eagle Medium (DMEM;
Thermo Fisher; Cat# 11885084) supplemented with 10% fetal bovine serum (FBS;
Lonza, Cat# 14-507 or Thermo Fisher, Cat# 12484028) and 1X PSF (antibioticantimycotic solution; Corning, Cat# 30-004-CI).
All in vitro studies were performed with at least four different donor preparations (N)
conducted at different times, and more than two experimental replicates (n) each time.
All bm-MPC preparations were used before sub-passage 7. To induce adipogenic
differentiation, bm-MPCs were plated at a density of 40,000 cells/cm2. Cultured cells
were then exposed to adipogenesis-inducing medium (StemPro Adipogenesis
Supplement; Thermo Fisher; Cat# A1007001) for various time points. Although the
formulation is proprietary, adipogenesis in human mesenchymal precursors is easily
induced in medium containing FBS, insulin, dexamethasone, isobutylmethylxanthine, and
indomethacin. However, for consistency, the pre-formulated medium was used. We did
confirm that the medium formulation does not contain peroxisome proliferator activated
receptor gamma (PPARG) agonists such as pioglitazone, which would confound the
results. Control medium consisted of Dulbecco's Modified Eagle Medium supplemented
with 10% FBS. Media was changed every other day. To determine the effect of TGFB1
on bm-MPC differentiation, exogenous human TGFB1 (R&D Systems, Cat# 100-B-001)
was added to the induction medium at 10 ng/mL. To determine how TGFB1 mediates its
effect in bm-MPC differentiation, downstream signalling proteins that are responsive to
TGFB1 were inhibited using commercially available inhibitors (Table 3-1).
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To explore whether Wnt receptor proteins are involved in adipogenic differentiation,
recombinant Frizzled-8 protein (FZD8; R&D Systems; Cat# 6129-FZ-050) at 100 ng/mL
and recombinant human secreted frizzled-related protein-4 (sFRP4; R&D Systems; Cat#
1827-SF-025/CF) at 1 μg/mL and 10 μg/mL were added into the culture media.
For some studies, bm-MPCs were induced to differentiate into osteoblasts. For this, bmMPCs were plated at a density of 40,000 cells/cm2. Cultured cells were then exposed to
osteogenesis-inducing medium (StemPro Osteogenesis Supplement; Thermo Fisher; Cat#
A1007201) for various time points.
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Table 3-1: Inhibitors of TGFB signalling pathway.
Reagent

Target
protein

Acronym

Concentrations

Source
(Catalogue)

1 µmol/L
GW 788388

ALK5

ALK5i

10 µmol/L

Tocris Bioscience
(3264)

50 µmol/L
0.1 µmol/L
Chelerythrine
Chloride

PKC

PKCi

1 µmol/L

Cayman Chemical
(11314)

5 µmol/L
1 µmol/L
SB203580

p38 MAPK

p38i

10 µmol/L

Millipore (559395)

50 µmol/L
1 µmol/L
(5Z)-7Oxozeaenol

TAK1

TAK1i

10 µmol/L

Cayman Chemical
(17459)

50 µmol/L
1 µmol/L
JNK inhibitor
XVI

JNK

JNKi

10 µmol/L

Cayman Chemical
(18096)

50 µmol/L
1 µmol/L
SIS3

SMAD3

SMAD3i

10 µmol/L

Cayman Chemical
(15945)

50 µmol/L
1 µmol/L
PI 828

PI3K

PI3Ki

10 µmol/L

Tocris Bioscience
(2814)

50 µmol/L
1 µmol/L
PD98059

MEK1,2

MEKi

10 µmol/L
50 µmol/L

STEMCELL
Technologies
(72172)
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3.2.2

RNA isolation, mRNA profiling & quantitative RT-PCR

Total RNA was isolated using RNeasy Mini Plus Kit (Qiagen; Cat# 74134) or SingleShot
Cell Lysis Kit (Bio-Rad Laboratories; Cat# 172-5080). Total RNA amount was measured
using Qubit RNA Broad Range Assay (Thermo Fisher; Cat# Q10210) in a Qubit
Fluorometer (Thermo Fisher; Q32857). cDNA was synthesized using iScript cDNA
Synthesis Kit (Bio-Rad Laboratories; Cat# 1708841). qPCR reactions consisted of 10 µL
RT2 SYBR Green qPCR Mastermix (Qiagen; Cat# 330502), 2 µL of both forward and
reverse primers (Table 3-2) at 10 µmol/L concentration, 2 µL cDNA, and 6 µL nucleasefree H2O (Ambion; Cat# AM9937). All reactions were run on CFX Connect Real-Time
PCR Detection System (Bio-Rad). Target gene mRNA data were normalized to
housekeeping genes identified in the figure legends. SYBR Green-based reactions were
performed for 40 cycles using the following temperature profiles: 95°C for 15 seconds
(initial denaturation); and 60°C for 60 seconds (annealing and extension). Data were
analyzed by CFX Manager software (Bio-Rad; Cat# 1845000) using the normalized
(ΔΔCT) method.
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Table 3-2: Primers for qPCR.
Gene

Gene description

Catalogue*

ACTB

Actin, beta

PPH00073G;
QT01680476

ACVR1
(ALK2)

Activin A receptor, type I

PPH01909C

ACVR1B
(ALK4)

Activin A receptor, type IB

PPH01955A

ACVR1C
(ALK7)

Activin A receptor, type IC

PPH17613A

ACVR2A

Activin A receptor, type IIA

PPH01931C

ACVR2B

Activin A receptor, type IIB

PPH01923F

ACVRL1
(ALK1)

Activin A receptor type II-like 1

PPH01915F

AMHR2

Anti-Mullerian hormone receptor, type II

PPH01906A

B2M

Beta-2-microglobulin

PPH01094E

BGLAP

Bone gamma-carboxyglutamate protein

PPH01898A;
QT00232771

BMPR1A

Bone morphogenetic protein receptor, type IA

PPH01929C;
QT00085358

BMPR1B

Bone morphogenetic protein receptor, type IB

PPH01952C;
QT00084469

BMPR2

Bone morphogenetic protein receptor, type II
(serine/threonine kinase)

PPH00401B;
QT00226065

CCND1

Cyclin D1

QT00495285

CEBPB

CCAAT/enhancer binding protein beta

QT00237580

CTNNB1

Catenin (cadherin-associated), beta 1

PPH00643F;
QT00077882

ENG

Endoglin

PPH01140G

FABP4

Fatty acid binding protein 4

QT01667694

FGF1

Fibroblast growth factor 1 (acidic)

PPH00067F

FGF2

Fibroblast growth factor 2 (basic)

PPH00257C

FGFR1

Fibroblast growth factor receptor 1

PPH00372F

FGFR2

Fibroblast growth factor receptor 2

PPH00391F

FZD1

Frizzled family receptor 1

PPH02476B
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FZD2

Frizzled family receptor 2

PPH02470A

FZD3

Frizzled family receptor 3

PPH02457B

FZD4

Frizzled family receptor 4

PPH02427B

FZD5

Frizzled family receptor 5

PPH02411F

FZD6

Frizzled family receptor 6

PPH02402B

FZD7

Frizzled family receptor 7

PPH02420B

FZD8

Frizzled family receptor 8

PPH02446C

FZD9

Frizzled family receptor 9

PPH02416A

GAPDH

Glyceraldehyde-3-phosphate dehydrogenase

PPH00150F;
QT00079247

HPRT1

Hypoxanthine phosphoribosyltransferase 1

PPH01018C

IGF1

Insulin-like growth factor 1 (somatomedin C)

PPH00167C

IGF1R

Insulin-like growth factor 1 receptor

PPH00350F

IGF2

Insulin-like growth factor 2 (somatomedin A)

PPH00168B

LEF1

Lymphoid enhancer-binding factor 1

PPH02778C;
QT00021133

LTBP1

Latent transforming growth factor beta binding
protein 1

PPH14851B

LTBP2

Latent transforming growth factor beta binding
protein 2

PPH00405A

LTBP3

Latent transforming growth factor beta binding
protein 3

PPH16193A

LTBP4

Latent transforming growth factor beta binding
protein 4

PPH10314F

PPARG2

Peroxisome proliferator-activated receptor gamma,
isoform 2

QT00029841

RGMA

RGM domain family, member A

PPH15433A

RPLP0

Ribosomal protein, large, P0

PPH21138F;
QT00075012

RTC

Reverse Transcription Control

PPX63340A

RUNX2

Runt-related transcription factor 2

PPH01897C;
QT00020517

SERPINH1

Serpin peptidase inhibitor, clade H (heat shock
protein 47), member 1, (collagen binding protein 1)

PPH01194C

SMAD1

SMAD family member 1

PPH01174A
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SMAD2

SMAD family member 2

PPH01949F

SMAD3

SMAD family member 3

PPH01921C

SMAD4

SMAD family member 4

PPH00134C

SMAD5

SMAD family member 5

PPH01940C

SMAD6

SMAD family member 6

PPH01910F;
QT00025242

SMAD7

SMAD family member 7

PPH01905C;
QT00076391

SMAD9

SMAD family member 9

PPH00629A

SP7

Sp7 transcription factor

PPH00705A;
QT00213514

TBX2

T-box 2

QT00091266

TCF7

Transcription factor 7 (T-cell specific, HMG-box)

PPH02757B;
QT00095410

TCF7L1

Transcription factor 7-like 1 (T-cell specific, HMGbox)

PPH02745B;
QT00091735

TCF7L2

Transcription factor 7-like 2 (T-cell specific, HMGbox)

PPH06890C;
QT00071120

TGFB1

Transforming growth factor, beta 1

PPH00508A;
QT00000728

TGFB2

Transforming growth factor, beta 2

PPH00524B

TGFB3

Transforming growth factor, beta 3

PPH00531F

TGFBR1

Transforming growth factor, beta receptor 1

PPH00237C;
QT00083412

TGFBR2

Transforming growth factor, beta receptor II
(70/80kDa)

PPH00339C

TGFBR3

Transforming growth factor, beta receptor III

PPH00399E

TGFBRAP1

Transforming growth factor, beta receptor associated
protein 1

PPH21352A

WISP1

WNT1 inducible signaling pathway protein 1

QT00079492

WNT11

Wingless-type MMTV integration site family,
member 11

QT00018270

*Qiagen
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3.2.3

Transcriptome-wide gene-level expression profiling

Total RNA was sent to the Genetic and Molecular Epidemiology Laboratory, David
Braley Research Institute (Hamilton, ON) for the Clariom S Assay, human (Thermo
Fisher; Cat# 902926) with standard input (“Plus” assay). Raw data files were provided to
be viewed using the Transcriptome Analysis Console Software (Thermo Fisher).

3.2.4

Gene Set Enrichment Analyses

Gene ontology (GO) analysis was performed using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) online bioinformatics program
(https://david.abcc.ncifcrf.gov; [32, 33]). Gene set enrichment analysis (GSEA) was
performed with the GSEA software (http://www.broadinstitute.org/gsea/; [34, 35]).
Enrichment score (ES) is the degree to which a gene set is over-represented in the
expression dataset. Normalized enrichment score (NES) is the enrichment score that has
been normalized across analyzed gene sets. Venn diagrams were created with
InteractiVenn (http://www.interactivenn.net/index.html; [36]) and are not plotted to scale.

3.2.5

Phospho-protein measurements

To detect and quantify phosphorylated proteins (as a proxy for activation) in the TGFB
signalling pathway, the Human TGF beta Pathway Phosphorylation Array C1
(RayBiotech, Inc; Cat# AAH-TGFB-1-2) was used. Using this platform, levels of c-Jun
(P-Ser73), SMAD1 (P-Ser463/465), SMAD5 (P-Ser463/465), SMAD4 (P-Thr277),
ATF2 (P-Thr69/71), c-Fos (P-Thr232), SMAD2 (P-Ser245/250/255), and TAK1 (PSer412) were detected. Total protein lysates were prepared by lysing cells in Cell
Extraction Buffer (Thermo Fisher; Cat# FNN0011) containing Halt Combined Protease
and Phosphatase Inhibitor (Thermo Fisher; Cat# PI-78440). Total protein levels were
measured using Pierce BCA (Thermo Fisher; Cat# PI-23227). A total of 50 μg of total
protein was applied to the membranes. The signals were detected by the ChemiDoc
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XRS+ System (Bio-Rad Laboratories) and analyzed using the Image Lab software (BioRad Laboratories).

3.2.6

Cell staining

Cultured cells were plated at a density of 40,000 cells/cm2 on 8-chambered Nunc LabTek Chamber Slide System slides (Thermo Fisher; Cat# 177402). Cells were allowed to
attach for 24 hours. Cells were fixed in cold methanol for 10 minutes on ice. Cells were
then permeabilized with 0.25% Triton X-100 (VWR; Cat# VWRVM143) in PBS before
incubating with primary antibodies, p-SMAD1/5 (Ser463, Ser465; Thermo Fisher; MA515124; 1:100 dilution) and TLE1 (Abcam; ab183742; 1:200 dilution). Following 1 hour
of primary incubation, FITC-conjugated secondary antibody (Vector Laboratories; FI1000, FI-2000) was applied for 1 hour at room temperature. Slides were counterstained
with DAPI and mounted using a mounting medium containing DAPI (Sigma-Aldrich;
Cat# F6057). Images were taken using an Olympus BX-51 microscope (Olympus
Canada) equipped with Spot Pursuit digital camera (SPOT Imaging Solutions).
To detect intracellular lipid accumulation in cells, HCS LipidTOX Green neutral lipid
stain (Thermo Fisher; Cat# H34475) was used. After various treatments, cells were fixed
with 3-4% paraformaldehyde (Electron Microscopy Sciences; Cat# 15710) for 10
minutes. LipidTOX staining solution was then added for 30 minutes. Cells were
counterstained with DAPI. The number of adipocytes and lipid droplets were measured
by the CellProfiler software [37].
To detect osteoblast differentiation and mineralization, Alizarin Red S staining was
performed. Cells were fixed in 10% neutral buffered formalin for 30 minutes. A 2%
Alizarin Red S solution (Sigma-Aldrich; Cat# A5533) was added for 5 minutes. Slides
were then cleared in 50% xylene and 50% acetone. Slides were mounted for imaging
using a water-based mounting medium. To quantify the staining, a similar staining
procedure was followed. A 10% acetic acid was added to each well and heated at 85°C
for 10 minutes. The solution was allowed to cool and was centrifuged at 20,000 xg for 15
minutes. The supernatant was then transferred to a new tube and sodium hydroxide
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solution was added to neutralize the acid to a pH between 4.1 and 4.5. Absorbance was
measured at 405 nm using Thermo Scientific Multiskan FC Microplate Photometer
(Thermo Scientific).

3.2.7

Statistical Analysis

All data were expressed as Mean ± standard deviation (SD). Statistical and graphical
analyses were performed using GraphPad Prism 7 and Microsoft Excel (basic analysis).
Data were tested for normality. When comparing parametric data from two groups, a
student’s unpaired t-test was used. For multiple comparisons, an analysis of variance
(ANOVA) followed by Bonferroni post hoc analysis was performed. P values <0.05 were
considered statistically significant.
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3.3
3.3.1

Results
High glucose exposure affects TGFB1 signalling pathway in cultured
mesenchymal progenitor cells.

Previous reports have shown that TGFB inhibits adipogenic differentiation of
mesenchymal cell lines in culture [28]. Furthermore, our laboratory has shown that
culture conditions that mimic diabetes cause enhanced adipogenic differentiation with
suppressed osteogenic differentiation in human bm-MPCs [2]. Streptozotocin-induced
diabetic mice also show a suppressed TGFB signalling pathway in bone tissues (Chapter
2). This led me to investigate the effect of high levels of glucose on signalling pathways,
including the TGFB pathway, in human mesenchymal cells. Bm-MPCs were cultured in
normal growth medium containing elevated levels of glucose for 21 days (Figure 3-1). To
identify target signalling pathways that may be affected in this elevated glucose
condition, I used quantitative PCR to screen for genes associated with adipogenic
differentiation. Using this approach, I found that cells cultured in medium containing 25
mmol/L glucose (high glucose; HG) exhibited suppressed mRNA levels of the TGFB
family, including the downstream signalling mediators, SMAD2, SMAD3, and SMAD4,
compared with the cells cultured in medium with 5 mmol/L glucose (Figure 3-1D). In
contrast to the TGFB pathway, no changes were observed in the fibroblast growth factor
and the insulin-like growth factor signalling pathways (Figure 3-1E,F respectively). This
suggests that hyperglycemia potentially suppresses TGFB signalling in bm-MPCs to
regulate cell fate changes.
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Figure 3-1: High levels of glucose reduce TGFB1 pathway genes in bone marrow
progenitor cells.
Human bone marrow-derived progenitor cells were cultured in high glucose (25 mmol/L)
for 21 days. Control cells were cultured in medium containing 5 mmol/L glucose. Media
was changed every other day. mRNA levels of TGFB ligands (A), TGFB receptors (B),
BMP receptors (C), SMADs (D), fibroblast growth factor (FGF) signalling pathway (E),
and insulin-like growth factor (IGF) signalling pathway (F) were measured. Red dashed
line showing levels in control cells [Data normalized to ACTB, B2M, GAPDH, HPRT1,
and RPLP0; Mean + SD; n = 2; two-tailed student’s t-test: * p<0.05].
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3.3.2

TGFB1 exposure inhibits adipogenic differentiation of bone marrow
mesenchymal progenitor cells.

As the mRNA levels of downstream signalling mediators of the TGFB pathway were
significantly decreased, I next explored the effect of exogenously supplied TGFB1 on
adipogenic differentiation of bm-MPCs. I exposed bm-MPCs in adipogenic
differentiation medium or adipogenic medium supplemented with 10 ng/mL TGFB1 for
72 hours. This time point has been previously reported to be sufficient for cultured cells
to initiate differentiation [38, 39]. TGFB1 exposure significantly inhibited adipogenic
differentiation as illustrated by a significant reduction in PPARG2 mRNA (Figure 3-2A),
which supports the findings from a mouse pre-adipocyte cell line [28]. Moreover, TGFB1
reduced the number of adipocytes in culture and the level of lipid accumulation in the
cells (Figure 3-2B,C). To directly examine targets that may be responsible for mediating
the effect of TGFB1 in preventing adipogenic differentiation, I screened the TGFB
superfamily, including the Activin and BMP pathways by qPCR (Figure 3-2E-I). After 72
hours, cells in adipogenic differentiation medium significantly induced ALK7 and
TGFBR3, which were normalized to control levels with TGFB1 (Figure 3-2E,G). In
addition, SMAD7 and SMAD9 were significantly increased with TGFB1 exposure
compared with the adipogenic medium (Figure 3-2H). Interestingly, SMAD2/3 levels did
not change with TGFB1 (Figure 3-2H), suggesting SMAD2/3 may not be involved in
TGFB responses that inhibit adipogenic differentiation of bm-MPCs. In contrast, latent
TGFB binding protein-1 (LTBP1) mRNA was normalized with TGFB1 exposure (Figure
3-2I). Overall, it appears that the TGFB pathway is suppressed during adipogenesis and
the addition of TGFB normalizes some of the suppression.
I also tested whether elevated glucose levels in the experimental platform led to
exaggerated changes. The addition of 25 mmol/L glucose to adipogenic differentiation
medium significantly increased PPARG2 levels compared with the adipogenic
differentiation medium with only 5 mmol/L glucose (Figure 3-3). These results support
our previous studies [40] and support the hypothesis that hyperglycemia in diabetes
enhances adipogenesis. Interestingly, the addition of exogenous TGFB1 in high glucose
adipogenic medium decreased PPARG2 to levels comparable to adipogenic medium with
5 mmol/L glucose and accumulated less lipid droplets within the cells (Figure 3-3).
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Figure 3-2: TGFB1 exposure inhibits adipogenic differentiation of bone marrow
mesenchymal progenitor cells.
Human bone marrow-derived progenitor cells (bm-MPCs) were induced to differentiate
into adipocytes (ADP), with or without TGFB1 (10 ng/mL) for 72 hours. (A) mRNA
levels of PPARG2 in bm-MPCs [Data normalized to ACTB, GAPDH, and RPLP0; Mean
+ SD; n = 4; ANOVA followed by Bonferroni post hoc analysis: * p<0.05]. (B) bmMPCs, treated as indicated in panel A, were stained with LipidTOX (green) to detect
intracellular lipid accumulation. Cells were counterstained with DAPI (blue). Inserts
showing higher magnification. (C, D) The number of adipocytes and frequency of lipid
droplets were measured by CellProfiler [Mean + SD; n = 4; 3 images per replicate were
measured; ANOVA followed by Bonferroni post hoc analysis: * p<0.05]. (E-G) mRNA
levels of Activin receptors (E) BMP receptors (F), and TGFB receptors (G) [Data
normalized to ACTB, B2M, GAPDH, HPRT1, and RPLP0; Mean + SD; n = 2; ANOVA
followed by Bonferroni post hoc analysis: * p<0.05 compared with Control, † p<0.05
compared with ADP]. (H, I) mRNA levels of SMADs (H) and latent TGFB binding
proteins (LTBPs) (I) in bm-MPCs [Data normalized to ACTB, B2M, GAPDH, HPRT1,
and RPLP0; Mean + SD; n = 2; ANOVA followed by Bonferroni post hoc analysis: *
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p<0.05 compared with Control, † p<0.05 compared with ADP]. For panels E to I, mRNA
levels in control cells are indicated by a red dashed line.
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Figure 3-3: TGFB1 suppresses the high glucose-mediated increase in PPARG2
mRNA.
Bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were cultured in
control, adipogenic medium (ADP), or ADP supplemented with TGFB1 (10 ng/mL) or
high glucose (HG; 25 mmol/L) for 7 days. (A) mRNA levels of PPARG2 in bm-MPCs
[Data normalized to ACTB; Mean + SD; n = 2-3; ANOVA followed by Bonferroni post
hoc analysis: * p<0.05 compared with control, † p<0.05 compared with ADP]. (B)
Detection of intracellular lipid accumulation in bm-MPCs by LipidTOX (green). Cells
were counterstained with DAPI (blue).
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3.3.3

Adipogenic differentiation activates SMAD1/5, but BMP does not enhance
adipogenic differentiation of MPCs.

To assess the activation of downstream mediators upon TGFB1 exposure, phosphorylated
proteins were measured by immunoblotting. Exposure of bm-MPCs to TGFB1 was
associated with increased phospho- (p-) SMAD4 and TAK1 (Figure 3-4A). Interestingly,
p-SMAD4 increase was not seen when bm-MPCs were cultured in adipogenic
differentiation medium with TGFB1. Adipogenic differentiation medium suppressed
TAK1, which was normalized with TGFB1 exposure (Figure 3-4A). Moreover,
adipogenic differentiation medium alone increased p-SMAD1 and p-SMAD5, and this
increase was completely neutralized by the addition of TGFB1 (Figure 3-4A), suggesting
that SMAD1/5 may be involved in the inhibitory action of TGFB1. Immunostaining of
cells cultured in adipogenic differentiation medium showed nuclear localization of pSMAD1/5 (Figure 3-4B). The addition of TGFB1 was associated with reduced nuclear pSMAD1/5 (Figure 3-4B).
I then assessed for inhibitory SMAD6 and SMAD7 mRNA after 7 days. SMAD6 was
induced with adipogenic differentiation, whereas the levels normalized with the addition
of TGFB1 (Figure 3-4C). This suggested that the BMP signalling pathway may be
involved as SMAD6 has been identified to inhibit the BMP signalling pathway [13, 41].
However, activation of the BMP pathway with either BMP4 or BMP7 did not enhance
adipogenic differentiation (Figure 3-4D-G).
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Figure 3-4: Adipogenic differentiation of mesenchymal progenitor cells induces
SMAD1/5.
(A) Bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were exposed to
TGFB1 (10 ng/mL), adipogenic medium (ADP), or adipogenic medium supplemented
with TGFB1 (10 ng/mL) for 72 hours. Phosphorylated signalling proteins involved in the
TGFB pathway were detected by immunoblotting. Densitometric quantification is shown
[Data shown as Mean + SD; n=2; Two-way ANOVA followed by Bonferroni post hoc
analysis: * p<0.05 compared with Control, † p<0.05 compared with TGFB1, ‡ p<0.05
compared with ADP]. (B) bm-MPCs, treated as indicated in panel A, were stained for
phosphorylated SMAD1/5 (green). Cells were counterstained with DAPI (blue). Insert
showing higher magnification. (C) bm-MPCs were cultured in ADP with and without
TGFB1 (10 ng/mL) for 7 days. mRNA levels of inhibitory SMADs were measured [Data
normalized to ACTB, GAPDH, and RPLP0; Mean + SD; n = 3; ANOVA followed by
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Bonferroni post hoc analysis: * p<0.05]. (D, E) Bm-MPCs were cultured in adipogenic
medium (ADP) with (D) BMP4 (10 ng/mL) or BMP7 (10 ng/mL); or (E) BMP4 (25
ng/mL) or BMP7 (100 ng/mL) for 72 hours. Levels of PPARG2 mRNA were measured
[Data normalized to ACTB and GAPDH; Mean + SD; n = 3; ANOVA followed by
Bonferroni post hoc analysis]. (F, G) Bm-MPCs were cultured in (F) adipogenic media
(ADP) supplemented with BMP4 (25 ng/mL) or BMP7 (100 ng/mL); or (G) ADP with
TGFB1 (10 ng/mL) supplemented with BMP4 (25 ng/mL) or BMP7 (100 ng/mL) for 72
hours. Lipid accumulation was detected by LipidTOX (green). Cells were counterstained
with DAPI (blue) at 10x magnification [n=2]. Inserts showing higher magnification.
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3.3.4

TGFB1 exposure causes sustained suppression of bm-MPC differentiation
into adipocytes.

I next examined whether inhibition of bm-MPC differentiation into adipocytes by TGFB1
was long-lasting. To test this, I cultured bm-MPCs in control medium or adipogenic
differentiation medium, both containing TGFB1, for 72 hours. The media was replaced
with adipogenic differentiation medium (without TGFB) for 4 additional days to assess.
When the cells were exposed to TGFB1 in control or adipogenic differentiation media,
mRNA levels of PPARG2 and FABP4 were significantly reduced (Figure 3-5A,B). The
diminished transcription of these genes was accompanied by a significant reduction in the
number of adipocytes and lipid droplets (Figure 3-5D-F). Next, I sought to determine
whether the cells maintained their precursor phenotype. For this purpose, I measured
TBX2 mRNA levels as our laboratory has previously found that TBX2 is a surrogate
marker for cell differentiation (low TBX2 is observed in undifferentiated cells and
increased levels in differentiated cells) [42]. Interestingly, TGFB1 exposure in control
medium significantly decreased TBX2 mRNA levels compared with control (Figure
3-5C). Expectedly, levels of TBX2 mRNA were not significantly different between
control and adipogenic differentiation media as these cells have been exposed to
adipogenic differentiation medium for a minimum of 72 hours where the majority of the
cells have fully committed and/or have differentiated into adipocytes [28].
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Figure 3-5: Early TGFB1 exposure sustains the inhibition of adipogenic
differentiation in bone marrow-derived mesenchymal progenitor cells.
Bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were exposed to normal
growth medium (control) or adipogenic differentiation medium (ADP), with or without
TGFB1 (10 ng/mL) for 72 hours. Cells were then cultured in adipogenic differentiation
medium for an additional 4 days. (A,B) mRNA levels of PPARG2 (A) and FABP4 (B) at
day 7 [Data normalized to ACTB; Mean + SD; n = 3; ANOVA followed by Bonferroni
post hoc analysis: * p<0.05 compared with control, † p<0.05 compared with ADP]. (C)
mRNA levels of TBX2 after 7 days [Data normalized to ACTB; Mean + SD; n = 3;
ANOVA followed by Bonferroni post hoc analysis: * p<0.05 compared with control, †
p<0.05 compared with ADP]. (D) Lipid accumulation in bm-MPCs as detected by
LipidTOX (green). Cells were counterstained with DAPI (blue). (E, F) The Number of
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adipocytes (E) and the number of lipid droplets (F) were measured by CellProfiler [Mean
± SD; n = 3; 10 images per condition were used for measurements; ANOVA followed by
Bonferroni post hoc analysis: * p<0.05 compared with control, † p<0.05 compared with
ADP].
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3.3.5

Non-canonical TGFB signalling inhibits adipogenic differentiation of bmMPCs.

Next, I used a variety of inhibitors of the TGFB signalling pathway to identify which arm
of the pathway may be inhibiting adipogenesis in bm-MPCs. The inhibition of ALK5,
TGFB-associated kinase 1 (TAK1), and JNK significantly rescued PPARG2 and lipid
accumulation in cells, negating the effects of TGFB1 (Figure 3-6A,B). This triggered the
question of whether cells would enhance adipogenic differentiation potential with these
inhibitors under normal growth medium. Although, ALK5 inhibition did not change the
PPARG2 levels, inhibiting JNK significantly induced PPARG2 (Figure 3-6C). A
dampened response was also seen with TAK1 inhibitor.
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Figure 3-6: TAK1-JNK axis mediates TGFB1 signalling to inhibit mesenchymal
progenitor cell differentiation into adipocytes.
Bone marrow-derived mesenchymal progenitor cells (bm-MPCs) cultured in adipogenic
medium (ADP) with TGFB1 (10 ng/mL) were screened with various inhibitors of the
TGFB signalling pathway. All inhibitors were tested at 10 µmol/L concentration and for
72-hour exposure. (A) Levels of PPARG2 mRNA in bm-MPCs [Data normalized to
ACTB, GAPDH, and RPLP0; Mean + SD; n = 4; two-tailed student’s t-test: * p<0.05
compared with adipogenic medium and TGFB1]. (B) bm-MPCs, treated as indicated in
Panel A, were stained for intracellular lipid accumulation by LipidTOX (green). Cells
were counterstained with DAPI (blue). Inserts showing higher magnification. (C) bmMPCs cultured in control (DMEM) medium supplemented with TAK1 inhibitor (TAK1i;
10 µmol/L) or JNK inhibitor (JNKi; 10 µmol/L) for 72 hours were analyzed for PPARG2
mRNA levels [Data normalized to ACTB, GAPDH, and RPLP0; Mean + SD; n = 2-3;
two-tailed student’s t-test: * p<0.05 compared with control].
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3.3.6

TGFB1 induces canonical Wnt signalling target genes in bm-MPCs.

I next performed a microarray analysis to understand the mechanisms of TGFB1mediated inhibition of adipogenesis and to identify targetable pathways. I cultured bmMPCs in control growth medium (Control), adipogenic differentiation medium (ADP),
adipogenic differentiation medium with TGFB1 (TGFB1), and adipogenic differentiation
medium with TGFB1 and TAK1 inhibitor (TAK1i). With a threshold of p=0.05 (Figure
3-7A), I found a total of 193 genes that were significantly higher in ADP and TAK1i
groups and reduced in the TGFB1 group (Appendix 5). On the other hand, 154 genes
were downregulated in ADP and TAK1i groups and normalized in the TGFB1 group
(Appendix 6). From the 347 identified genes, Control and TGFB1 groups, and ADP and
TAK1i groups displayed similar gene expression signatures and were clustered together
(Figure 3-7B).

126

Figure 3-7: Identifying TGFB-responsive genes in bm-MPCs.
(A) A threshold of p=0.05 was used to identify differentially regulated genes between the
groups. The patterns sought, either 1) upregulated with adipogenic medium with/without
TAK1 inhibitor (TAKi), which is normalized with TGFB1; or 2) downregulated with
adipogenic medium with/without TAK1i, which is normalized with TGFB1. The
identified targets were further analyzed with the DAVID informatics tool to identify
significant biological processes. (B) A heatmap of the differentially expressed genes (347
genes) from the Clariom S Assay (n=2 for each group) that clusters Control and TGFB1,
and ADP and TAK1i.
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To identify biological process targets, I performed a GO analysis of the identified genes. I
found that the upregulated genes in ADP and TAK1i groups are largely involved in fatty
acid and lipid metabolism and regulation, with 38 GO biological processes identified
with a p<0.05. This is not unexpected in stem cell differentiation studies where most of
the genes and pathways would be related to the phenotype of cells being derived. More
interestingly, the downregulated genes are involved in various biological processes,
including osteoblast differentiation and the Wnt signalling pathway, with 19 GO
biological processes identified with a p<0.05 (Table 3-3, Table 3-4).
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Table 3-3: Gene ontology (GO) biological processes from target genes that are
upregulated in adipogenic differentiation and TAK1 inhibitor exposure.
Biological Process Term

p-value

GO:0055114

oxidation-reduction process

1.27E-05

GO:0006635

fatty acid beta-oxidation

8.83E-05

GO:0006098

pentose-phosphate shunt

1.70E-04

GO:0015909

long-chain fatty acid transport

2.25E-04

GO:0006629

lipid metabolic process

2.34E-04

GO:0042493

response to drug

0.001295

GO:0006631

fatty acid metabolic process

0.002047

GO:0010886

positive regulation of cholesterol storage

0.002167

GO:0043524

negative regulation of neuron apoptotic process

0.002535

GO:0034383

low-density lipoprotein particle clearance

0.002869

GO:0055085

transmembrane transport

0.003987

GO:0098869

cellular oxidant detoxification

0.006003

GO:0042953

lipoprotein transport

0.010259

GO:0006646

phosphatidylethanolamine biosynthetic process

0.010259

GO:0050731

positive regulation of peptidyl-tyrosine phosphorylation

0.010409

GO:0010595

positive regulation of endothelial cell migration

0.011979

GO:0070542

response to fatty acid

0.013109

GO:0051968

positive regulation of synaptic transmission, glutamatergic 0.016261

GO:0022904

respiratory electron transport chain

0.017946

GO:0035902

response to immobilization stress

0.019702

GO:0007173

epidermal growth factor receptor signaling pathway

0.020296

GO:0009051

pentose-phosphate shunt, oxidative branch

0.020617

GO:0042412

taurine biosynthetic process

0.020617

GO:0019322

pentose biosynthetic process

0.020617

GO:0019915

lipid storage

0.025376

GO:0033344

cholesterol efflux

0.027397

GO:0006656

phosphatidylcholine biosynthetic process

0.027397

GO:0032496

response to lipopolysaccharide

0.028214

GO:0006549

isoleucine metabolic process

0.030767
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GO:0000255

allantoin metabolic process

0.030767

GO:0032868

response to insulin

0.032316

GO:0051881

regulation of mitochondrial membrane potential

0.033832

GO:0070374

positive regulation of ERK1 and ERK2 cascade

0.035667

GO:0006642

triglyceride mobilization

0.040812

GO:0046449

creatinine metabolic process

0.040812

GO:0006573

valine metabolic process

0.040812

GO:0032869

cellular response to insulin stimulus

0.045823

GO:0019221

cytokine-mediated signaling pathway

0.047437
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Table 3-4: Gene ontology (GO) biological processes from target genes that are
downregulated in adipogenic differentiation and TAK1 inhibitor exposure.
Biological Process Term

p-value

GO:0007017

microtubule-based process

2.04E-04

GO:0098609

cell-cell adhesion

3.86E-04

GO:0045892

negative regulation of transcription, DNA-templated

0.002616

GO:0090190

positive regulation of branching involved in ureteric
bud morphogenesis

0.010318

GO:0001649

osteoblast differentiation

0.010401

GO:0032922

circadian regulation of gene expression

0.011277

GO:1900275

negative regulation of phospholipase C activity

0.016251

GO:0042384

cilium assembly

0.018749

GO:0008652

cellular amino acid biosynthetic process

0.018895

GO:0007265

Ras protein signal transduction

0.019547

GO:0060271

cilium morphogenesis

0.025299

GO:0045893

positive regulation of transcription, DNA-templated

0.025357

GO:0001501

skeletal system development

0.025888

GO:0007155

cell adhesion

0.034578

GO:0030177

positive regulation of Wnt signaling pathway

0.034745

GO:0060071

Wnt signaling pathway, planar cell polarity pathway

0.039448

GO:0055129

L-proline biosynthetic process

0.040138

GO:0007411

axon guidance

0.041325

GO:0006561

proline biosynthetic process

0.047971
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To further extract biological insight from the microarray dataset, I performed a Gene Set
Enrichment Analysis (GSEA) for hallmark gene sets (v7.4; 50 gene sets) comparing two
groups at a time. The groups that were compared were 1) Control vs ADP (Figure 3-8,
Table 3-5); 2) ADP vs TGFB1 (Figure 3-8, Table 3-6); and 3) TGFB1 vs TAK1i (Figure
3-8, Table 3-7). Control and TGFB1 groups were indicated with negative normalized
enrichment scores, whereas ADP and TAK1i groups were indicated with positive
normalized enrichment scores. Next, common enriched gene sets were identified within
the groups that displayed similar gene expression signatures. A total of 12 gene sets were
enriched in the control and TGFB1 groups, and 10 gene sets were enriched in the ADP
and TAK1i groups (Figure 3-8D,E). Of the 12 gene sets that were identified in the control
and TGFB1 groups, the “Wnt beta-catenin signalling” was of great interest, as our
laboratory has previously identified that high-glucose induced adipogenic differentiation
of bm-MPCs involves the switch from canonical to non-canonical Wnt signalling [2].
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Figure 3-8: GSEA normalized enrichment score for hallmark gene sets.
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(A-C) The gene set enrichment analysis for groups: (A) Control versus adipogenic differentiation; (B) adipogenic differentiation
versus adipogenic differentiation with TGFB1; and (C) adipogenic differentiation with TGFB1 versus adipogenic differentiation with
TGFB1 and TAK1 inhibitor. A positive normalized enrichment score indicates gene sets that are enriched in mesenchymal progenitor
cells exposed to adipogenic differentiation medium (A,B), and adipogenic differentiation medium with TGFB1 and TAK1 inhibitor
(C). (D, E) A Venn diagram illustrating the enriched pathways found in the control and TGFB1 groups (D), and adipogenic
differentiation and TAK1 inhibitor groups (E). The list of pathways is the common pathways found in all three comparisons.
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Table 3-5: Gene sets enriched in bm-MPCs exposed to control and adipogenic differentiation media (ADP).
Condition

Gene Set

Size

NES

p-value

FDR

ADP

Adipogenesis

187

2.658365

0

0

Fatty Acid Metabolism

152

2.406275

0

0

Xenobiotic Metabolism

191

1.972802

0

0

Cholesterol Homeostasis

69

1.875002

0.002268

0.001414

Oxidative Phosphorylation

176

1.788628

0

0.002573

Peroxisome

99

1.587389

0.002375

0.014536

Myc Targets V2

51

1.538435

0.026846

0.019612

Bile Acid Metabolism

110

1.517775

0.00907

0.021075

Androgen Response

92

1.491636

0.011494

0.024066

Apical Surface

42

1.352561

0.090551

0.069815

Reactive Oxygen Species Pathway

45

1.237397

0.147752

0.155475

Pancreas Beta Cells

39

1.207659

0.209607

0.177652

Angiogenesis

34

1.15252

0.263393

0.234508

KRAS Signaling Dn

190

1.075596

0.266366

0.355486

UV Response Up

154

1.057003

0.310945

0.369972

Myc Targets V1

174

1.040503

0.340376

0.379482

Spermatogenesis

129

1.016069

0.412301

0.409409

Interferon Alpha Response

91

-2.11756

0

0

Control
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136

Interferon Gamma Response

192

-2.11069

0

0

Mitotic Spindle

193

-2.02258

0

2.75E-04

Epithelial Mesenchymal Transition

192

-2.05704

0

3.67E-04

TNFa Signaling via NFKB

192

-1.91684

0

6.50E-04

Apical Junction

187

-1.86246

0

9.58E-04

G2/M Checkpoint

180

-1.89573

0

0.001117

Inflammatory Response

195

-1.77894

0

0.002031

p53 Pathway

185

-1.76275

0

0.002376

IL2 STAT5 Signaling

190

-1.72817

0

0.003334

Protein Secretion

92

-1.68879

0.001825

0.004221

Apoptosis

154

-1.69173

0

0.004408

Unfolded Protein Response

97

-1.59861

0.003584

0.008945

Coagulation

134

-1.59909

0

0.009584

Estrogen Response Early

188

-1.60237

0.001689

0.010118

E2F Targets

181

-1.52685

0.003565

0.016091

UV Response Dn
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-1.45121

0.017794

0.032148

Complement

192

-1.43812

0.005474

0.034237

KRAS Signaling Up

192

-1.42564

0.007156

0.036671

Allograft Rejection

188

-1.39622

0.028319

0.045073

Notch Signaling

31

-1.3424

0.102703

0.06793

Hypoxia

192

-1.33269

0.021311

0.069599
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Estrogen Response Late

190

-1.24963

0.084577

0.132398

TGF Beta Signaling

53

-1.21881

0.164602

0.160584

PI3K AKt mTOR Signaling

100

-1.13364

0.207294

0.270295

IL6 JAK STAT3 Signaling

85

-1.1351

0.242321

0.277975

Heme Metabolism

185

-1.11822

0.216028

0.286274

mTORC1 Signaling

192

-1.07734

0.289116

0.353933

Myogenesis

190

-1.05333

0.328026

0.391704

Glycolysis

192

-1.02774

0.389545

0.435953

Hedgehog Signaling

34

-0.93503

0.551595

0.641383

Wnt Beta Catenin Signaling

41

-0.86948

0.642857

0.781315

DNA Repair

138

-0.76945

0.939338

0.927302

Table 3-6: Gene sets enriched in bm-MPCs exposed to adipogenic differentiation medium (ADP) with or without TGFB1.
Condition

Gene Set

Size

NES

p-value

FDR

ADP

Interferon Alpha Response

91

2.191829

0

0

Adipogenesis

187

2.017069

0

0

Xenobiotic Metabolism

191

1.895772

0

9.95E-04

Fatty Acid Metabolism

152

1.871451

0

7.46E-04

Bile Acid Metabolism

110

1.725169

0

0.002389

Interferon Gamma Response

192

1.638922

0.003247

0.007206

Apical Surface

42

1.406108

0.058076

0.061861

Cholesterol Homeostasis

69

1.393647

0.039076

0.058884

Complement

192

1.36985

0.016474

0.065428

Peroxisome

99

1.352695

0.055077

0.069613

Reactive Oxygen Species Pathway

45

1.271546

0.136937

0.128324

KRAS Signaling Dn

190

1.237835

0.074919

0.152356

IL6 JAK STAT3 Signaling

85

1.105878

0.272727

0.347811

Myogenesis

190

1.088949

0.271829

0.357887

Allograft Rejection

188

1.079157

0.288525

0.354051

Coagulation

134

1.034265

0.390048

0.426172

Oxidative phosphorylation

176

0.96039

0.56042

0.57492

Spermatogenesis

129

0.90317

0.684474

0.679257

TGF Beta Signaling

53

-2.12261

0

0

TGFB1
138

139

Unfolded Protein Response

97

-2.09296

0

0

mTORC1 Signaling

192

-2.0696

0

0

Epithelial Mesenchymal Transition

192

-2.03528

0

0

Hypoxia

192

-2.01353

0

0

Glycolysis

192

-1.94226

0

0

TNFa Signaling via NFKB

192

-1.90582

0

6.19E-04

G2/M Checkpoint

180

-1.77283

0

0.001843

p53 Pathway

185

-1.62084

0

0.009627

E2F Targets

181

-1.57311

0

0.015059

IL2 STAT5 Signaling

190

-1.55387

0.002681

0.017656

Hedgehog Signaling

34

-1.51943

0.033113

0.022994

Inflammatory Response

195

-1.4207

0.010309

0.047972

Estrogen Response Early

188

-1.35651

0.01061

0.078547

Myc Targets V1

174

-1.33254

0.02267

0.088333

UV Response Dn

132

-1.32667

0.031818

0.087379

Wnt Beta Catenin Signaling

41

-1.30854

0.096552

0.097154

Protein Secretion

92

-1.30152

0.06988

0.096993

UV Response Up

154

-1.2737

0.062035

0.116662

KRAS Signaling Up

192

-1.25186

0.046392

0.131479

Androgen Response

92

-1.24269

0.088095

0.133734

Apoptosis

154

-1.19927

0.099237

0.17918

140

PI3K AKT mTOR Signaling

100

-1.18508

0.16152

0.189661

Pancreas Beta Cells

39

-1.17789

0.210526

0.19274

Mitotic Spindle

193

-1.17033

0.097297

0.194721

Angiogenesis

34

-1.06676

0.339713

0.376011

Apical Junction

187

-1.04731

0.315294

0.408796

Estrogen Response Late

190

-1.01412

0.395161

0.475929

Notch Signaling

31

-0.96412

0.486301

0.595359

Myc Targets V2

51

-0.92005

0.586605

0.696053

DNA Repair

138

-0.91215

0.698565

0.695802

Heme Metabolism

185

-0.8993

0.716456

0.705125

Table 3-7: Gene sets enriched in bm-MPCs exposed to adipogenic differentiation medium (ADP) and TGFB1, with or without
TAK1 inhibitor (TAK1i).
Condition

Gene Set

Size

NES

p-value

FDR

TAK1i

Adipogenesis

187

2.356003

0

0

Fatty Acid Metabolism

152

2.139756

0

0

Xenobiotic Metabolism

191

2.105543

0

0

Interferon Alpha Response

91

2.003802

0

5.90E-04

Cholesterol Homeostasis

69

1.897892

0

0.001146

Complement

192

1.807903

0

0.001466

p53 Pathway

185

1.811716

0

0.001711

Reactive Oxygen Species Pathway

45

1.750302

0.001815

0.003332

Oxidative Phosphorylation

176

1.693126

0

0.004221

Bile Acid Metabolism

110

1.688197

0

0.004421

Coagulation

134

1.576186

0.001712

0.012847

Peroxisome

99

1.518858

0.00495

0.019752

Interferon Gamma Response

192

1.491824

0.006462

0.023758

Apoptosis

154

1.371015

0.025682

0.076556

TNFa Signaling via NFKB

192

1.341559

0.027157

0.08899

Apical Junction

187

1.347214

0.023256

0.090629

Myogenesis

0.304618

0.030303

0.099075

0.79

KRAS Signaling Up

0.298357

0.03882

0.110163

0.837

141

TGFB1

142

UV Response Dn

0.312613

0.080268

0.121307

0.878

Heme Metabolism

0.296372

0.0384

0.11931

0.883

Estrogen Response Late

0.281801

0.094574

0.186286

0.98

IL6 JAK STAT3 Signaling

0.316327

0.160584

0.211486

0.988

Estrogen Response Early

0.270939

0.158516

0.259587

0.998

Hypoxia

0.265547

0.178571

0.247971

0.999

Apical Surface

0.344719

0.272381

0.257506

0.999

Inflammatory Response

0.267227

0.189627

0.261144

0.999

DNA Repair

0.272035

0.193493

0.267666

1

UV Response Up

0.236674

0.470978

0.542542

1

KRAS Signaling Dn

0.21025

0.728988

0.783954

1

Androgen Response

0.228339

0.694946

0.809356

1

Angiogenesis

0.258062

0.753271

0.901269

1

Notch Signaling

0.252517

0.784133

0.942504

1

Protein Secretion

0.146962

1

0.998405

1

G2/M Checkpoint

180

-1.95638

0

0

Unfolded Protein Response

97

-1.86891

0

4.47E-04

E2F Targets

181

-1.65828

0

0.009373

Hedgehog Signaling

34

-1.58959

0.015119

0.014036

Myc Targets V1

174

-1.48678

0.004878

0.027491

Epithelial Mesenchymal Transition

192

-1.50045

0

0.028229
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Mitotic Spindle

193

-1.29085

0.028947

0.119671

Myc Targets V2

51

-1.27503

0.124434

0.121352

mTORC1 Signaling

192

-1.25921

0.040284

0.125785

Spermatogenesis

129

-1.29553

0.061905

0.13208

Pancreas Beta Cells

39

-1.18443

0.21322

0.206505

Allograft Rejection

188

-1.16725

0.113208

0.215174

IL2 STAT5 Signaling

190

-1.11181

0.176923

0.295312

TGF Beta Signaling

53

-1.05677

0.367206

0.369251

PI3K AKT mTOR Signaling

100

-1.05738

0.315673

0.393633

Glycolysis

192

-1.0338

0.3625

0.395607

Wnt Beta Catenin Signaling

41

-0.92121

0.594406

0.654772

To investigate the potential Wnt signalling mechanism downstream of the TGFB
pathway, I exposed bm-MPCs to TGFB1 in adipogenic medium and examined mediators
involved in the canonical Wnt pathway using qPCR. Apart from TCF7L1, other canonical
Wnt mediators, including CTNNB1 and LEF1, were significantly induced with TGFB1
exposure (Figure 3-9A). Moreover, TLE1 protein localization in nuclei of the cells was
lost with TGFB1 exposure (Figure 3-9B), suggesting activation of the canonical Wnt
pathway. Exposure to TGFB1 in normal growth medium was able to significantly
increase CTNNB1, while decreasing CCND1 mRNA (Figure 3-9C). TGFB1 also
significantly decreased PPARG2 mRNA, increased actin alpha 2, smooth muscle
(ACTA2; commonly referred to as α-smooth muscle actin, α-SMA) mRNA, but did not
alter RUNX2 (Figure 3-9D). Furthermore, TAK1 inhibition in the presence of TGFB1 and
adipogenic differentiation signals significantly increased PPARG2, while significantly
decreasing WISP1 (canonical Wnt target gene) transcript levels (Figure 3-9E,F). This
suggests that TGFB1 may activate the canonical Wnt signalling pathway in bm-MPCs.
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Figure 3-9: TGFB1 modulates canonical Wnt regulators.
(A) Bone marrow-derived progenitor cells (bm-MPCs) were cultured in adipogenic
medium (ADP) with or without TGFB1 (10 ng/mL) for 72 hours. mRNA levels of
canonical Wnt pathway in bm-MPCs were measured [Data normalized to ACTB, B2M,
GAPDH, HPRT1, and RPLP0; Mean + SD; n = 2; ANOVA followed by Bonferroni post
hoc analysis: * p<0.05 compared with control, † p<0.05 compared with ADP]. (B)
Immunofluorescence staining of bm-MPCs for TLE1 (green). Cells were cultured in ADP
medium, TGFB1 (10 ng/mL), or ADP medium containing TGFB1 (10 ng/mL) for 72
hours. Cells were counterstained with DAPI (blue). (C) mRNA levels of Wnt signalling
response genes in bm-MPCs cultured in TGFB1 (10 ng/mL) for 72 hours. Red dashed
line showing levels in control cells [Data normalized to ACTB; Mean + SD; n = 3; twotailed student’s t-test: * p<0.05 compared with control]. (D) mRNA levels of
mesenchymal lineage markers in bm-MPCs exposed to TGFB1 (10 ng/mL) for 72 hours.
Red dashed line showing levels in control cells [Data normalized to ACTB; Mean + SD; n
= 3; two-tailed student’s t-test: * p<0.05 compared with control]. (E, F) bm-MPCs were
cultured in adipogenic medium (ADP) with TGFB1 (10 ng/mL) and (5Z)-7-Oxozeaenol
(TAK1 inhibitor, TAK1i; 1 μmol/L and 10 μmol/L) for 72 hours. mRNA levels of
PPARG2 (E) and WISP1 (F) were determined [Data normalized to ACTB; Mean + SD; n
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= 2-4; ANOVA followed by Bonferroni post hoc analysis: * p<0.05 compared with ADP,
† p<0.05 compared with ADP+TGFB1].
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Next, I sought to determine whether TGFB1 crosstalks with or modulates the noncanonical Wnt pathway. FZD8 was recently identified to be a major WNT11 receptor and
was shown to be associated with TGF-beta receptor type-1 (TGFBR1) to regulate the
canonical TGFB pathway [43]. As FZD8 was a target identified from the FZD screen
(Figure 3-10A) and as we previously found that WNT11 is induced with high glucose
exposure [2], I explored whether FZD8 would affect adipogenic differentiation of bmMPCs. Interestingly, no statistical difference was observed when comparing adipogenic
medium and FZD8-exposed cells to adipogenic medium alone (Figure 3-10B). Next, I
exposed the cells in human secreted Frizzled Related Protein 4 (shFRP4), a known
inhibitor of canonical Wnt signalling that is involved in bone remodelling [44, 45].
Surprisingly, shFRP4 did not normalize the repressed PPARG2 mRNA with TGFB1
exposure at different concentrations (Figure 3-10C). To supplement this finding, WNT11
transcription remained unchanged after 72 hours of TAK1 and JNK inhibitors (Figure
3-10D), which has been shown to increase the abundance of PPARG2 mRNA transcripts
(Figure 3-10C). These findings suggest that TGFB1 does not directly regulate noncanonical Wnt signalling to module adipogenesis in bm-MPCs.
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Figure 3-10: Wnt response factors (Frizzled) downstream of TGFB do not
contribute to adipogenic differentiation.
(A) Bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were cultured in
adipogenic medium (ADP) with and without TGFB1 (10 ng/mL) for 72 hours. mRNA
levels of canonical Wnt pathway genes were determined [Data normalized to ACTB,
B2M, GAPDH, HPRT1, and RPLP0; Mean + SD; n = 2; ANOVA followed by Bonferroni
post hoc analysis: * p<0.05 compared with control, † p<0.05 compared with ADP]. (B)
bm-MPCs were cultured in adipogenic medium (ADP) with or without recombinant
Frizzled-8 protein (100 ng/mL) for 72 hours. mRNA levels of adipogenesis-associated
genes were measured [Data normalized to ACTB; Mean + SD; n = 2-3; ANOVA
followed by Bonferroni post hoc analysis: * p<0.05 compared with control]. (C) Cells
were cultured in adipogenic medium (ADP) with and without TGFB1 (10 ng/mL) and
recombinant human secreted frizzled-related protein-4 (sFRP4; 1 μg/mL and 10 μg/mL).
mRNA levels of PPARG2 were determined. Levels in cells cultured in control medium
are indicated by a red dashed line [Data normalized to ACTB; Mean + SD; n = 3;
ANOVA followed by Bonferroni post hoc analysis: * p<0.05 compared with control, †
p<0.05 compared with ADP]. (D) bm-MPCs were exposed to (5Z)-7-Oxozeaenol (TAK1
inhibitor, TAK1i; 10 μmol/L) or JNK inhibitor XCI (JNKi; 10 μmol/L) for 72 hours.
mRNA levels of WNT11 were determined [Data normalized to ACTB; Mean + SD; n = 2;
two-tailed student’s t-test: * p<0.05].

148

3.3.7

Effect of TGFB1 on osteogenic differentiation of bm-MPCs.

As TGFB1 inhibits adipogenic differentiation, it is possible that one underlying
mechanism is skewing the differentiation of bm-MPCs towards the osteogenic lineage. In
addition, the osteoblast pathway was identified in the microarray analysis in cells
exposed to TGFB1. Therefore, I examined the effect of exogenous TGFB1 exposure on
osteogenic differentiation of bm-MPCs. Previous studies have shown that TGFB1 can
regulate mesenchymal cell differentiation [46]. No changes were seen in osteogenesisassociated RUNX2 (Figure 3-11A). However, levels of SP7 were induced by TGFB1. In
addition, the late marker of osteoblast differentiation, BGLAP (also known as
Osteocalcin) was significantly downregulated (Figure 3-11A). Staining of cells with
Alizarin Red S, which marks mineralization, showed reduced levels in cells exposed to
TGFB1 (Figure 3-11B,C). Hence, these results suggest that TGFB1 primes bm-MPCs to
differentiate into osteoblasts, but these cells do not reach maturation, possibly due to
continued exposure to TGFB1.
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Figure 3-11: TGFB1 inhibits late osteogenic differentiation factor in bone marrowderived progenitor cells and may hinder mineralization.
Bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were cultured in
osteogenic medium (OST) with or without TGFB1 (10 ng/mL) for 9 days. (A) mRNA
levels of osteogenesis-associated transcription factors [Data normalized to ACTB,
GAPDH, and RPLP0; Mean + SD; n = 3; two-tailed student’s t-test: * p<0.05]. (B) bmMPCs cultured in osteogenic medium (OST) with TGFB1 (10 ng/mL) for 9 days were
assessed for mineralized matrix and calcium deposition by Alizarin Red S staining
[representative of n=3]. (C) Quantification of the Alizarin Red S staining was performed
by measuring absorbance at 405 nm [Data normalized to control conditions; Mean + SD;
n = 3; two-tailed student’s t-test: * p<0.05 compared with OST].
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3.4

Discussion

Many pathways have been identified that regulate adipogenesis, such as the Wnt and the
TGFB signalling pathways [as reviewed in [47]]. The results from the present study show
that differentiation of human bm-MPCs is associated with increased nuclear localization
of SMAD1/5. The addition of TGFB1 inhibits differentiation of human bm-MPCs and
reduces the levels of nuclear SMAD1/5. I also show that TGFB1 mediates its inhibitor
actions through activation of the non-canonical TAK1-JNK axis. Preventing TAK1 and
JNK activation blocks the action of TGFB1 on bm-MPC differentiation. Using
transcriptome analysis, I show that TGFB1 regulates lipid and nutrient metabolic
pathways to inhibit bm-MPC differentiation into adipocytes. These analyses also revealed
a potential involvement of the Wnt pathway and osteogenic differentiation programming
downstream of TGFB1 signalling. These studies have provided new fundamental insight
into adipogenic differentiation of mesenchymal cells, and potentially identified
mechanisms of enhanced bone marrow adipogenesis in diabetes.
TGFB1 has been shown to activate various downstream signalling pathways, broadly
categorized into canonical and non-canonical pathways [50, 51]. Studies exploring the
role of TGFB1 using pre-adipocyte cell lines have shown that adipocyte differentiation is
inhibited by the canonical arm. Specifically, the physical interaction of SMAD3/4 with
CEBPs, upon TGFB1 stimulation, repressed the transcriptional activity from the Pparg
promoter [28]. As I have observed a significant reduction in SMAD2, SMAD3, and
SMAD4 levels in bm-MPCs exposed to high levels of glucose, these downstream
molecules that act as repressors of PPARG may not be available, which in turn, may
result in enhanced adipogenic differentiation. In mice, where Tgfbr2 and Smad4 in
mesenchymal cells were deleted using a doxycycline-repressible Sp7 (Osterix)-Cre
transgene (Osx-Cre), there was a significant increase in marrow adipogenesis [31]. It is
interesting to note that the Osx-Cre, Smad4fl/fl had reduced marrow adiposity compared
with Osx-Cre, Tgfbr2fl/fl, suggesting that both canonical and non-canonical TGFB
signalling may be involved in adipogenic differentiation [31]. My results show that
SMAD2/3 were not induced with TGFB1 exposure of primary bm-MPCs. Instead, I
observed that the non-canonical TAK1-JNK axis mediated the effects of TGFB1, which
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included reducing PPARG2 and limiting adipogenic differentiation. The involvement of
the non-canonical TGFB signalling has also been previously reported, where cell cultures
exposed to MAPK inhibitor negated the effects of TGFB and caused adipocyte
differentiation [31]. MAPK has previously been shown to phosphorylate PPARG to
decrease its transcriptional activity [52]. Thus, this may be the mechanism for TGFBmediated suppression of adipocyte specification in MPCs [31].
My studies also revealed that one possible mechanism of inhibited adipogenesis in bmMPCs upon TGFB1 exposure is the modulation of osteogenic factors. Furthermore, my
results show that TGFB significantly induces SP7 but downregulates BGLAP. This
suggests that TGFB increases the osteoprogenitor cell pool but fails to differentiate the
cells into mature osteoblasts. Previous studies utilizing the Osx-Cre, Tgfbr2fl/fl mice have
shown changes to the trabecular and cortical bones. Specifically, the bone volume and the
bone mineral density in trabecular bone, and bone thickness and bone area in cortical
bone were all shown to be reduced using micro-CT [31].
TAK1 can be activated in response to TGFB1 to promote JNK activation [51]. In this
study, I pharmacologically inhibited various TGFB signalling pathway mediators and
observed that the effect of TGFB1 is mediated by the TAK1-JNK axis in bm-MPCs
directed to differentiate into adipocytes. In undifferentiated myoblasts, activation of JNK
has been shown to inhibit cell differentiation through myoblast determination protein
(MYOD) suppression [53]. In stem-like glioblastoma cells, JNK is involved in
maintaining self-renewal and inhibition of JNK induced the expression of differentiation
markers [54]. In mice, Tak1 deletion that inactivated JNK signalling resulted in bone
marrow failure due to marrow cell apoptosis [55]. In our model, I observed an increase in
PPARG2 when the cells were exposed to the TAK1 and JNK inhibitors. As TAK1
activity has been shown to interfere with nuclear translocation of SMAD1 [56], this may
be a mechanism of TGFB1-mediated inhibition of adipogenic differentiation and
maintenance of progenitor phenotype in bm-MPCs.
My results further demonstrate that the TGFB1 pathway regulates the canonical Wnt
signalling in bm-MPCs. Accumulating evidence suggest the role of the Wnt pathway in
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maintaining stem cell phenotype by stabilizing pluripotency transcription factors, OCT-4,
NANOG, and SOX2 [57-59]. Under long-term hyperglycemic conditions, however, stem
cell growth has been reported to be hindered with an increase in oxidative stress and
suppressed Wnt/CTNNB1 signalling [60]. It is interesting to note that adipogenic
differentiation enriched the “Reactive Oxygen Species Pathway” gene set, whereas
TGFB1 exposure enriched the “Wnt Beta Catenin Signaling” gene sets. In preadipocytes, Wnt signalling decreased as cells differentiated into mature adipocytes, and
the expression of CTNNB1 showed an inverse relationship with levels of CEBPA, a key
regulator of adipogenesis [61]. In our study, the TGFB1-mediated activation of the
canonical Wnt pathway was evident with the loss of nuclear expression of TLE1 along
with the induction of CTNNB1.
Previously, we have shown that high levels of glucose selectively induced non-canonical
WNT11 expression in bm-MPCs [2]. The addition of WNT11 enhanced lipid
accumulation in bm-MPCs and knockdown prevented adipogenic differentiation of cells.
WNT11 has been shown to increase the levels of phosphorylated SMAD1/5/8 [62].
Hence, bm-MPCs in high glucose conditions may induce WNT11 to activate SMAD1/5
signalling and favour adipogenic differentiation. In support of the SMAD1/5 preference
in high glucose conditions, a 1-month experimental diabetic mouse model displayed
reduced TGFB signalling-associated gene transcription, including Smad6 (Chapter 2).
Since SMAD6 is known to inhibit SMAD1/5 signalling [13, 41], these studies show that
diabetes fine-tunes TGFB/SMAD signalling to induce adipogenic differentiation in bmMPCs.
One limitation of the study is the phospho-protein analyses that were performed at 72
hours. Kinase activity is rapid and may peak in minutes to hours. For example, although
no differences were detected with ATF2, c-Fos, and c-Jun proteins after 72 hours in my
study, it is possible that these proteins were activated earlier due to their short half-lives
[48, 49]. The rationale for assessing phospho-proteins at 72 hours was to identify
potential targets that could be inhibited to test their functional role. In most of these
inhibition studies, either through knockout, knockdown, or pharmacological inhibition,
the activity of the protein of interest is supressed until the endpoint and not just in the
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first few minutes to hours. However, this is a limitation and requires further investigation
through a time-course study.
The results of the present study demonstrate that TGFB1-mediated TAK1-JNK axis
activation in bm-MPCs plays an important role in preventing adipogenic differentiation
(Figure 3-12). Therefore, exploring avenues to activate the non-canonical TGFB
signalling in the marrow may be important to maintain the stem cell niche and the bone
marrow composition in diabetes.
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Figure 3-12: Schematic showing the role of canonical and non-canonical TGFB
signalling in adipogenic differentiation of bone marrow mesenchymal progenitor
cells.
TGFB1 inhibits adipogenic differentiation in bone marrow-mesenchymal progenitor cells
(bm-MPCs) by activating the non-canonical TAK1-JNK axis. Adipogenic differentiation
suppresses TAK1-JNK and activates SMAD1/5 protein. A dashed arrow indicates
putative and yet to be tested mechanisms.
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Chapter 4
4
4.1

Characterizing the effect of inhibiting PPARG in the bone marrow
of streptozotocin-induced diabetic mice
Introduction

Enhanced bone marrow adiposity is clinically evident in chronic diabetes [1, 2]. My
previous studies also showed diabetes-induced adipogenesis in mouse tibia (Chapter 2).
Associated with such changes in the bone marrow, we and others have observed a
significant reduction in CD45-negative vascular regenerative stem cells [2, 3]. Inhibiting
adipogenesis to potentially preserve the fate of vascular regenerative stem cells is of great
interest to us and has great implications for diabetic complications research.
Adipogenesis is generally categorized into two phases. First, the determination phase
occurs where cells commit to the adipocyte lineage. Then, the differentiation phase
allows these pre-adipocytes to mature into adipocytes [as reviewed in [4]]. Peroxisome
proliferator-activated receptor gamma (PPARG) is a key regulator of adipogenesis.
PPARG together with CCAAT/enhancer-binding protein alpha, beta, and delta (CEBPA,
CEBPB, and CEBPD) mediate both phases of adipogenesis [5]. Initially, CEBPB and
CEBPD are induced, which activate CEBPA and PPARG [6]. CEBPA and PPARG will
then create a positive feedback loop to reinforce and maintain the terminally
differentiated state of an adipocyte [7, 8].
To inhibit adipogenesis in a mouse model of diabetes, we need to target Pparg. However,
we know that homozygous Pparg-deficiency is lethal due to placental dysfunction [9]. In
addition, heterozygous Pparg-deficient mice show high bone mass with increased
osteoblastogenesis [10], which would generate another variable in assessing the effects of
adipogenic inhibition in diabetes. An alternative strategy is pharmacological PPARG
inhibition. For this alternative approach, PPARG could be inhibited by treating mice with
Bisphenol A diglycidyl ether (BADGE), which is a potent and selective antagonist of
PPARG [11]. Support for the use of this model comes from studies showing that
inhibition of PPARG by BADGE reduces adipocyte content in the bone marrow of
streptozotocin-induced diabetic BALB/c mice [12]. Similarly, studies have shown that
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hematopoietic recovery, following chemotherapy, is improved by BADGE-induced
inhibition of adipogenesis [13]. Even though this would be a systemic administration of
PPARG inhibitor, at a minimum, this BAGDE-treated diabetic mouse model system will
allow us to establish whether inhibiting adipogenesis is associated with preservation of
vascular regenerative stem cells.
The goal of the present study was to explore the effects of BADGE treatment on
streptozotocin-induced diabetic mice. Here, I show that BADGE is ineffective against
diabetes-induced adipogenesis in the tibiae of mice. Although BADGE reduced lipid
accumulation in the liver tissues of diabetic mice, no changes were seen in the bone
tissues. Analysis of the bones also revealed that mRNA alterations of key genes are also
not prevented by BADGE treatment. Based on these results, I explored other PPARG
inhibitors in a culture model of bone marrow-derived mesenchymal progenitor cells.
Results of these in vitro studies suggest that resveratrol may be a potential PPARG
inhibitor to test in mouse models of diabetes.
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4.2
4.2.1

Materials and methods
Isolation, culture, and differentiation of MPCs

Human bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were prepared
from freshly isolated human bone marrow mononuclear cells (Lonza Inc., Walkerville,
MD). Multiple donors were used in these studies (Lot# 081032A, 43Y Caucasian female;
Lot# 081109A, 43Y Hispanic male; Lot# 080511A, 20Y Black female; Lot# 080500B,
19Y Black male; Lot# 081362A, 27Y Caucasian female; Lot# 080455B, 19Y Black
male; Lot# 081393A, 19Y Black female). Bone marrow mononuclear cells were seeded
on tissue culture plates in low glucose Dulbecco’s Modified Eagle Medium (DMEM;
Thermo Fisher; Cat# 11885084) supplemented with 10% fetal bovine serum (FBS;
Lonza, Cat# 14-507 or Thermo Fisher, Cat# 12484028) and 1X PSF (antibioticantimycotic solution; Corning, Cat# 30-004-CI).
All in vitro studies were performed with at least four different donor preparations (N)
conducted at different times, and more than two experimental replicates (n) each time.
All bm-MPC preparations were used before sub-passage 7. To induce adipogenic
differentiation, bm-MPCs were plated at a density of 40,000 cells/cm2. Cultured cells
were then exposed to adipogenesis-inducing medium (StemPro Adipogenesis
Supplement; Thermo Fisher; Cat# A1007001) for various time points. To determine the
effect of PPARG inhibitors, BADGE and other inhibitors known to antagonize PPARG,
increasing concentrations of inhibitors were tested (Table 4-1). Key readouts included
cell viability and inhibition of lipid accumulation and adipogenic differentiation.
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Table 4-1: PPARG inhibitors and tested concentrations.
Reagent

Concentration

Source (Catalogue)

100 nmol/L
Bisphenol A diglycidyl ether
(BADGE)

1 µmol/L
10 µmol/L

Cayman Chemical (70790)

100 µmol/L
1 µmol/L
T0070907

5 µmol/L

R&D Systems (2301)

10 µmol/L
10 µmol/L
Diclofenac

25 µmol/L
50 µmol/L

Cayman Chemicals (70680)

100 µmol/L
10 µmol/L
Resveratrol

25 µmol/L
50 µmol/L

Cayman Chemicals (70675)

100 µmol/L
1 µmol/L
Lovastatin

2.5 µmol/L
5 µmol/L

Cayman Chemicals
(10010338)

10 µmol/L
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4.2.2

Cell viability assays

To determine the effect of various PPARG inhibitors on total viable cell number, bmMPCs were plated at 5,000 cells/cm2 in normal growth medium (described above). After
24 hours, the medium was removed, and cells were exposed to increasing concentrations
of the PPARG inhibitors in fresh medium. The total number of live cells was determined
after 48 hours using Scepter 2.0 Automated Cell Counter (Millipore; Cat# PHCC00000)
with 60 μm sensors (Millipore; Cat# PHCC60050).

4.2.3

RNA isolation, mRNA profiling & Quantitative RT-PCR

Total RNA was isolated using RNeasy Mini Plus Kit (Qiagen; Cat# 74134) or SingleShot
Cell Lysis Kit (Bio-Rad Laboratories; Cat# 172-5080). Total RNA amount was measured
using Qubit RNA Broad Range Assay (Thermo Fisher; Cat# Q10210) in a Qubit
Fluorometer (Thermo Fisher; Q32857). cDNA was synthesized using iScript cDNA
Synthesis Kit (Bio-Rad Laboratories; Cat# 1708841). qPCR reactions consisted of 10 µL
RT2 SYBR Green qPCR Mastermix (Qiagen; Cat# 330502), 2 µL of both forward and
reverse primers (Table 4-2) at 10 µmol/L concentration, 2 µL cDNA, and 6 µL nucleasefree H2O (Ambion; Cat# AM9937). All reactions were run on CFX Connect Real-Time
PCR Detection System (Bio-Rad). Target gene mRNA data were normalized to
housekeeping genes identified in the figure legends. SYBR Green-based reactions were
performed for 40 cycles using the following temperature profiles: 95°C for 15 seconds
(initial denaturation); and 60°C for 60 seconds (annealing and extension). Data were
analyzed by CFX Manager Software (Bio-Rad; Cat# 1845000) using the normalized
(ΔΔCT) method.
qPCR on mouse tissues was performed on RNA prepared as indicated above. Mouse
forward and reverse primers are presented in Table 4-3, Table 4-4. SYBR Green-based
chemistry was used as described above. For some studies, the TaqMan assay was used.
For this, the reactions consisted of 5 µL TaqMan Fast Advanced Master Mix (Thermo
Fisher; Cat# 4444963), 0.5 µL of the gene probe (Table 4-5), 1 µL cDNA, and 3.5 µL
nuclease-free H2O. TaqMan-based reactions were performed for 40 cycles using the
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following temperature profiles: 95°C for 3 seconds (initial denaturation); and 60°C for 30
seconds (annealing and extension). Data were analyzed by CFX Manager Software (BioRad; Cat# 1845000) using the normalized (ΔΔCT) method.
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Table 4-2: Primers for qPCR.
Gene name Description

Catalogue*

ACTB

Actin, beta

PPH00073G;
QT01680476

CEBPA

CCAAT/enhancer binding protein alpha

QT00203357

CEBPB

CCAAT/enhancer binding protein beta

QT00237580

FABP4

Fatty acid binding protein 4

QT01667694

PPARG2

Peroxisome proliferator-activated receptor gamma,
isoform 2

QT00029841

*Qiagen
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Table 4-3: Mouse primers for SYBR Green-based qPCR.
Gene

Gene description

bp

Catalogue*

Actb

Actin, beta

149

QT00095242

Pparg

Peroxisome proliferator activated receptor gamma

144

QT00100296

Sp7

Sp7 transcription factor 7

69

QT00293181

Tgfb1

Transforming growth factor, beta 1

145

QT00145250

Tgfbr1

Transforming growth factor, beta receptor I

120

QT00135828

Tgfbr2

Transforming growth factor, beta receptor 2

76

QT00135646

*Qiagen
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Table 4-4: Mouse primer sequence for SYBR Green-based qPCR.
Gene

Gene description

Sequence

Atp5f1

ATP synthase, H+
transporting,
mitochondrial F0
complex, subunit B1

Cxcl12

C-X-C Motif
Chemokine Ligand 12

CTGTGCCCTTCAGATTGTT

Pgk1

Phosphoglycerate
kinase 1

GGGTGGATGCTCTCAGCAAT

GTCCAGGGGTATTACAGGCAA
TCAGGAATCAGCCCAAGACG

AGCTTTCTCCAGGTACTCTT
GTTCCTGGTGCCACATCTCA

[Ref.]

[14]

[15]
[14, 16]

Source: Thermo Fisher
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Table 4-5: Mouse primers for TaqMan-based qPCR.
Gene

Gene description

bp

Assay ID*

Actb

Actin, beta

143

Mm02619580_g1

Gapdh

Glyceraldehyde-3-phosphate dehydrogenase

107

Mm99999915_g1

Kit

Kit oncogene

71

Mm00445212_m1

Kitl

Kit ligand

91

Mm00442972_m1

Cxcl12

Chemokine (C-X-C motif) ligand 12

85

Mm00445553_m1

Runx2

Runt related transcription factor 2

91

Mm00501584_m1

Tgfbr2

Transforming growth factor, beta receptor II

86

Mm00436977_m1

Tgfb1

Transforming growth factor, beta 1

59

Mm01178820_m1

Tgfbr1

Transforming growth factor, beta receptor I

85

Mm00436964_m1

Sp7

Sp7 transcription factor 7

63

Mm04933803_m1

Bmp4

Bone morphogenetic protein 4

61

Mm00432087_m1

Smad2

SMAD family member 2

72

Mm00487530_m1

Smad3

SMAD family member 3

59

Mm01170760_m1

Smad6

SMAD family member 6

71

Mm00484738_m1

*Thermo Fisher
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4.2.4

Cell staining

Cultured cells were plated at a density of 40,000 cells/cm2 on 8-chambered Nunc LabTek Chamber Slide System slides (Thermo Fisher; Cat# 177402). Cells were allowed to
attach for 24 hours. To detect intracellular lipid accumulation in cells, HCS LipidTOX
Green neutral lipid stain (Thermo Fisher; Cat# H34475) was used. After various
treatments, cells were fixed with 3-4% paraformaldehyde (Electron Microscopy Sciences;
Cat# 15710) for 10 minutes. LipidTOX staining solution was then added for 30 minutes.
Cells were counterstained with DAPI. The number of adipocytes and lipid droplets were
assessed by the CellProfiler software [17].
For Oil Red O staining, cells were fixed in 10% neutral buffered formalin and placed in
100% 1,2-propanediol (Alfa Aesar; Cat# 30948) for 5 minutes. Oil Red O solution
(Sigma-Aldrich; Cat# O0625) was used to identify lipid droplets. Semi-quantifications
were performed by measuring the absorbance of plates at 492 nm in Thermo Scientific
Multiskan FC Microplate Photometer (Thermo Scientific), as per PromoCell’s Oil Red O
staining protocol (PK-CA577-K580).

4.2.5

Animal model

All mouse studies were initiated after receiving approval (Animal Use Protocol: 2019125) from the Western University and Animal Care and Veterinary Services.
Four-week-old male C57BL/6 mice (Charles River Canada) were obtained and allowed
to acclimate for 1 week. Mice were kept on a light/dark (12 h/12 h) cycle at 23°C and
received food (standard lab chow) and water ad libitum. Mice were divided into diabetic
and non-diabetic groups by ensuring the body weights were similar between the two
groups. Diabetes was induced by multiple low-dose intraperitoneal injections of freshly
prepared streptozotocin (STZ; 50 mg/kg in citrate buffer, pH 4.5; Sigma-Aldrich; Cat#
S0130) for 5 consecutive days [18]. Non-diabetic control mice received an equivalent
volume of freshly prepared citrate buffer alone. Body weights were measured daily for
the duration of the study. Mice were also monitored daily for body condition scores and
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overall health. Hyperglycemia was confirmed 1 week after the last STZ injection by
measuring the non-fasting blood glucose level from the tail vein using a glucometer
(CONTOUR Next One, Ascensia Diabetes Care). This day was considered as day 0 (d0).
Mice with non-fasting blood glucose levels greater than 11.1 mmol/L (>200 mg/dL) were
considered diabetic. Mice that did not meet the threshold were measured again after 2
days to confirm hyperglycemia.
Half of the STZ-induced diabetic mice were subjected to daily intraperitoneal injection of
bisphenol A diglycidyl ether (BADGE; 30 mg/kg in 15% DMSO; Cayman Chemical;
Cat# 70790) for 1 month. Untreated diabetic mice received an equivalent volume of 15%
DMSO alone. The injection sites were alternated between the right and left sides to
reduce discomfort. Non-diabetic mice were also treated with BADGE to examine
toxicity, where the same aforementioned process was followed. Each experimental group
contained six to eight mice.
One day prior to euthanasia, blood glucose levels were measured. Following CO2
euthanasia, mice were monitored for cessation of breathing/heartbeat. An incision in the
chest wall was made immediately to reach the heart. A small slit was made into the right
atrium. Mice were then perfused with 5 mL of cold PBS by inserting a 28G needle into
the left ventricle. Femurs and tibiae were then removed and freed from soft tissue. Limbs
from one side were used for histology, and the other side was used for preparing flush
samples. For histological analyses, the bones were fixed in formalin (Sigma-Aldrich;
Cat# HT501128) overnight at room temperature, decalcified in 0.5 mol/L
ethylenediaminetetraacetic acid (EDTA; Fisher Scientific; Cat# S311) for 7 days at 4°C,
and rehydrated in 30% sucrose solution (Sigma-Aldrich; Cat# 84100) overnight at 4°C
prior to being embedded in paraffin. Tissues were sectioned at 4 μm thickness.
For gene expression analyses, the epiphyses of the femurs and tibiae were removed and
centrifuged at 10,000 xg for 15 seconds to flush the bone marrow. The resulting flush
was stored in a cell freezing medium solution (90% fetal bovine serum and 10% DMSO;
Millipore; Cat# S-002-5F) at -20°C until further analysis. For RNA isolation from the
marrow cells, the flush samples were quickly thawed to 37 °C in a water bath and
171

centrifuged at 300 xg to pellet the cells. Cells were then suspended in RLT cell lysis
buffer (RNeasy Plus Mini Kit; Qiagen, Cat# 74134).
In addition to the bone tissues, most other tissues from mice were also collected.
Specifically, eyes, heart, lung, kidney, liver, pancreas, and epididymal adipose tissue
were removed for histology. The tissues were fixed in formalin (Sigma-Aldrich; Cat#
HT501128) overnight at room temperature prior to paraffin embedding. Non-bone tissues
were sectioned at 5 μm thickness for staining and other histological studies

4.2.6

Histomorphometric analysis

Histomorphometric analyses were performed on mouse retina, epididymal fat, and bone
tissues. The thickness of retinal layers and bone lengths were quantified using QuPath
[19]. The frequency of the area of adipocytes found in the white adipose tissue was
analyzed using Adiposoft, an automated software [20]. The number of nuclei per area in
tissues was determined by QuPath [19]. Bone marrow analysis was conducted while
considering the guidelines and standards previously reported [21]. The bone marrow
histological sections were analyzed using MarrowQuant [22] and QuPath [19].

4.2.7

Hematoxylin & Eosin (H&E), Picro-Sirius Red, and PAS staining

The deparaffinized tissue sections were stained using hematoxylin (Leica Biosystems;
Cat# 3801561) and eosin (Leica Biosystems; Cat# 3801601) for routine histological
analysis. Picro-Sirius Red (Abcam; Cat# ab246832) was used to mark collagen
deposition. Periodic Acid-Schiff (PAS) stain kit (Abcam; Cat# ab150680) was used to
detect the presence of carbohydrates and carbohydrate compounds such as
polysaccharides, mucin, and glycogen. Liver sections were also subjected to α-amylase
(Sigma-Alrich; Cat# A3176) treatment prior to PAS (PAS-diastase Staining) to remove
glycogen. The stained slides were digitalized using Aperio slide scanning system (Aperio
Technologies, Inc., Vista, CA) with a 20X and 40X objective and saved in Tagged Image
File Format (TIFF format). Image analyses were performed with the ImageJ software
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package (National Institutes of Health, Bethesda, MD, USA). Picro-Sirius Red-stained
area was automatically assessed by means of a macro
(https://github.com/northcottj/picrosirius-red). The Picro-Sirius Red-positive area of the
specimens was quantified using ImageJ software and shown as a percentage of the total
section area.

4.2.8

Immunostaining of liver tissue

Liver sections were deparaffinized in xylene, hydrated in an ethanol gradient, and
subjected to a heat-induced antigen retrieval process using Citrate/EDTA buffer (10
mmol/L sodium citrate, 1 mmol/L EDTA, 0.05% Tween-20, pH 6.0) in 2100 Retriever
(Electron Microscopy Science, Hatfield, PA). Sections were incubated with rabbit antimouse perilipin-1 (PLIN1; Abcam; ab3526; 1:200 dilution) at room temperature for 1
hour. FITC-conjugated secondary antibodies (Vector Laboratories, Burlington, ON) were
used for detection. Sections were exposed to Vector TrueVIEW Autofluorescence
Quenching Kit (Vector Laboratories; Cat# SP-8400-15) for 5 minutes, followed by
counterstaining with DAPI (Sigma Aldrich; Cat# F6057). Fluorescence images were
captured by an Olympus BX51 epi-fluorescence microscope equipped with Infinity 3-1
Color CCD (Teledyne Lumenera, Ottawa, Canada) and Infinity Analyze software
(Teledyne Lumenera).

4.2.8.1 Bone immunostaining
Bone tissue sections were deparaffinized in xylene and rehydrated through an ethanol
gradient. Tissue sections were then subjected to a heat-induced antigen-retrieval process
using a microwave. Briefly, jars containing the antigen retrieval buffer (10 mmol/L
sodium citrate, 1 mmol/L EDTA, 0.05% Tween-20, pH 6.0 or 10 mmol/L Trizma base, 1
mmol/L EDTA, 0.05% Tween-20, pH 9.0) were placed in the microwave and the buffer
was boiled. Tissue sections were then immersed in the jar when the buffer had cooled and
was not boiling. This process was repeated until the tissues had been subjected to a total
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of 15 minutes in a heated buffer. Sections were then blocked in 1% bovine serum
albumin (Sigma-Aldrich; Cat# A7906) solution in PBS containing 0.1% Tween-20
(Sigma-Aldrich; Cat# P9416) for 1 hour then incubated with primary antibody (Table 46) for 1 hour at room temperature followed by Alexa Fluor 488-conjugated anti-goat
(Thermo Fisher Scientific; A-11079), FITC-conjugated anti-rabbit (Thermo Fisher
Scientific; F-2765), or FITC-conjugated anti-mouse (Vector Laboratories; Cat# FL-2000)
secondary antibodies incubation for 1 hour at room temperature. All sections were then
exposed to Vector TrueVIEW Autofluorescence Quenching Kit (Vector Laboratories;
Cat# SP-8400-15) for 5 minutes, followed by counterstaining with DAPI (Sigma Aldrich;
Cat# F6057). Negative control sections were included for all staining studies and
consisted of the same tissue and same procedure except for the omission of the primary
antibody. Fluorescence images were captured using an Olympus BX51 microscope.
Where fluorescence intensity was measured, sections from all experimental conditions
were subjected to the same exposure time. Fluorescence staining intensity per area of the
sections was performed using QuPath and ImageJ.
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Table 4-6: Antibodies tested on paraffin-embedded mouse bone marrow tissues.

Target

CD31

CD45

CXCL12

FABP4
PLIN1
TGFB1
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Alternative
names

PECAM1

Ly5, LCA

SDF-1

AP2

Clone

Company

Catalogue
number

Target Species

Host
Species

Working

Poly

Novus
Biologicals

AF3628

Mouse, Rat

Goat

Yes

EPR17259

Abcam

ab182981

Mouse, Rat, Human

Rabbit

Yes

Poly

Santa Cruz

sc-1505

Human

Goat

No

Poly

Thermo Fisher 20103-1-AP

Human, Mouse, Rat

Rabbit

Yes

Poly

Abcam

Mouse, Rat, Human

Rabbit

Yes

Poly

Thermo Fisher 14-7992-81

Mouse, Rat

Rabbit

Yes

Poly

Thermo Fisher PA5-114344

Human, Mouse, Rat

Rabbit

Yes

79018

R&D Systems

MAB350

Mouse, Human

Mouse

Yes

Poly

Novus
Biologicals

NBP2-29480

Human, Rat

Rabbit

No

Poly

Thermo Fisher 12802-1-AP

Human, Mouse, Rat

Rabbit

Yes

Poly

Abcam

Mouse

Rabbit

No

Poly

Thermo Fisher PA5-55046

Human, Mouse, Rat

Rabbit

Yes

Poly

Proteintech

Human, Mouse, Rat

Rabbit

Yes

ab10558

ab3526
21898-1-AP

4.2.9

Statistical Analysis

All data were expressed as Mean ± standard deviation (SD). Statistical and graphical
analyses were performed using GraphPad Prism 7 and Microsoft Excel (basic statistical
functions). Data were tested for normality. When comparing parametric data from two
groups, a student’s unpaired t-test was used. For multiple comparisons, an analysis of
variance (ANOVA) followed by Bonferroni post hoc analysis was performed. Where the
D’Agostino and Pearson omnibus normality test failed, the Kruskal-Wallis test followed
by Dunn’s post hoc analysis was performed. P values <0.05 were considered statistically
significant.
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4.3
4.3.1

Results
PPARG inhibitor BADGE prevents adipogenic differentiation of cultured
bm-MPCs.

My previous studies have shown that diabetes enhances adipogenesis in tibiae of mice
(Chapter 2). My main objective is to test an inhibitor of adipogenesis and determine
whether I can inhibit marrow adipogenesis in diabetic mice with a drug/inhibitor
treatment. To select an inhibitor, I first examined the effect of BADGE in culture by
exposing increasing concentrations of BADGE to human bm-MPCs induced to
differentiate into adipocytes. I observed a significant decrease in the number of
adipocytes and lipid droplets as examined by CellProfiler [1] at 1 µmol/L and 100
µmol/L (Figure 4-1A,B). Moreover, I also used Oil Red O staining to verify the
CellProfiler analysis (Figure 4-1D) and found a significant decrease in optical density at
1 µmol/L, 10 µmol/L, and 100 µmol/L of BADGE treatment compared with the
adipogenic differentiation medium alone (Figure 4-1F). To complement the
morphometric analysis, mRNA levels of genes associated with adipogenesis were
examined and showed repressed levels with 100 µmol/L of BADGE (Figure 4-1H).
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Figure 4-1: PPARG inhibitor, BADGE, prevents adipogenic differentiation of bone
marrow mesenchymal progenitor cells.
Bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were exposed to
adipogenic differentiation medium (ADP) with different concentrations of PPARG
inhibitor BADGE for 7 days. (A, B) Adipocyte number (A) and lipid droplet number (B)
were measured using CellProfiler software [Mean ± SD; n = 4; a minimum of 2 images
per replicate were used in measurements; ANOVA followed by Bonferroni post hoc
analysis: * p<0.05 compared with control, † p<0.05 compared with ADP]. (C) Frequency
of lipid droplet size in cells [n = 4; at least 2 images per replicate were used for
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measurements; Kruskal-Wallis test followed by Dunn’s post hoc analysis: * p<0.05]. (D)
Oil Red O staining of bm-MPCs after 7 days in adipogenic differentiation medium with
different concentrations of BADGE. Images are shown in greyscale. (E, F) Quantification
of Oil Red O staining, as determined by measuring absorbance at 493 nm [Mean + SD; n
= 4; two-tailed student’s t-test; for panel E, * p<0.05; for panel F, * p<0.05 compared
with ADP]. (G, H) bm-MPCs were cultured in adipogenic medium (ADP) with different
concentrations of BADGE for 7 days. mRNA levels of CEBPB, PPARG2, and FABP4
were measured [Data normalized to ACTB; Mean + SD; n = 3; for panel G, two-tailed
student’s t-test, * p<0.05; for panel H, ANOVA followed by Bonferroni post hoc
analysis, * p<0.05 compared with ADP].
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4.3.1.1 BADGE has no toxic effects when administered in mice.
Based on the effective inhibition of adipogenesis in culture, I investigated whether
BADGE exposure causes any toxicity in mice. For these studies, I treated healthy, nondiabetic mice with BADGE at 30 mg/kg daily for 1 month. H&E staining of bone tissues,
both tibia and femur, showed no discernible differences between vehicle-treated and
BADGE-treated mice (Figure 4-2A,B). Analysis of retina, kidney, heart, lung, liver,
pancreas, and epididymal fat also showed no alterations induced by BADGE (Figure
4-2C). I then stained select tissues with PAS (glycogen) or Picro-Sirus Red (collagen
deposition) and no changes were observed (Figure 4-2D,E). These results show that
BADGE treatment of mice does not cause pathological changes in tissues of interest.
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Figure 4-2: BADGE treatment of mice does not cause histopathological changes.
(A, B) Representative H&E-stained images of the bone marrow of tibia (A) and femur
(B) of C57BL/6 male mice. Mice were administered BADGE (30 mg/kg) daily for 1
month. Control mice received DMSO. Inserts showing higher magnification. (C)
Representative images of H&E-stained retina, heart, lung, kidney, liver, pancreas, and
white adipose tissue (WAT; epididymal fat). (D) Periodic Acid-Schiff-stained sections of
retina, heart, kidney, and liver of mice. (E) Picro-Sirius Red-stained sections of heart,
lung, and kidney of C57BL/6 mice.
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4.3.2

Inhibiting PPARG with BADGE does not restore impaired body weight gain
or alter blood glucose levels in diabetic mice.

Since no pathological changes were seen when mice were treated with BADGE for 1
month, I proceeded to test the effect of BADGE treatment on diabetic mice. I used the
same model as described in Chapter 2 and made 5-week-old C57BL/6 mice diabetic by
multiple low-dose streptozotocin (STZ). I then initiated BADGE treatment in diabetic
mice at the time of hyperglycemia confirmation. No changes were seen in body weight
gain or blood glucose levels between vehicle-treated diabetic mice and diabetic mice
treated with BADGE (Figure 4-3B-D). Furthermore, the lengths of the femur and tibia
showed no difference between the two groups (Appendix 3C,D). These studies show that
PPARG inhibition has no effect on glycemia and impaired body weight gain in diabetes.
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Figure 4-3: BADGE does not cause alterations in body weight, blood glucose levels,
nor bone length in streptozotocin-induced diabetic mice at 1 month.
(A) Experimental scheme for mouse study. Diabetes was induced in C57BL/6 mice with
daily intraperitoneal injections of streptozotocin (STZ; 50 mg/kg) for 5 consecutive days.
Non-diabetic control mice received citrate buffer. Hyperglycemia was confirmed 1 week
after the last STZ injection. Mice were then treated daily with intraperitoneal injections of
BADGE (30 mg/kg). (B) Body weight difference at the end of the study [Mean ± SD; n =
7-8; each data point represents a mouse; two-tailed student’s t-test: * p<0.05]. (C) Nonfasting blood glucose levels in mice at the conclusion of the study [Mean ± SD; n = 7-8;
each data point represents a mouse; two-tailed student’s t-test: * p<0.05]. (D) Cumulative
average body weight difference from d-11 to d29 in mice [Mean ± SD; n = 7-8; Two-way
ANOVA followed by Bonferroni post hoc analysis: * p<0.05].
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4.3.3

PPARG inhibition by BADGE reduces lipid accumulation in livers of
diabetic mice.

I then examined whether BADGE treatment had any effects on various tissues in diabetic
mice. Similar to the results of BADGE treatment in non-diabetic mice, no pathological
changes were seen in the kidney, lung, heart, retina, pancreas, and epididymal fat tissues
of diabetic mice (Figure 4-4). However, liver tissues of BADGE-treated diabetic mice
showed reduced vacuoles in PAS-diastase-stained sections and reduced PLIN1
immunostaining (p-value of 0.06) compared to vehicle-treated diabetic mice (Figure
4-5C), suggesting that BADGE treatment inhibited lipid accumulation in the liver.

184

Figure 4-4: BADGE treatment does not affect peripheral tissues in diabetic mice at
1 month.
C57BL/6 male mice were made diabetic by streptozotocin (STZ; 50 mg/kg) and then
treated with BADGE (30 mg/kg) daily for 1 month. (A) Representative images of H&Estained tissues of mice. (B) Periodic Acid-Schiff-stained tissue sections. (C) Picro-Sirius
red-stained tissues. (D-F) Quantification of Picro-Sirius red staining by ImageJ showing
heart (D), lung (E), and kidney (F) [Mean ± SD; n = 3-4; each data point represents a
mouse; two-tailed student’s t-test: * p<0.05].
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Figure 4-5: BADGE treatment reduces lipid accumulation in the liver of diabetic
mice at 1 month.
(A) Representative images of Periodic Acid-Schiff (PAS) and PAS-diastase-stained liver
sections. Inserts showing higher magnification. (B) Immunofluorescence staining of liver
tissues for perilipin-1 (PLIN1; green). Tissues were counterstained with DAPI (blue).
Inserts showing higher magnification. (C) Quantification of PLIN1 intensity per area per
nuclei, as determined by ImageJ [Mean + SD; n = 3; 2 images per mouse were measured;
two-tailed student’s t-test: * p<0.05].
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4.3.4

Hyperglycemia-induced changes in the bone marrow are not normalized
with PPARG inhibitor, BADGE.

Histomorphological examination of the tibia from diabetic mice showed no difference in
marrow adiposity with BADGE treatment (Figure 4-6A-D). Similar to the tibia, no
difference was observed in femur tissues (Figure 4-6E-H). These results were surprising
because BADGE reduced lipid accumulation in the liver of these diabetic mice.
Furthermore, previous studies reported reduced bone marrow adiposity in mice following
BADGE treatment [2]. It is possible that the previously published studies focused on agerelated adipogenesis of the tibia and/or femur.
I next examined whether daily BADGE treatment of diabetic mice normalizes key genes
that were significantly affected by STZ administration (Chapter 2)—namely TGFB
pathway genes. As expected, based on no differences seen in adipogenesis by BADGE,
transcript levels of the TGFB signalling pathway were unaltered in diabetic mice treated
with BADGE (Figure 4-7). Similarly, stem cell niche factors were not normalized (Figure
4-8). Interestingly, when osteogenesis-specific genes were measured, the levels showed
some promise in both the tibia and femur, although the p-value was at 0.08 (Figure 4-9).
Immunostaining of tibia sections showed no statistically significant difference in
immunoreactivity to endothelial cell marker, CD31; and stem cell niche factor, CXCL12
(Figure 4-10, Figure 4-11). However, TGFB1 immunostaining intensity showed
increased levels in diabetic mice treated with BADGE compared with the vehicle-treated
diabetic mice (Figure 4-12). In contrast, immunostaining for CD45, FABP4, and PLIN1
did not show any difference between the two groups (Figure 4-13, Figure 4-14, Figure
4-15).
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Figure 4-6: BADGE treatment does not prevent diabetes-induced bone marrow
adiposity.
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Tibia and femur were harvested from streptozotocin (STZ)-induced diabetic mice, and
diabetic mice treated with BADGE for 1 month. (A) Representative H&E-stained tibia
sections. Inserts showing higher magnification. (B-D) Quantification of adiposity in tibia
showing adipocyte area (B), adipocyte number (C), and nucleated area (D). Parameters
were measured by MarrowQuant [Mean ± SD; n = 6-7; each data point represents a
mouse; two-tailed student’s t-test: * p<0.05]. (E) Representative H&E-stained femur
sections. Inserts showing higher magnification. (F-H) Quantification of adiposity in
femur showing adipocyte area (F), adipocyte number (G), and nucleated area (H).
Parameters were measured by MarrowQuant [Mean ± SD; n = 6-7; each data point
represents a mouse; two-tailed student’s t-test: * p<0.05].
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Figure 4-7: BADGE treatment of diabetic mice does not normalize the altered
TGFB pathway genes.
mRNA levels of TGFB pathway genes were detected in the tibia (A-E) or femur (F-I) of
diabetic (STZ) mice and diabetic mice treated with BADGE (STZ-BADGE) for 1 month
[For panel A, data normalized to Actb, Atp5f1, and Pgk1; for panels B-I, data normalized
to Actb and Gapdh; Mean ± SD; n = 5-7; each data point represents a mouse; two-tailed
student’s t-test: * p<0.05].
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Figure 4-8: BADGE treatment of diabetic mice for 1 month does not normalize stem
cell niche factor genes.
mRNA levels of stem cell niche factors Cxcl12, Kit, and Kitlg were detected in the tibia
(A-B) or femur (C-D) of diabetic (STZ) mice and diabetic mice treated with BADGE
(STZ-BADGE) for 1 month [Data normalized to Actb and Gapdh; Mean ± SD; n = 5-7;
each data point represents a mouse; two-tailed student’s t-test: * p<0.05].
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Figure 4-9: Osteogenesis-associated genes are not significantly induced with
BADGE treatment of diabetic mice.
Runx2 and Sp7 mRNA levels were detected in the tibia (A) and femur (B) of diabetic
(STZ) mice and diabetic mice treated with BADGE (STZ-BADGE) for 1 month [Data
normalized to Actb and Gapdh; Mean ± SD; n = 5-7; each data point represents a mouse;
two-tailed student’s t-test: * p<0.05].
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Figure 4-10: No effect of BADGE treatment on CD31 expression in the bone
marrow of diabetic mice.
Diabetes was induced in mice with streptozotocin (STZ; 50 mg/kg) injection. Mice were
then treated with BADGE (30 mg/kg) daily for 1 month. (A) Representative
immunofluorescence staining of tibia sections for CD31 (green). Tissues were
counterstained with DAPI (blue). (B) Quantification of CD31 staining intensity per area,
as determined by ImageJ [Mean + SD; n = 3; 9-10 images per replicate were used for
quantification; two-tailed student’s t-test: * p<0.05].
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Figure 4-11: No effect of BADGE treatment on CXCL12 expression in the bone
marrow of diabetic mice.
Diabetes was induced in mice with streptozotocin (STZ; 50 mg/kg) injection. Mice were
then treated with BADGE (30 mg/kg) daily for 1 month. (A) Representative
immunofluorescence staining of tibia sections for CXCL12 (green). Tissues were
counterstained with DAPI (blue). Inserts showing higher magnification. (B)
Quantification of CXCL12 staining intensity per area, as determined by ImageJ [Mean +
SD; n = 3; 8 images per replicate were used for quantification; two-tailed student’s t-test:
* p<0.05].
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Figure 4-12: BADGE treatment increases TGFB1 in the bone marrow of diabetic
mice.
Diabetes was induced in mice with streptozotocin (STZ; 50 mg/kg) injection. Mice were
then treated with BADGE (30 mg/kg) daily for 1 month. (A) Representative
immunofluorescence staining of tibia sections for TGFB1 (green). Tissues were
counterstained with DAPI (blue). Inserts showing higher magnification. (B)
Quantification of TGFB1 staining intensity per area, as determined by ImageJ [Mean +
SD; n = 3; 5-7 images per replicate were used for quantification; two-tailed student’s ttest: * p<0.05].
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Figure 4-13: Immunostaining of diabetic mouse tibia sections for CD45.
Diabetes was induced in mice with streptozotocin (STZ; 50 mg/kg) injection. Mice were
then treated with BADGE (30 mg/kg) daily for 1 month. (A) Representative
immunofluorescence of tibia sections of diabetic (STZ) mice and diabetic mice treated
with BADGE (STZ-BADGE) for CD45 (green). Sections were counterstained with DAPI
(blue). Inserts showing higher magnification. (B) Quantification of CD45 staining
intensity per area, as determined by ImageJ [Mean + SD; n = 2-3; 8 images per replicate
were used for quantification].
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Figure 4-14: Effect of BADGE treatment on FABP4 levels in bone tissues of diabetic
mice.
Diabetes was induced in mice with streptozotocin (STZ; 50 mg/kg) injection. Mice were
then treated with BADGE (30 mg/kg) daily for 1 month. (A, B) Representative
immunofluorescence staining images of tibia shaft (A) and distal regions (B) for FABP4
(green). Sections were counterstained with DAPI (blue). (C) Quantification of tibia
FABP4 staining intensity per area, as determined by ImageJ [Mean + SD; n = 3; 7 images
per replicate were used for quantification].
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Figure 4-15: No effect of BADGE treatment on PLIN1 levels in bone tissues of
diabetic mice.
Diabetes was induced in mice with streptozotocin (STZ; 50 mg/kg) injection. Mice were
then treated with BADGE (30 mg/kg) daily for 1 month. (A, B) Representative
immunofluorescence staining images of tibia shaft (A) and distal regions (B) for
perilipin-1 (PLIN1; green). Sections were counterstained with DAPI (blue). (C)
Quantification of tibia PLIN1 staining intensity per area, as determined by ImageJ [Mean
+ SD; n = 3; 10-13 images per replicate were used for quantification].
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4.3.5

Resveratrol is effective in preventing adipogenic differentiation of bm-MPCs.

Since BADGE was not effective in preventing adipogenesis in bone marrows of diabetic
mice, I screened other potential drugs that were identified using GeneSetDB [3] and the
Drug Gene Interaction Database [4] by inputting the 193 target genes that were identified
to be significantly higher in ADP and TAK1i groups and reduced in the TGFB1 group
(Chapter 3). I selected three drugs with differing properties: diclofenac, resveratrol, and
lovastatin. Diclofenac is a commonly used non-steroidal anti-inflammatory drug that has
analgesic, anti-inflammatory, and antipyretic properties [5]. There have been various
mechanisms of action for diclofenac that have been suggested, including inhibition of
cyclooxygenase (COX) enzymes and PPARG [reviewed in [5]]. Resveratrol is a natural
polyphenol that is found in various fruits and vegetables. There have been many studies
investigating the effect of resveratrol with respect to metabolic disease, obesity, and
ageing, with mixed results being reported [6-9]. Lovastatin is a lipid-lowering agent
belonging to the statin class of medications that lower the level of low-density lipoprotein
(LDL) cholesterol by reducing the production of cholesterol by the liver. T0070907 was
used as a positive control that is known to inhibit PPARG [10]. My objective was to
determine the effect of the different classes of drugs on adipogenic differentiation of bmMPCs and the possible lipolysis of cells that have differentiated.
To ensure the effect on differentiation was not due to the effect on the growth of bmMPCs, I cultured the cells with increasing concentrations of the drugs and assayed for
viable cell number after 48 hours (Figure 4-16A,B). The concentrations tested have also
been examined in previous studies focused on differentiation [11-13]. Results showed
that diclofenac and resveratrol do not reduce viable cell counts up to 50 µmol/L (Figure
4-16A,B). Lovastatin did not reduce cell viability when used to 2.5 µmol/L
concentration. Based on these results, I used 25 µmol/L diclofenac, 50 µmol/L
resveratrol, and 2.5 µmol/L lovastatin and examined the effect of these drugs on bmMPC differentiation. Cells were cultured in adipogenic differentiation medium with or
without these drugs for 72 hours, and levels of PPARG, CEBPA, and FABP4 were
measured. T0070907 (PPARG inhibitor) suppressed PPARG and FABP4 but had no
effect on CEBPA (Figure 4-16C-E). Resveratrol had the same profile as T0070907. The
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other two agents, diclofenac and lovastatin had no significant effect on adipogenesisassociated genes. Moreover, the number of adipocytes, lipid droplets per adipocyte, and
the lipid droplet area were determined by the CellProfiler software [1]. I found that the
lipid droplet area was significantly reduced with T0070907 and resveratrol (Figure
4-16I), whereas the number of adipocytes and lipid droplets showed no difference (Figure
4-16G,H).
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Figure 4-16: Resveratrol and T0070907 effectively reduce FABP4 mRNA.
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(A, B) Total viable bone marrow-derived mesenchymal progenitor cells (bm-MPCs) after
48 hours of exposure to different concentrations of diclofenac, resveratrol, and lovastatin
(A), and T0070907 (B). T0070907 was used as a positive control, which is known to
inhibit PPARG [Plating density = 5,000 cells/cm2; Mean + SD; n = 3; two-tailed
student’s t-test: * p<0.05 compared with control medium]. (C-E) bm-MPCs were exposed
to adipogenic differentiation medium (ADP) supplemented with different drugs for 72
hours (25 µmol/L diclofenac, 50 µmol/L resveratrol, 2.5 µmol/L lovastatin, or 5 µmol/L
T0070907). mRNA levels of CEBPB (C), PPARG2 (D), and FABP4 (E) were detected
after 72 hours [Plating density = 40,000 cells/cm2; Data normalized to ACTB; Mean +
SD; n = 3-4; ANOVA followed by Bonferroni post hoc analysis: * p<0.05 compared with
control, † p<0.05 compared with ADP]. (F) bm-MPCs were exposed to adipogenic
differentiation medium (ADP), with or without different drugs for 72 hours. Cells were
then labelled with LipidTOX (neutral lipid stain; green) and counterstained with DAPI
(blue). The number of adipocytes (G) and lipid droplets (H) were measured using
CellProfiler software [Mean ± SD; n = 3; ANOVA followed by Bonferroni post hoc
analysis: * p<0.05 compared with control, † p<0.05 compared with adipogenic medium].
(I) Frequency of lipid droplet area as measured by CellProfiler [n = 2; 3 images per
replicate were used for quantification; Kruskal-Wallis test followed by Dunn’s post hoc
analysis: * p<0.05].
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Next, I determined the effect of these agents on lipolysis of differentiated bm-MPCs. The
cells were directed to differentiate into adipocytes for 3 days and then were exposed to
the agents for the next 4 days (a total of 7 days in culture). When the cells were exposed
to T0070907 after adipogenic differentiation, it significantly reduced the levels of
PPARG2 and FABP4 (Figure 4-17E,F). Interestingly, resveratrol, diclofenac, and
lovastatin showed no significant difference in the level of CEBPB mRNA (Figure
4-17A). However, resveratrol significantly increased PPARG2 mRNA levels, whereas no
significant change was observed with cells exposed to diclofenac and lovastatin (Figure
4-17B). Although diclofenac displayed a significant increase in FABP4 levels compared
with control, no significant difference was observed when cells were exposed to
resveratrol and lovastatin (Figure 4-17C).
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Figure 4-17: T0070907 induces lipolysis in bone marrow-derived mesenchymal
progenitor cell-derived adipocytes.
Bone marrow-derived mesenchymal progenitor cells (bm-MPCs) were exposed to
adipogenic differentiation medium (ADP) for 3 days. Cells were then exposed to 25
µmol/L diclofenac, 50 µmol/L resveratrol, 2.5 µmol/L lovastatin, or 5 µmol/L T0070907
(dissolved in control medium) for 4 days. mRNA levels of CEBPB (A, D), PPARG2 (B,
E), and FABP4 (C, F) were determined after a total of 7 days [Data normalized to ACTB;
Mean ± SD; n=2-3; ANOVA followed by Bonferroni post hoc analysis: * p<0.05
compared with control, † p<0.05 compared with ADP → Control].
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4.4

Discussion

In this study, I conducted a 4-week intervention with a PPARG inhibitor, BADGE, to
determine its impact on the bone marrow of diabetic mice. The main findings of my study
are: 1) BADGE does not cause toxicity in target organs of mice at the tested dose, 2)
BADGE does not normalize increased adiposity in the tibia nor the transcriptional
changes in TGFB signalling and Cxcl12 in the STZ-induced diabetic mouse marrows,
and 3) BADGE may protect against TGFB1 and CXCL12 protein suppression in the
marrow of diabetic mice.
PPARG is necessary for adipogenesis and is expressed predominantly in adipose tissue.
PPARG heterodimerizes with the retinoid X receptor (RXR), which can bind to the
peroxisome proliferator response elements and modulate gene transcription. BADGE, a
PPARG antagonist, has been previously reported to inhibit adipogenic differentiation of
preadipocytes in culture [14]. Studies have also reported that BADGE causes cytotoxic
effects in human colon cancer cells, HCT-116 [15]. Based on these studies, I first
exposed bm-MPCs in culture to BADGE and observed no cytotoxic effects.
Administration of BADGE did inhibit lipid accumulation and adipogenic differentiation
of bm-MPCs. Next, I treated mice with BADGE to systematically assess the effects of the
treatment, as such an investigation has not been performed previously. I investigated
various organs in mice, some of which are known to be affected in diabetes. Histological
examination of the retina, heart, lung, kidney, pancreas, and white adipose tissues of mice
treated with BADGE showed no histopathological aberrations.
Previous studies have reported that BADGE is effective in preventing bone marrow
adiposity in mice [2, 16]. Botolin and colleagues treated STZ-induced BALB/c diabetic
mice with 30 mg/kg BADGE daily for 28 days and observed suppressed adipocyte
numbers in the proximal tibia [2]. Duque and colleagues treated non-diabetic C57BL/6
mice with the same dose of BADGE for 6 weeks and observed reduced adipocytes in the
femurs [16]. There are a few differences between my study and these two published
reports on in vivo BADGE treatment that may explain the contradictory results. First, the
study by Botolin and colleagues examined the effects of BADGE in 15-week-old
BALB/c mice. In addition to strain differences that may exist between BALB/c and
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C57BL/6, studies have shown a rapid increase in proximal tibia adipocytes associated
with increasing age [17]. Specifically, starting at 12 weeks of age, there is an expansion
of regulated adipogenesis from the proximal end of bones. Therefore, it is possible that
diabetes may affect changes to regulated marrow adipocytes differently compared to the
cells in the shaft and distal regions. It is also possible that analysis of proximal tibia
highlights the effect of BADGE predominantly on age-related adipogenesis in later life.
Similarly, the study by Duque examined the effects of BADGE treatment in 36-week-old
C57BL/6 mice. The mechanisms regulating diabetes-induced and age-associated marrow
adiposity may be different. Furthermore, Duque and colleagues treated the mice for 6
weeks. Therefore, one possibility is that a longer duration of treatment may have
generated detectable changes in marrow adipocytes, which we were unable to observe,
following a 4-week treatment design. Two future studies would be extremely important:
1) testing the effect of a higher dose of BADGE in the experimental platform as I have
used (age of mice, timing/duration of the treatment, and region of the bones showing
diabetes-induced adipogenesis), and 2) investigating the effect of diabetes in older mice
to identify whether diabetes modulates ageing-associated marrow adipogenesis, in
addition to de novo adipogenesis as observed in my studies.
It is interesting to note that BADGE prevented lipid accumulation in the liver tissues of
diabetic mice. Although lipid uptake in hepatocytes is not ‘adipogenesis’, lipid uptake
proteins, such as FABP4, are regulated by PPARG activity. Therefore, these results show
that the BADGE treatment was somewhat effective but not sufficient to prevent diabetesinduced adipocyte differentiation in the tibia. In addition to the ineffectiveness of
BADGE in preventing diabetes-induced adiposity in the tibia, transcript levels of the
TGFB pathway and Cxcl12 did not change with BADGE treatment. Interestingly, at the
protein level, TGFB1 immunostaining intensity was normalized with BADGE treatment.
This could be the result of BADGE treatment regulating the extracellular environment to
prevent TGFB1 degradation. It is possible that BADGE treatment modulated the
extracellular environment through altered adipocyte activity, but not differentiation,
which involves cooperation between PPARG and other factors such as CEBPs. In support
of an activity change in marrow cells, CXCL12 immunostaining also showed some
normalization. Previous studies have shown that CXCL12 is regulated at both
206

transcriptional and posttranslational levels. Proteolytic cleavage of CXCL12 is necessary
for stem cell mobilization in the bone marrow [18]. Therefore, it is possible that PPARG
activity may be involved in CXCL12 protein regulation in diabetes. However, further
studies are needed to confirm these ideas.
Although BADGE is used in research settings to investigate the effects of PPARG
inhibition, it is also a potential endocrine disruptor [reviewed in [19]]. Due to this
confounding variable, I examined the effects of other PPARG inhibitors in culture to
identify effective inhibitors to test in future preclinical models of diabetic complications.
My studies show that resveratrol and lovastatin may be effective in preventing enhanced
cell adipogenesis. This is interesting as resveratrol and lovastatin are readily available as
a dietary supplement and an FDA-approved drug, respectively. Particularly, resveratrol, a
plant-derived dietary compound, has gained much attention due to its reported benefits to
human health [reviewed in [20]]. In an ovariectomized rat model of osteoporosis,
resveratrol administered orally for 8 weeks at 80 mg/kg/day presented significantly
higher levels of RUNX2 and lower levels of PPARG in the marrow [21]. Similarly,
enhancing osteogenic differentiation and preventing adipogenic differentiation of human
marrow-derived mesenchymal progenitor cells was observed in culture with resveratrol
[22]. Therefore, it may be an interesting future direction to explore the effect of
resveratrol in STZ-induced diabetic mice. If effective, resveratrol may be a more
accessible and feasible alternative treatment to preserve the bone marrow.
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Chapter 5
5
5.1

Summary and future directions
Overall findings and implications

In lieu of the extensive discussion accompanying Chapters 2-4 and, in an attempt, to
reduce redundancy, I have focused my final chapter to provide a summary of the main
findings, the implication of the key results, limitations of my study, and a few future
directions.
Vascular complications are inevitable in chronic diabetes. Studies have also shown
impaired angiogenic responses downstream of endothelial cell dysfunction. Therefore,
capitalizing on vasculogenesis, from non-endothelial stem cells, would be a solution to
combat these secondary complications in diabetic patients. Towards this goal, my studies
have focused on identifying diabetes-induced alterations in the bone marrow that houses
vascular regenerative stem cells. I investigated the effects of STZ-induced diabetes in the
mouse tibia and femur after 1 month. My studies identified enhanced bone marrow
adiposity in the tibia of diabetic mice. This structural change was seen before other
known diabetic complications, such as excessive fibrosis and inflammation in the heart
and kidney, and retinal dysfunction. I further show that enhanced adipogenesis is not seen
in the femur. Such a detailed investigation of regional differences have not been
performed previously. While only the tibiae showed enhanced adiposity in the marrow,
both femurs and tibiae showed suppression of the TGFB signalling pathway in
hyperglycemia. This early change in reducing TGFB signalling in the bone marrow
formed the basis for investigating the signalling mechanism in MPCs cultured in high
glucose conditions.
Recently, TGFB signalling has been identified to play an important role in lineage
determination of bone marrow MPCs in vivo [1]. In addition, culture studies show that
TGFB1 inhibits adipogenic differentiation of MPCs [2]. To investigate the underlying
mechanisms, I exposed bm-MPCs to high levels of glucose and observed suppressed
TGFB signalling, which is the exact readout in bones of diabetic mice. I then used a
comprehensive approach to study both canonical (SMAD-dependent) and non-canonical
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(SMAD-independent) pathways. I have identified the novel role of the TAK1-JNK axis
in mediating the inhibitory effect of TGFB1 on adipogenic differentiation of bm-MPCs.
TAK1-JNK activation is able to induce the canonical Wnt pathway, which has been
identified to inhibit adipogenesis [reviewed in [3]]. Moreover, in high glucose conditions,
the canonical SMAD2/3 pathway was shown to be downregulated, skewing the signal
towards SMAD1/5 to induce adipogenic differentiation of MPCs.
As enhanced bone marrow adiposity has been associated with a reduced number of
vascular regenerative stem cells [4], and stem cell phenotype is reduced when cells are
cultured with adipocytes [5], I investigated whether inhibiting PPARG - the master
regulator of adipogenesis - could normalize the changes mediated by hyperglycemia. To
do this, I employed a 4-week intervention by administering a specific PPARG inhibitor,
BADGE, daily in mice. Although there were no transcriptional differences in the genes
associated with the TGFB pathway, BADGE treatment of diabetic mice
increased/normalized TGFB1 protein levels. However, BADGE treatment did not prevent
enhanced adipogenesis in the tibiae of diabetic mice. A longer intervention could
preserve the marrow cellular composition as identified by previous studies [6].
Collectively, my studies show that in the healthy bone marrow, TGFB signalling is
active, adipogenesis is kept in check, and CXCL12 expression is observed. Moreover,
TGFB1 activates the TAK1-JNK axis to prevent adipogenic differentiation of bm-MPCs
as evident from culture studies. However, in a high glucose environment, such as in
diabetes, TGFB pathway-associated genes are downregulated, adipogenesis is enhanced,
and CXCL12 expression is reduced. Altered TGFB genes included Tgfb1, Bmp4, Smad3,
and Smad6. Similar to the in vivo results, elevated glucose levels in culture significantly
downregulate SMAD2, SMAD3, and SMAD4. The suppression of TGFB signalling
downregulates TAK1-JNK signalling and diminishes transcription of target genes of the
canonical Wnt signalling pathway. Furthermore, the reduction of the Smad2/3 and Smad6
levels in diabetes may skew the signal to favour SMAD1/5. The activation of SMAD1/5
may be responsible for triggering adipogenic differentiation induction and ultimately
enhance adiposity in the marrow in diabetes (Figure 5-1).
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Overall, there are vast implications of these studies that require further exploration.
TGFB signalling is an important niche signal in the bone marrow that affects resident
precursor cells [7, 8]. Quiescent HSCs have an active TGFB pathway, characterized by
nuclear localization of SMAD2/3 [7]. Interestingly, non-myelinating Schwann cells were
identified to be responsible for activating the TGFB pathway in HSCs in the marrow [9].
Denervation of the sympathetic nerves significantly reduced the number of Schwann cells
that affected the HSCs (CD34-Lineage-Sca-1+c-Kit+). Notably, this decline in Schwann
cells, consequently, decreased HSC numbers in the marrow. Moreover, the detected
HSCs in the marrow, after denervation, were actively cycling [9], which may exacerbate
the loss of the marrow HSCs. Therefore, it is quite possible that the reduction of TGFB
and/or HSCs in the bone marrow can consequently affect other non-HSCs and their niche
[10]. Another source of TGFB is megakaryocytes. In the bone marrow, when
megakaryocytes were ablated or conditional Tgfb1 deletion in megakaryocytes was
performed, this reduced active TGFB1 in the bone marrow that ultimately triggered
activation of quiescent HSCs [11]. One interesting thing to note is that within the myeloid
lineage of blood cells, megakaryocyte ploidy and platelet morphology/activation in
patients with diabetes were altered, although the precise biological significance of this is
unknown [12]. Furthermore, megakaryocyte-erythroid progenitors were less proliferative
in the adipocyte-rich environment [13]. These data suggest that in the fat-rich marrow of
diabetic patients, alterations in megakaryocytes and the loss of TGFB activation that
affects the cellular composition can influence stem cells residing within the marrow.
Understanding the mechanisms involved in supporting the stem cells and their niche
would also assist with cellular therapies. As TGFB may be regulating the differentiation
potential of MPCs, it could also have implications in this area. Autologous cell therapy
has been shown to have beneficial effects in various diseases, including osteoarthritis
[14-16] and diabetes [17, 18]. Many pre-clinical and clinical studies have used
autologous cultures expanded from bone marrow transplantations for cellular therapy.
Although autologous cell therapy has been highlighted as a promising regenerative
therapy, serious limitations of autologous MPCs are often overlooked. MPCs are most
prevalent in the bone marrow. However, the number of cells that are required for
therapeutic applications outnumber what can be isolated in the bone marrow aspirates;
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therefore, it is necessary for ex vivo culture expansion. Unfortunately, the ex vivo
expansion causes replicative ageing and progressive differentiation over time [19-21].
Furthermore, cells cultured in vitro long-term show changes in morphology with longer
population doubling times [20]. Although bm-MPCs display genomic stability when
expanded ex vivo, there is a significant difference in DNA methylation patterns between
early- and late-passage human MPCs [20]. Moreover, changes in chromosomal
morphology were observed when MPCs were compared with the freshly isolated bone
marrow mononuclear cells [21]. Similarly, aged rat and porcine MPCs progressively lost
their differentiation potential; aged MPCs were only able to differentiate into adipocytes,
as osteogenic differentiation potential was lost [22, 23]. Therefore, targeting the TGFB
signalling pathway to preserve an undifferentiated phenotype may be an avenue of
research to explore in the future.
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Figure 5-1: Schematic illustrating the working model of diabetes-induced bone
marrow dysfunction.
Transforming growth factor-beta (TGFB) signalling in healthy bone tissues maintains
osteoblastogenesis and adipogenesis. At least for adipogenesis, TGFB participates
through the non-canonical TGFB-activated kinase 1 (TAK1) mechanism. Elevated
glucose levels in diabetes suppress the TGFB signalling pathway, which through
alleviation of TAK1, favours adipogenesis in the marrow. Dashed black arrows indicate
putative molecular mechanisms. Green and yellow colour codes indicate the key factors
identified in the mouse model of diabetes and the culture system, respectively.
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5.2

Limitations of the study

Several limitations exist in these studies. The animal studies investigate the effect of
diabetes on the marrow in its entirety and were not able to identify the marrow
microenvironment at a single-cell resolution. Identifying the niche populations at a
single-cell resolution under control and diabetic conditions would help to identify the
cells that are responsible for diminished TGFB signalling or CXCL12 and the direct
consequence of these changes on resident vascular regenerative stem cells. Moreover, the
systemic effect of BADGE is unknown and there needs to be further clarity with respect
to how much of the injected inhibitor is reaching the organs and identify the long-term
effects of the drug. As with any PPARG antagonist, concentration reaching the target
cells is important in conveying either an agonistic role or an antagonistic role. Although
BADGE suppressed lipid accumulation in the hepatocytes in my study, it is important to
determine different concentrations and the long-term effect in other organs, including the
bone marrow.
Another limitation is the ability to recapitulate the in vivo environment in a cell culture
model. Disregarding the cellular and molecular complexity of the bone marrow
microenvironment, including the crosstalk between the cells as well as the cells and the
matrix, may fail to capture the holistic consequence of diabetes. Moreover, although I
used an animal model of diabetes, it would be helpful to determine whether a reduction in
TGFB signalling can be observed in human marrow samples from diabetic patients. This
would strengthen the pre-clinical findings from this study.
Lastly, TGFB1-supplemented cell culture model was used to understand the signalling
mechanisms in the bm-MPCs. It is unlikely that such a high concentration of TGFB1
would be observed under physiological conditions in the marrow. Since TGFB ligands
(TGFB1, TGFB2, and TGFB3) are secreted as biologically inactive latent complexes that
are converted into an active form, perhaps the only reliable means of assessing TGFB
signalling strength is by measuring activated SMAD and TAK1 levels. Despite this,
however, the culture model was necessary to decipher the signalling mechanism in the
MPCs.
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5.3
5.3.1

Future directions
Dissecting TGFB expression in the bone marrow

The next immediate step to build on the findings of my study should be to identify the
TGFB1 synthesizing and responsive/target cell. Previous studies examining TGFB1
distribution in mouse embryos of 10.5 to 15.5 days show expression in as early as at
embryonic day (E) 11 [24]. High expression levels using high stringency methods in
mouse embryos were found in three central locations: 1) osteocytes and megakaryocytes,
2) mesenchymal tissue, and 3) epithelial cells undergoing morphogenesis [24]. In
neonatal and adult mice, TGFB1 protein is detected in bone marrow cells, chondrocytes,
and cartilaginous matrix [25]. To the best of my knowledge, no detailed information is
available on the protein expression of TGFB2 or TGFB3 in adult mice. Studies in human
bones show that all three TGFB isoforms are expressed but TGFB1 is the most abundant,
ranging from 27 to 580 ng per g bone tissue [26]. Although no differences were found in
TGFB1 protein levels between males and females, the levels did decline with enhanced
age. I have provided evidence that TGFB signalling is downregulated in bone marrow in
diabetes, which may lead to enhanced marrow adiposity. Therefore, it would be
important to determine which cells in the marrow synthesize and respond to TGFB1, and
whether these cells are specifically targeted in diabetes.

5.3.2

TGFB signalling in mesodermal/vasculogenic stem cells

TGFB pathway has been previously shown to be important for supporting and
maintaining HSCs in the bone marrow [7, 9, 11]. It is quite possible that the reduction of
TGFB in the bone marrow can affect other non-HSCs and their niche [10]. Therefore,
exploring the direct role of the TGFB pathway in other stem/progenitor cells would
provide further insight into the pathogenesis of diabetes-induced bone marrow
complications.
Studies have shown that mouse embryonic stem cell phenotype is critically dependent on
physical interactions between potency factors and transcriptional mediators of key
pathways. For example, intermediate proteins in the Wnt, BMP, and TGFB pathways co216

occupy the genome with OCT4, SOX2, and NANOG to promote the stem cell state [2730]. Specifically, TGFB pathway intermediate SMAD3 occupies the genome with OCT4
in embryonic stem cells, MYOD1 in myotubes, and PU.1 in pro-B cells [30]. TGFB also
regulates the phenotype of other somatic stem cells [reviewed in [31]]. Therefore, it is
likely that the TGFB pathway in the bone marrow directly regulates vascular regenerative
stem cells, in addition to adipogenesis and indirect effects on the bone marrow stem cell
niche.

5.3.3

PPARG inhibition in the marrow

Although no difference was observed in my animal model with a 4-week BADGE
intervention, we cannot rule out the possibility that more time is required for BADGE
treatment to have an effect. Therefore, exploring the effect of BADGE after 8 weeks may
provide a beneficial effect. In addition, as BADGE may potentially be an endocrine
disruptor, it may be important to test other PPARG inhibitors in diabetic mice. I have
shown that resveratrol could possibly serve this purpose. At least in culture studies,
resveratrol inhibited adipogenic differentiation of MPCs. In addition, resveratrol has been
extensively studied in various animal models of human diseases and appears to be welltolerated.

5.3.4

Lineage tracing to identify adipocyte precursor

The precise precursor cell lineage that differentiates into adipocytes is unclear. Recent
studies have employed genetic lineage tracing approaches to determine the origin of
marrow adipocytes. Zhou and colleagues determine that leptin receptor-positive bone
marrow cells gave rise to bone marrow adipocytes that were observed in 2- to 14-monthold leptin receptor (LepR)-cre; tdTomato mice. Although LepR+ stromal cells represented
a rare population at E19.5 in the marrow, a sharp increase was found as early as postnatal
day (P) 0.5 that further increased with age [32]. Approximately 0.3% of bone marrow
cells were LepR+, where the cell populations largely overlap with the Nestin-GFP+ bone
marrow population. LepR+ stromal cells are normally quiescent in the adult murine bone
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marrow and a major source of HSC niche factors to support HSC maintenance [32]. A
recent study has identified a unique adipose lineage cell population that regulates the
bone marrow environment using single-cell transcriptomics. The marrow adipose lineage
precursors (MALPs) express many adipocyte markers but lack lipid droplets, suggesting
that MALPs may be a transitional cell type after mesenchymal progenitors towards a
mature adipocyte [33]. It would be important to identify the cell of origin of adipocytes to
further investigate its function and progression not only in normal development but also
in pathological contexts, such as diabetes. Identification of these cells may also uncover
specific targets to prevent their deleterious differentiation in diabetes.
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6

Appendices

Appendix 1: Quality control of the bone marrow flush method.
Representative hematoxylin and eosin (H&E)-stained sections of mouse tibia and femur
after marrow flush (‘Flushed’) or without flush (‘Whole’). Figure showing areas of the
bone shaft (A), distal ends (B), and the entire bone (C).
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Appendix 2: Effect of diabetes on adipogenesis and/or osteogenesis examined in bone tissues.
Diabetes
induction
method

Confirmation RNA
and duration preparation
of diabetes?

Adipogenesis
via RNA?

Osteogenesis
via RNA?

Preparation for Histological
histology or
findings
micro-CT
analyses

Daily IP
injections
with STZ
(40 or 60
μg/g) for 5
days

7 days after
the final STZ
injection; 2
weeks

Fabp4 mRNA
level
significantly
increased with
STZ (dosedependent).

Bglap
(osteocalcin)
mRNA level
significantly
decreased with
STZ (dosedependent).

Tibia fixed for
micro-CT
analyses in
formalin;
transferred to
70% ethanol
after 24 hours.

Significant reduction [1]
in bone volume
fraction; no change
in tibia length.

Daily IP
injection of
STZ (50
μg/g) for 5
days

9 days after
N/A
STZ injection;
15 weeks

-

-

Femur fixed in
10% formalin
for 48 hours,
then decalcified
in 10% formic
acid for 7 days
before being
embedded in
paraffin.

Significant reduction [2]
in bone volume
density, trabecular
thickness, trabecular
spacing.
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Whole tibiae
crushed under
liquid nitrogen
conditions and
homogenized

Ref.

7 days after
the final STZ
injection; 8
weeks

Bone marrow
flushed from
the femur and
frozen in liquid
nitrogen;
cortical bone
crushed under
liquid nitrogen
conditions

Fabp4 mRNA
level nonsignificantly
increased
(P=0.08) in the
marrow.

Runx2 mRNA
level
significantly
decreased; no
change in
Bglap mRNA
in the cortical
bone.

Femur analyzed
by micro-CT.
Tibia was placed
in 70% ethanol
before
dehydration
with acetone.
Tibia was
embedded in
methyl
methacrylate
and was not
decalcified.

Diabetic femurs
displayed a
significant reduction
in bone mineral
density, cortical
thickness, trabecular
thickness and bone
volume. Tibia
presented a nonsignificant increase
in adipocyte volume
and number of
adipocytes.

Daily IP
injection
with STZ
(40 μg/g)
for 5 days

7 days after
the final STZ
injection; 5
weeks

Whole tibiae
crushed under
liquid nitrogen
conditions and
homogenized

Pparg2 and
Fabp4 mRNA
levels
significantly
increased.

Runx2 and
Bglap mRNA
levels were
significantly
reduced.

Tibia fixed in
10% formalin.
Fixed samples
were processed
and embedded
in paraffin for
histological and
micro-CT
analyses.

Diabetic tibia
[4]
presented a
significant increase
in adipocyte number.
micro-CT analysis
showed a significant
reduction in bone
mineral content and
density, and bone
volume fraction of
the tibia trabecular
region. Only the
bone volume
fraction was
significantly reduced
in the cortical
region.
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Daily IP
injection
with STZ
(50 μg/g)
for 5 days

223

[3]

Daily IP
injection
with STZ
(40 μg/g)
for 5 days
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7 days after
the final STZ
injection; 4
weeks

Whole tibiae
crushed under
liquid nitrogen
conditions and
homogenized

Pparg2 and
Fabp4 mRNA
levels
significantly
increased.

Bglap mRNA
level
significantly
decreased; no
significant
difference in
Runx2 mRNA
level.

Proximal tibia
fixed in 10%
formalin. Fixed
samples were
processed and
embedded in
paraffin for
histological and
micro-CT
analyses.

micro-CT analysis
[5]
showed a significant
reduction in bone
mineral density and
content, and bone
volume fraction of
the tibia trabecular
region. Only the
bone volume
fraction was
significantly reduced
in the cortical
region. Tibia
displayed a
significant increase
in adipocyte number.

Daily IP
injection
with STZ
(50 μg/g)
for 5 days
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four days after
the final STZ
injection; 8
weeks

Tibia (after
marrow
removed)
crushed under
liquid nitrogen
conditions and
homogenized.

Pparg mRNA
level
significantly
increased.

Runx2 and
Bglap mRNA
levels were
significantly
reduced.

Femurs stored in
70% ethanol for
micro-CT
analysis. Femurs
were also fixed
in 4% PFA for
48 hours for
histological
assessment.
Fixed femurs
were decalcified
in 10% EDTA
for 4 weeks
before being
embedded in
paraffin.

Diabetic femurs
[6]
displayed
significantly reduced
bone mineral density
and content,
trabecular thickness,
trabecular number.
Trabecular spacing
was significantly
increased. The
number of
osteoblasts was
significantly reduced
in the diabetic
femurs. Femurs from
diabetic mice
displayed impaired
bone strength
measured by threepoint bending
testing.

Daily IP
injection
with STZ
(40 μg/g)
for 5 days

At time of
sacrifice; 4
weeks

Daily IP
At time of
injection
sacrifice; 4
with STZ
and 12 weeks
(100 μg/g)
for 2
consecutive
days

Whole tibiae
crushed under
liquid nitrogen
conditions and
homogenized

Fabp4 mRNA
level
significantly
increased.

Bglap mRNA
level
significantly
decreased.

Femurs stored in
70% ethanol for
micro-CT
analysis. Femurs
were also fixed
in 10% formalin
for 24 hours for
histological
assessment.
Fixed femurs
were embedded
in paraffin.

Diabetic femurs
[7]
displayed a
significant reduction
in the bone mineral
density in trabecular
and cortical areas.
Trabecular spacing
in the trabecular area
was significantly
increased.
Significantly
increased number of
adipocytes in the
distal femur.

N/A

-

-

Femur fixed
with 4% PFA
for 72 hours at
room
temperature then
fixed with 20%
EDTA at room
temperature for
96 hours. The
samples were
then processed
and embedded
in paraffin.

Diabetic femurs
displayed a
significant reduction
in bone mineral
density, as well as a
reduction in osteoid
volume and
thickness.

Abbreviations: IP: intraperitoneal; STZ: streptozotocin; PFA: paraformaldehyde; CT: computed tomography; EDTA:
Ethylenediaminetetraacetic acid.
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[8]

Appendix 3: Changes in femurs/tibiae length after 1 month of diabetes.
(A,B) Lengths of tibiae (A) and femurs (B) were measured by QuPath in control and
streptozotocin (STZ)-induced diabetic mice after 1 month. (C,D) Lengths of tibiae (C)
and femurs (D) in STZ-induced diabetic mice and diabetic mice treated with BADGE for
1 month [Mean ± SD; n=4-6; each data point represents a mouse; two-tailed student’s ttest: * p<0.05].
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Appendix 4: Femurs from control mice express more stem cell niche factors, Cd34,
and Ccnd1 in the bone marrow at 1 month.
(A-E) mRNA levels of Cxcr4 (A), Kit (B), Kitl (C), C34 (D), and Ccnd1 (E) were
detected in the femurs and tibiae of the control mice. [Data normalized to Actb and
Gapdh; Mean ± SD; n=5-6; each data point represents a mouse; two-tailed student’s ttest: * p<0.05].

228

Appendix 5: List of 193 genes that were significantly increased in the ADP and
TAK1i groups and normalized in the TGFB1 group.
ABCA5
ABCC3
ABCD2
ACADS
ACAT2
ACSS2
ADAM17
ADAMTSL4
ADGRG2
ADH1B
AIFM2
ALDH1A3
ALDH3A2
ANGPT1
ANKRD35
ANO10
ANPEP
AOC2
APOB
AQP7
ARRDC1-AS1
BBOX1
BBS10
BMPER
BTG2
C19orf12
C1GALT1C1
C9orf47; S1PR3
CACHD1
CACNA1G
CCDC69
CCDC97
CD36
CDKN2C
CDO1
CEP68
CEPT1
CLCN4

CLK4
CLSTN2
COX11
CSAD
CYB5D2
DAAM2
DBI
DLC1
DUSP15
DUSP4
EIF4EBP2
ELOVL3
EMC3
ETFB
FABP3
FAM110B
FAM213A
FHL1
FLVCR2
FMO3
FOXRED2
FZD4
G6PD
GAREM1
GHR
GLUL
GNAI1
GPC1
GRB14
H6PD
HADH
HADHA
HCAR1
HCN2
HIPK2
HP
HPR
HSD17B4

HSD17B7
HSDL2
IGF2
IGF2; INS-IGF2
IL17RC
IRAK3; MIR6502
ITFG1
ITPKC
KCNQ3
KLF15
LETMD1
LIN7A
LIPA
LMO3
LNPEP
LPIN1; MIR548S
LRRC66
MAN1A1
MAP2K6
MARC1
MARK1
MED18
METTL7A
MFSD2A
MGST1
MRAP
MRPL34
NAAA
NANOS1
NAPRT
NDUFAF6
NDUFB5
NFIA
NGFRAP1
NID1
NLGN1
NPTXR
NQO2

NUDT4; NUDT4P1
NUDT4P1;
NUDT4P2; NUDT4
PARK2
PARM1
PCLO
PDE7B
PDLIM1
PEMT
PEX19
PGD
PGRMC1
PGRMC2
PISD; MIR7109
PLCD1
PLIN2
PLIN4
POLG2
PPARG
PPM1L
PRDX6
PTGR1
PTK2B
PTPRG
PYGB
RASD1
RASSF4
RBBP5
RBMS1; MIR4785
REPS2
REV3L
RHOBTB3
RILPL2
RNASET2
RNF220
ROCK2
RSRC1
RXRA; MIR4669
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SCARB1
SDHD
SESN1
SGCB
SIDT2
SIK2
SLC19A3
SLC22A23
SLC25A1
SLC43A2
SLC5A3; MRPS6

SMAD6
SOBP
SOD2
SORT1
SOX5
SSH2
STAT5B
SYN2
THRSP
TKT
TMCC1

TMED5
TMEM100
TMEM120A
TMEM14A
TMEM150C
TNFRSF1A
TPRG1
TRIM16L
TRIM35
TSPAN14
TTF2

TUSC5
TWIST2
UBE2H
UCP2
UPF3B
WFS1
ZNF423
ZNF438
ZNF530
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Appendix 6: List of 154 genes that were significantly decreased in the ADP and
TAK1i groups and normalized in the TGFB1 group.
AARS
ABL1
ALDH18A1
ANOS1
ARHGAP19
ARNTL2
ATP13A3
BAIAP2L1
BBOF1
BCAT1
BICD1
BID
BMPR1B
BRIP1
BUB1
C10orf88
CALD1
CCNE2
CD200
CDK2AP1
CDK2AP2
CDK7
CLCF1
CLIP1
COL12A1
COTL1
CRY1
CSRP1
CTHRC1
CUX1
DAAM1
DAP
DBN1
DDX26B
E2F5
EIF5A2
EPHA2
EPYC

ERF
ETV5
ETV6
EVL
FAM111B
FAM129B
FAM155A
FAM171A1
FAM208B
FARP1; MIR3170
FICD
FILIP1L
FLNA
FNIP2
GALE
GALNT16
GARS
GBP1
GOLGA2
GOLGA4
GPX8
GRAMD4
GREM1
GREM1
HAPLN1
HAX1
HIST1H1B
HIST1H3B
HMCN1
IFT88
IGF1R
IL4R
IQCJ; SCHIP1; IQCJSCHIP1
ITGA11
JAG1
KCNJ15
KDM5B

KMT5A
LGR4
LIF
MAGED1
MAGED4;
MAGED4B;
SNORA11D;
SNORA11E
MAGED4B;
MAGED4;
SNORA11D
MAK16
MAP4K5
MARCH4
MBOAT2
METRNL
MLLT11
MSI2
MTMR2
MYO9B
MYO9B
MYPN
NAGK
NR1D1
OPCML
OR2W3
PLCB1
PLEKHS1
PLSCR3; TMEM256;
TMEM256-PLSCR3
PLXNA1
POLQ
POLR3D
PPP1R14B
PPP1R18
PRAMEF9
PRICKLE1
PRRX2
PSME4

PTPRF
PYCR1
RAB15
RAB23
RAB2A
RAD51B
RAI14
RALA
RALGDS
RASA2
RASGRP1
RASSF3
RGL2
RPS15
RRBP1
RRM2
SCUBE3
SNX30
SOX4
SPIN1
SPTLC2
SSX2IP
ST8SIA4
SULF1
TBCB
TCF4
TES
TGFB1I1
THAP5
TMEM237
TMEM87B
TMOD3
TNFAIP6
TNFSF11
TP53BP2
TRIM59
TSPAN13
TUBA1C
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TUBB
TUBB2A
TUBB2B

TUBB3; MC1R
VASP
XPOT

ZNF280B
ZNF358
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